Compositions, methods, and systems for genomic editing
The combination of Nme-nCas9 and DDP with tgRNA enhances genome editing efficiency in both dividing and non-dividing cells, addressing the limitations of CRISPR/Cas9 for templated edits by improving precision and reproducibility.
Patent Information
- Application Number
- PCT/IB2026/054790
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-14
- Filing Date
- 2026-05-14
- Publication Date
- 2026-11-19
AI Technical Summary
Conventional CRISPR/Cas9 genome editing methods are inefficient for generating templated genomic edits in non-dividing cells, limiting their therapeutic applications.
Utilizing Neisseria meningitidis Cas9 nickase (Nme-nCas9), DNA-dependent DNA polymerase (DDP), and template guide RNA (tgRNA) to facilitate template-based genome editing, with configurations that include fusion proteins and heterodimerization domains for enhanced efficiency.
Enables precise and reproducible templated edits in both dividing and non-dividing cells, overcoming the limitations of homology-directed repair (HDR) by leveraging the Nme-nCas9 and DDP system for efficient genomic modifications.
Smart Images

Figure IMGF000078_0001 
Figure IMGF000085_0001 
Figure IMGF000087_0001
Abstract
Description
COMPOSITIONS, METHODS, AND SYSTEMS FOR GENOMIC EDITINGCROSS REERENCE TO RELATED APPLICATIONSThis application claims priority to U. S. Provisional Application No. 63 / 805,592, filed May 14, 2025, the contents of which are incorporated herein by reference in their entirety.SEQUENCE LISTINGThe instant application contains a Sequence Listing which has been submitted in xml format and is hereby incorporated by reference in its entirety. Said xml copy, created on May 12, 2026, is named “U21468_l 130WO_SL” and is 3,304,468 bytes in size.INTRODUCTIONThe present disclosure relates to compositions, methods, and systems for genomic editing.The ability to introduce precise and reproducible edits into the genome of a cell is of interest for gene editing and clinical therapeutic applications. The ability to generate a templated edit at a disease-associated locus — thereby replacing the endogenous, pathogenic sequence with a non-pathogenic, exogenous sequence — is therefore of great therapeutic interest.CRISPR / Cas9 genome editing has been demonstrated to be highly efficient; however, it has been challenging to generate templated genomic edits. Conventional approaches for generating targeted genomic modifications often exploit the ability of the homology- directed repair (HDR) pathway to repair DNA breaks using a synthetic repair template comprising an insertion, deletion, or substitution. However, HDR is largely restricted to actively dividing cells, limiting its efficacy (Cox et al., Nature Medicine, 21:121-131 (2015). Thus, there is a need for a more robust and efficient approach for generating templated edits within the genome of a cell.SUMMARYThe methods provided herein comprise using a Neisseria meningitidis Cas9 nickase (Nme-nCas9), DNA-dependent DNA polymerase (DDP), and template guide RNA (tgRNA) for template-based genome editing applications, providing substantial advantages over traditionalmethods. In some aspects, the Nme-nCas9 can be a Neisseria meningitidis 2 Cas9 nickase (Nme2-nCas9).In some aspects, the present disclosure provides a system comprising a DNA-dependent DNA polymerase (e.g., a T5 DNA polymerase or a PolK DNA polymerase), an Nme-Cas9 nickase (e.g., an Nme2-nCas9 comprising a mutation in the HNH nuclease domain, e.g., a H588A substitution), and a template guide RNA (tgRNA) comprising a spacer, a scaffold, a template, and a DNA-dependent DNA polymerase recruiting sequence (DRS). In some embodiments, the system further comprises one or more accessory factors (e.g., nicking guide RNA (ngRNA), Fenl or VPX). In some embodiments the system further comprises a chromatin remodeler (e.g., HMGB1). Such systems can be provided in a variety of configurations, as described herein. These components can be used in the compositions and methods described herein.Accordingly, in some embodiments, the present disclosure provides for a polypeptide system comprising a Neisseria meningitidis 2 Cas9 nickase (Nme2-nCas9) and a DNA-dependent DNA polymerase (DDP). In certain embodiments, the Nme2-nCas9 and the DDP are covalently linked. In certain embodiments, the Nme2-nCas9 and the DDP form a fusion protein.In certain embodiments, the Nme2-nCas9 is positioned upstream of the N-terminus of the DDP or the Nme2-nCas9 is positioned downstream of the C-terminus of the DDP. In certain embodiments, the fusion protein comprises an intein scar; optionally wherein the intein scar is 6 amino acid long, optionally wherein the intein scar comprises the sequence RGKCFN, GWNCML, GLTCMY, RGKCWE, GALCWN, AEKCWL, and GDLCKQ.In certain embodiments, the Nme2-nCas9 and the DDP are not covalently linked. In certain embodiments, the Nme2-nCas9 and the DDP each comprise a heterodimerization domain which are complementary wherein the complementary heterodimerization domains are capable of self-assembling the Nme2-nCas9 and the DDP into a stable heterodimer. In certain embodiments, each heterodimerization domain is a coiled coil heterodimerization domain, optionally wherein the coiled coil heterodimerization domains are a KI domain and an El domain; or a KV domain and an EV domain.In certain embodiments, the DDP is selected from the group consisting of DNA polymerase kappa (polK), phage T5 DNA polymerase (T5 pol), DNA polymerase 0, E. coliDNA polymerase I, or DNA polymerase N, optionally wherein the DNA-dependent DNA polymerase is polK or T5 DNA polymerase.In certain embodiments, the DDP is a T5 DNA polymerase, e.g., a T5 pol comprising an amino acid sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO: 1116 or 1121; a T5 pol comprising one or more mutations at positions selected from D164, E166, N30, C24, C63, K425, and A593 relative to SEQ ID NO: 1116, optionally one or more mutations selected from DI 64 A, El 66 A, N30del, C24del, C63del, K425I, and A593R relative to SEQ ID NO: 1116. In certain embodiments, the T5 pol comprises a mutation at D164 or E166, or mutations at D164 and E166 relative to SEQ ID NO: 1116.In certain embodiments, the DDP is polK, e.g., a polK comprising an amino acid sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to amino acid residues 1-526, optionally amino acid residues 19-526 of SEQ ID NO: 1021, optionally wherein the polK includes or lacks an N-terminal methionine relative to SEQ ID NO: 1021; polK comprises a human polK; a polK comprising an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to ammo acids residues 1-526, optionally amino acid residues 19-526 of human polK. In certain embodiments, the polK comprises one or more mutations at one or both of G411R and E412V.In certain embodiments, the Nme2-nCas9 comprises an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 1, 8, 10, 14, 32, 69, 91, 311, and 322; e.g., comprising one or more mutations at positions K266, Q422, D418, E868, H588, E932, N1026, and / or K1044 relative to SEQ ID NO: 10 or 14; comprising one or more mutations selected from K266R, Q422K, D418K, E868R, H588A, E932R, E932K, N1026R, and K1044R relative to SEQ ID NO: 10 or 14.In certain embodiments, the Nme2-nCas9 or the DDP is operably linked, e.g., by a peptide bond, to an aptamer binding domain (ABD). In certain embodiments, the ABD is an MS2 coat protein (MCP). In certain embodiments, the ABD, e.g., MCP, is positioned upstream of the N-terminus of the DDP, downstream of the C-terminus of DDP, upstream of the N-terminus of the Nme2-nCas9, or downstream of the C-terminus of the Nme2-nCas9. In certain embodiments, the ABD, e.g., MCP, comprises an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 1520.In certain embodiments, the Nme2-nCas9 and / or the DDP is operably linked, e.g., by a peptide bond, to a peptide linker, optionally wherein the peptide linker comprises one or more heterologous nuclear localization signals (NLSs), e.g. SV40 NLS, SV40-c-Myc, or nucleoplasmin In certain embodiments, the NLS comprises an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NOs: 1666-1669 and 1671. In certain embodiments, the one or more NLSs are each upstream of the N-terminus of the DDP, downstream of the C-terminus of DDP, upstream of the N-terminus of the Nme2-nCas9, or downstream of the C-terminus of Nme2-nCas9. In certain embodiments, the NLS comprises the amino acid sequence set forth in SEQ ID NO: 1666-1669, 1671, 1706, and 1727.In certain embodiments, the Nme2-nCas9 and / or the DDP is operably linked, e.g., by a peptide bond, to a chromatin remodeler, e.g., High Mobility Group Box 1 (HMGB1), HMGN1, HMGN2, HMGN3a, HMGN3b, HMGN4, HMGN5, histone H1.0, histone H1.2, CHD1, ISWI, DNA helicase, TOPI, herpesvirus 8 LANA, CMV IE1; or a domain thereof. In certain embodiments, the chromatin remodeler is a High Mobility Group Box 1 (HMGB1). In certain embodiments, chromatin remodeler, e.g., HMGB1, is positioned upstream of the N-terminus of the DDP, downstream of the C-terminus of DDP, upstream of the N-terminus of the Nme2-nCas9, or downstream of the C-terminus of Nme2-nCas9. In certain embodiments, the HMGB1 comprises the amino acid sequence set forth in SEQ ID NO: 1783-1792 and 1803-1804, optionally SEQ ID NO: 1789.In certain embodiments, the DDP and Nme2-nCas9 are operably linked sequentially by a peptide bond, from N-terminus to C-terminus, in an order selected from:a) PolK - Nme2-nCas9;b) Nme2-nCas9 - PolK;c) T5 pol - Nme2-nCas9; andd) Nme2-nCas9 - T5 pol;e) PolK(GE> RV)-Nme2-nCas9;f) Nme2-nCas9-PolK(GE> RV);g) MCP-PolK (GE> RV)- Nme2-nCas9;h) MCP-PolK (GE> RV)- Nme2-nCas9-HMGB1;i) MCP-PolK(l-526, GE> RV)-linkerNLS- Nme2-nCas9;j) MCP-PolK(l-526, GE> RV)-linkerNLS- Nme2-nCas9-HMGB 1;k) MCP-PolK( 1-526, GE> RV)-linker-NLS-linker- Nme2-nCas9-HMGB 1; l) MCP-PolK(l-526, GE> RV)-linkerNLS-linker- Nme2-nCas9-HMGB1; m) MCP-PolK-Nme2-Cas9(H588A)n) MCP-PolK-Nme2-Cas9(H588A, E932K, Kl 044R);o) MCP-PolK-Nme2-Cas9(H588A)-HMGB 1;p) MCP-PolK-Nme2-Cas9(H588A, E932K, Kl 044R)-HMGB 1;q) MCP-PolK-Nme2-Cas9(H588S, E932K, Kl 044R)-HMGB 1;r) MCP-PolK (GE> RV, S423R)-Nme2-Cas9 (H588A / E932R)s) Nme2-Cas9 (H588A / E932R)-PolK 1-526 GE> RV;t) PolK 1-526 GE> RV-Nme2-Cas9 (H588A / E932R);u) polK-Nme2-nCas9(E932R);v) polK-Nme2-nCas9(E932R);w) MCP-polK-Nme2-nCas9(E932R);x) MCP-T5-Nme2-nCas9;y) MCP-T5-Nme2-nCas9-HMGB1;z) MCP-T5-Nme2-nCas9 (H588A / E932R); andaa) MCP-T5Pol-Nme2-nCas9 (H588A, E932R);optionally wherein the polypeptide system further comprises one or more of:a) a HMGB1 positioned downstream of the C-terminus of the DDP- Nme2-nCas9 fusion protein;b) a HMGB1 positioned upstream of the N-terminus of the DDP- Nme2-nCas9 fusion protein;c) a HMGB1 positioned between the DDP and Nme2-nCas9 fusion protein; d) a MCP positioned downstream of the C-terminus of the DDP- Nme2-nCas9 fusion protein;e) a MCP positioned upstream of the N-terminus of the DDP- Nme2-nCas9 fusion protein;f) a MCP positioned between the DDP and Nme2-nCas9;g) one or more NLSs positioned downstream of the C-terminus of the DDP-Nme2-nCas9 fusion protein;h) one or more NLSs positioned upstream of the N-terminus of the DDP- Nme2-nCas9 fusion protein;i) one or more NLSs positioned between the DDP and Nme2-nCas9; and j) the DDP and / or the Nme2-nCas9 comprises one or more mutations or one or more additional mutations.In certain embodiments, the polypeptide system of further comprises (a) an intein scar positioned between DDP and Nme2-nCas9; (b) an intein scar positioned within the DDP; or (c) an intein scar positioned within the Nme2-nCas9.In certain embodiments the polypeptide system is encoded by one or more mRNAs listed in Table 6 or exemplified in Examples 1-15, e.g., the polypeptide system comprises one or more amino acid sequences that are at least 90%, 91%, 92%, 93%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% of any one of the amino acid sequences listed in Tables 6 or exemplified in Examples 1-15. In certain embodiments, the mRNA comprises one or more of nucleotide sequences that are least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% of any one of SEQ ID NOs 1840, 1115, 1841, 1842 or 1843. In certain embodiments, the polypeptide system further comprises a Vpx and / or a FEN1, optionally wherein the Vpx and or the FEN1 is not covalently linked to DDP or Nme2-nCas9.In certain embodiments, the polynucleotide system encoding the polypeptide system of provided herein comprise (a) a first polynucleotide comprising a nucleotide sequence encoding the Nme2-nCas9 or a portion thereof; and (b) a second polynucleotide comprising a nucleotide sequence encoding the DDP or a portion thereof. In certain embodiments (a) the first polynucleotide is covalently linked to the second polynucleotide; or (b) the first polynucleotide is not covalently linked to the second polynucleotide.In certain embodiments (a) the first polynucleotide encodes the Nme2-nCas9, or a portion thereof, operably linked to a first split intein; and (b) the second polynucleotide encodes the DDP or a portion thereof, operatively linked to a second split-intein, wherein the first split-intein and the second split-intein are capable of undergoing trans-splicing reaction, resulting in the formation of a single fusion polypeptide comprising, the Nme2-nCas9 and the DDP. In certain embodiments (1) the first split intein and the second splitintein are CfaN and CfaC, respectively; or (2) the first split intein and the second split intein are CfaC and CfaN, respectively. In certain embodiments the mass ratio between the first polynucleotide and the second polynucleotide is between 10: 1 and 1:10, between 4: 1 and 1:4, between 2: 1 and 1:2, or about 1:1.In certain embodiments (a) the first polynucleotide encodes the Nme2-nCas9 that is operatively linked to a first heterodimerization domain; and (b) the second polynucleotide encodes the DDP that is operatively linked to a second heterodimerization domain, wherein the first and the second heterodimerization domains are complementary and capable of self-assembling the Nme2-nCas9 and the DDP into a stable heterodimer.In certain embodiments the polynucleotide is a mRNA. In certain embodiments the mRNA comprises one or more nucleotide sequences that are at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% of any one of the mRNA sequences listed in Table 6 or exemplified in Examples 1-15. In certain embodiments the mRNA wherein at least 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99%, or 100% of uridine in the mRNA is substituted with a modified uridine, optionally wherein the modified uridine is one or more of N1 -methyl-pseudouridine, pseudouridine, 5-methoxyuridine, or 5 -iodouridine. In certain embodiments at least 90%, 95%, 99%, or 100% of the uridine in the mRNA is substituted with N1 -methyl-pseudouridine.In certain embodiments, the polynucleotide system further comprising a nicking guide RNA (ngRNA), wherein the ngRNA comprises a spacer that is complementary to the non-target strand of the DNA duplex target nucleic acid. In certain embodiments the ngRNA comprises a spacer that hybridizes to a sequence on the non-target strand such that (i) the nick site of the ngRNA is within 200 nucleotides 5’ or 3’ from the nick site of the template guide RNA; (ii) the nick site of the ngRNA is 20-200 nucleotides 5’ or 3’ from the nick site of the template guide RNA; or (iii) the nick site of the ngRNA is outside of the genomic locus of the spacer sequence of the template guide RNA.In certain embodiments, the polynucleotide therein is a DNA, optionally wherein the DNA is a plasmid DNA or ssDNA, optionally wherein the ssDNA is a viral genome (e.g., rAAV).In certain embodiments, the disclosure provides a template guide RNA (tgRNA), wherein the tgRNA comprises a first polynucleotide and a second polynucleotide, wherein:a) the first polynucleotide is an Nme single guide RNA (sgRNA) comprising, from 5’ to 3’: i) a spacer that is complementary to a target region of a target strand of a DNA duplex target nucleic acid; and ii) a scaffold comprising, from 5’ to 3’: a repeat / antirepeat region, a hairpin 1 region and a hairpin 2 region; wherein the first polynucleotide is capable of specifically binding to an Nme2Cas9, andb) the second polynucleotide comprises, 5’ to 3’: i) a template sequence that is complementary to at least a portion of a non-target strand of the DNA duplex target nucleic acid and the template comprising DNA nucleotides; and ii) a DNA-dependent DNA polymerase recruiting sequence (DRS) having a 3’ end and a 5’ end; wherein the 5’ end of the DRS is covalently attached to the 3’ end of the template sequence, and wherein the DRS comprises a sequence that is complementary to at least 6 nucleotides of a DRS-complementary region of the non-target strand of the DNA duplex target nucleic acid, and optionally wherein the DRS comprises one or more of: i) one or more RNA nucleotide bases; ii) a sequence not fully complementary to the DRS-complementary region of the non-target strand of the DNA duplex target nucleic acid; or iii) a 1-5 nucleotide, optionally a 1-3 nucleotide 3’ terminal tail comprising a 3’ terminal modified uridine nucleotide.In certain embodiments, the first polynucleotide comprises:a) a spacer region 20-25 nucleotides in length;b) a shortened repeat / anti-repeat region, wherein the shortened repeat / anti-repeat region lacks 2-24 nucleotides within nucleotides 25-76 of SEQ ID NO: 253, wherein i) one or more of nucleotides 37-48 and 53-64 is deleted and optionally one or more of nucleotides 37-64 is substituted relative to SEQ ID NO: 253; and ii) nucleotide 36 is linked to nucleotide 65 of SEQ ID NO: 253 by at least 2 nucleotides or an internal linker; or(c) a shortened hairpin 1 region, wherein the shortened hairpin 1 lacks 2-10, optionally 2-8 nucleotides within nucleotides 78-100 of SEQ ID NO: 253, wherein i) one or more of nucleotides 82-86 and 91-95 is deleted and optionally one or more of positions82-96 is substituted relative to SEQ ID NO: 253; and ii) nucleotide 81 is linked to nucleotide 96 of SEQ ID NO: 253 by at least 4 nucleotides or an internal linker; or(d) a shortened hairpin 2 region, wherein the shortened hairpin 2 lacks 2-18, optionally 2-16 nucleotides within nucleotides 102-143 of SEQ ID NO: 253, wherein i) one or more of nucleotides 113-121 and 126-134 are deleted and optionally one or more of nucleotides 113-134 are substituted relative to SEQ ID NO: 253; and ii) nucleotide 112 is linked to nucleotide 135 of SEQ ID NO: 253 by at least 4 nucleotides or an internal linker; wherein one or both nucleotides 144-145 are optionally deleted relative to SEQ ID NO: 253.In certain embodiments, the first polynucleotide comprises (a) a shortened repeat / anti-repeat region, wherein the shortened repeat / anti-repeat region lacks 2-24 nucleotides within nucleotides 25-76 of SEQ ID NO: 253, wherein (i) one or more of nucleotides 37-48 and 53-64 is deleted and optionally one or more of nucleotides 37-64 is substituted relative to SEQ ID NO: 253; and (ii) nucleotide 36 is linked to nucleotide 65 of SEQ ID NO: 253 by at least 2 nucleotides or an internal linker.In certain embodiments, the spacer region has a length of 23-24 nucleotides, optionally wherein the spacer region has a length of 24 nucleotides. In certain embodiments, the first polynucleotide comprises an internal linker in at least one of the repeat / anti-repeat region, the hairpin 1 region, or the hairpin 2 region, optionally wherein the internal linker comprises one or more internal linkers, e.g., an SI 8 or dS linkers. In certain embodiments, the tgRNA further comprises a 3’ tail, wherein the 3’ tail is optionally 1-4 nucleotides in length.In certain embodiments, the first polynucleotide of the tgRNA is covalently linked to the second polynucleotide. In certain embodiments, a) the first polynucleotide and the second polynucleotide are covalently linked to each other by a phosphodiester or phosphorothioate bond; or the first polynucleotide and the second polynucleotide are covalently linked to each other by a flexible internal linker, optionally wherein the internal linker comprises one or more S18 or dS linkers. In certain embodiments, the 3’ end of the first polynucleotide is covalently linked to the 5’ end of the second polynucleotide. In certain embodiments, the second polynucleotide is inserted into the hairpin 2 region of the first polynucleotide. In certain embodiments, the first polynucleotide and the secondpolynucleotide are not directly linked to each other by a phosphodiester or phosphorothioate bond. In certain embodiments, the first polynucleotide is not covalently linked to the second polynucleotide.In certain embodiments, the second polynucleotide is covalently linked to one or more affinity tags, optionally wherein the one or more affinity tags comprise an aptamer sequence, optionally wherein the aptamer sequences is covalently linked to the 5’ terminus of the second polynucleotide. In certain embodiments, the one or more affinity tags comprises one or more MS2 hairpins, optionally wherein the one or more affinity tags comprises a single MS2 hairpin.In certain embodiments, the first polynucleotide comprises a nucleotide sequence selected from SEQ ID NO: 238-245.In certain embodiments, one or both of the first polynucleotide and the second polynucleotide comprise chemically modified nucleotides. In certain embodiments, both the first polynucleotide and the second polynucleotide comprise chemically modified nucleotides are modified at at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the nucleotides. In certain embodiments, the first polynucleotide comprises a chemically modified nucleotide structure selected from SEQ ID NO: 258-278.In certain embodiments, the disclosure provides a template guide RNA (tgRNA), wherein the tgRNA comprises a first polynucleotide and a second polynucleotide, wherein:a) the first polynucleotide is an Nme single guide RNA (sgRNA) comprising, from 5’ to 3’: i) a spacer that is complementary to a target region of a target strand of a DNA duplex target nucleic acid; and ii) a scaffold comprising, from 5’ to 3’: a repeat / antirepeat region, a hairpin 1 region and a portion of a hairpin 2 region wherein the portion of the hairpin 2 region does not comprise a duplex portion; wherein the first polynucleotide capable of binding to an NmeCas9, andb) the second polynucleotide comprises, 5’ to 3’: i) a template sequence that is complementary to at least a portion of a non-target strand of the DNA duplex target nucleic acid and the template comprising DNA nucleotides; ii) a DNA-dependent DNA polymerase recruiting sequence (DRS) having a 3’ end and a 5’ end; wherein the 5’ end of the DRS is covalently attached to the 3’ end of the template sequence, and wherein the DRS comprises a sequence that is complementary to at least 6 nucleotides of a DRS-complementary region of the non-target strand of the DNA duplex target nucleic acid; and iii) a nucleotide sequence capable of forming a duplex with the hairpin 2 region of the first polynucleotide, wherein the duplex comprises 6 base pairs, optionally wherein the duplex comprises 10 base pairs.In certain embodiments the first polynucleotide comprises:(a) a spacer region 20-25 nucleotides in length;(b) a shortened repeat / anti-repeat region, wherein the shortened repeat / anti-repeat region lacks 2-24 nucleotides within nucleotides 25-76 of SEQ ID NO: 253, wherein (i) one or more of nucleotides 37-48 and 53-64 is deleted and optionally one or more of nucleotides 37-64 is substituted relative to SEQ ID NO: 253; and (ii) nucleotide 36 is linked to nucleotide 65 of SEQ ID NO: 253 by at least 2 nucleotides or an internal linker; or(c) a shortened hairpin 1 region, wherein the shortened hairpin 1 lacks 2-10, optionally 2-8 nucleotides within nucleotides 78-100 of SEQ ID NO: 253, wherein i) one or more of nucleotides 82-86 and 91-95 is deleted and optionally one or more of positions 82-96 is substituted relative to SEQ ID NO: 253; and ii) nucleotide 81 is linked to nucleotide 96 of SEQ ID NO: 253 by at least 4 nucleotides or an internal linker; or(d) a hairpin 2 region comprising nucleotides 102-112 of SEQ ID NO: 253; and(e) the second polynucleotide comprises a nucleotide sequence that forms a duplex with nucleotides 102-112 of SEQ ID NO: 253, wherein the duplex comprises 6 base pairs, optionally wherein the duplex comprises 10 base pairs.In certain embodiments, the second polynucleotide comprises, from 5’ to 3’, (a) 5’ -template - DRS - duplex forming nucleotide sequence-3’; or (b) 5’ - duplex forming nucleotide sequence - template - DRS. In certain embodiments, the second polynucleotide comprises an internal linker adjacent to the duplex forming nucleotide sequence, optionally wherein the internal linker comprises one or more S18 or dS linkers. In certain embodiments, one or both of the first polynucleotide and the second polynucleotide comprise chemically modified nucleotides. In certain embodiments, both the first polynucleotide and the second polynucleotide comprise chemically modified nucleotides and are modified at at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, orfirst polynucleotide and the second polynucleotide comprise at least two modified nucleotides.In certain embodiments, the first polynucleotide or the second polynucleotide comprises a modified nucleotide selected from: a) 2’-O-methyl (2’-0-Me) modified nucleotide; b) 2’ -fluoro (2’-F) modified nucleotide; c) an amine modified nucleotide; d) an alkoxy modified nucleotide; e) an LNA modified nucleotide; f) methoxy ethyl modified nucleotide; g) a halo modified nucleotide; or h) phosphorothioate (PS) linkage modified nucleotide. In certain embodiments, the first polynucleotide comprises a 2’-O-methyl (2’-0-Me) modified nucleotide or a phosphorothioate (PS) linkage modified nucleotide.In certain embodiments, the DRS comprises at least one of: a) one or more RNA nucleotide bases; b) a sequence not fully complementary to the DRS-complementary region of the non-target strand of the DNA duplex target nucleic acid; or c) a 1-5 nucleotide, optionally a 1-3 nucleotide 3’ terminal tail comprising a 3’ terminal modified uridine nucleotide. In certain embodiments, the 3’ terminal nucleotide of the template is a DNA nucleotide. In certain embodiments, a) the 5’ terminal nucleotide of the DRS is a DNA nucleotide; or b) the penultimate 5’ terminal nucleotide of the DRS is an RNA nucleotide. In certain embodiments, the 3’ terminal nucleotide of the template and the 5’ terminal nucleotide of the DRS are DNA nucleotides, and the penultimate 5’ terminal nucleotide of the DRS is an RNA nucleotide. In certain embodiments, the 3’ terminal nucleotide in the DRS is an RNA nucleotide and the remaining nucleotides in the DRS are DNA nucleotides.In certain embodiments, the template consists of DNA nucleotides. In certain embodiments, the DRS consists of RNA nucleotides.In certain embodiments, the template comprises a mismatch to the genomic sequence, optionally 1-4 mismatches to the genomic sequence. In certain embodiments, the mismatch that directs a template-based edit in the genomic DNA is within nucleotides T1-T25, optionally within nucleotides T1-T15 of the template. In certain embodiments, the template comprises DNA nucleotides. In certain embodiments, a) the 3’ terminal nucleotide of the template is a DNA nucleotide; or b) the template consists of DNA nucleotides from nucleotide 4 (T4) from the 3’ end of the template to the 5’ end of thetemplate. In certain embodiments, the template comprises RNA nucleotides. In certain embodiments, the template comprises both RNA nucleotide(s) and DNA nucleotide(s), optionally wherein at least one nucleotide at positions T1 or T2 of the template is an RNA nucleotide. In certain embodiments, (i) the DRS is 6-18 nucleotides in length, optionally 8-18 or 10-12 nucleotides in length; or (ii) the DRS is 10-16 or 12-14 nucleotides in length.In certain embodiments the disclosure provides template-based editing system comprising the polypeptide system provided herein and the tgRNA provided herein. In certain embodiments, the template-based editing system comprising any one of combinations of a polypeptide system and a tgRNA exemplified in Tables 1-2D, 4-6, and 8-21. In certain embodiments, the template-based editing system is a polypeptide system comprising an ABD, optionally wherein the ABD is a MCP, and a tgRNA comprising an aptamer, optionally wherein the aptamer is a MS2.In certain embodiments, the disclosure provides a template-based editing system comprising the polynucleotide system provided herein and a tgRNA provided here. In certain embodiments, the disclosure provides a template-based editing system comprising any one of combinations of a polynucleotide system and a tgRNA exemplified in Tables 1-2D, 4-6, and 8-21.In certain embodiments, the polynucleotide system comprises nucleic acid sequences encoding an ABD, optionally wherein the ABD is a MCP, and (b) the tgRNA comprises an aptamer, optionally wherein the aptamer is a MS2. In certain embodiments, the polynucleotide system comprises a) a first polynucleotide and a second polynucleotide encoding a Nme2-nCas9, or a portion thereof, that is operatively linked to a first split-intein; and b) a second polynucleotide encoding a DDP, or a portion thereof, that is operatively linked to a second split-intein, wherein the mass ratio between the first polynucleotide and the second nucleotide is 1: 1 and the mass ratio between tgRNA and total polynucleotide system is between 1:8 and 4:1, between 1:4 and 4:1, between 1:1 and 4:1, or about 2:1.In certain embodiments, the disclosure provides pharmaceutical compositions comprising the template-based editing system provided herein and a pharmaceutically acceptable carrier.In certain embodiments, the disclosure provides LNP compositions comprising the template-based editing system provided herein wherein the different components of the templatebased editing system are associated with the same LNP or the different components of the template-based editing system are associated with different LNPs.In certain embodiments, the disclosure provides cell comprising the template-based editing system provided herein, optionally wherein the cell is a mammalian cell.In certain embodiments, the disclosure provides methods for editing a target nucleic acid in a cell or a subject, the method comprising delivering the template-based editing system, the pharmaceutical composition of claim, or the LNP provided herein to the cell or the subject.In certain embodiments, the disclosure provides for the use of the polypeptide system, the polynucleotide system, the tgRNA, the composition, or the LNP provided herein for editing a target nucleic acid in a cell or a subject.BRIEF DESCRIPTION OF DRAWINGSFigures 1A-1B show the (Fig. 1A) steps of template-based genomic editing by Nme2Cas9 nickase, DNA-dependent DNA polymerase, and a template guide RNA, including (Fig. IB) subsequent repair of the nick site.Figure 2 shows schematics of an exemplary template guide RNA complexed with a DNA duplex target nucleic acid indicated as being present in genomic DNA. The guide RNA spacer is complementary to the target strand of the DNA duplex target nucleic acid and the DNA polymerase recruiting sequence (DRS) is complementary to the non-target strand of the DNA duplex target nucleic acid at a site 5’ of the nick in the non-target strand of the DNA duplex target nucleic acid. The template sequence represents incorporation of two templated edits in the target nucleic acid.Figure 3 is a graph showing editing efficiency at the SCAP locus in Huh7 cells treated with a tgRNA (G037346) and various mRNA constructs encoding a fusion protein comprising a T5 polymerase or a Polymerase Kappa moiety N-terminal or C-terminal relative to a Nme2Cas9 nickase moiety.Figure 4 is a graph showing editing efficiency at the SCAP locus in PHH cells treated with a tgRNA comprising a sgRNA (G037343) and a MS2-loop-linked 3’ extension (ST036058), an mRNA encoding Vpx; and mRNAs encoding a MCP sequence fused to the polymerasesequence and a nCas9 sequence, wherein the nCas9 and polymerase sequences are delivered in trans or in cis.Figure 5 is a graph showing editing efficiency at the SCAP locus in PHH cells treated with a tgRNA comprising a sgRNA (G025438) and a MS2-loop-linked 3’ extension (ST039208), along with a ngRNA (GO36183) and (i) a mRNA encoding a fusion protein comprising a Nme nickase moiety, a HMGB1 moiety, and optionally a coiled coil sequence (e.g., P4 or N6) or an intein moiety (e.g., InteinC), and (ii) a mRNA encoding a fusion protein comprising an aptamerbinding (MCP) sequence, a polymerase (e.g., T5 or PolK variant)Figure 6 is a graph showing editing efficiency at the SCAP locus in PHH cells treated with a tgRNA comprising a sgRNA (G025438) and a MS2-loop-linked 3’ extension (ST039208), ngRNA (GO36183), and various mRNAs encoding an aptamer-binding (MCP) sequence, a polymerase Kappa variant moiety, and a Nme2Cas9 variant moiety, wherein the polymerase Kappa variant moiety and the Nme2Cas9 variant moieties were delivered (i) in cis, (ii) in trans, or (iii) in trans with complementary intein moieties.Figure 7 is a graph showing editing efficiency at the SCAP locus in Huh7 cells treated with a gRNA comprising a sgRNA and a MS2-loop-linked 3’ extension, a ngRNA and various mRNA constructs encoding a fusion protein comprising a MCP sequence, a T5 polymerase or a Polymerase Kappa moiety and a Nme2Cas9 nickase moiety, without or with a HMGB1 moiety.Figure 8. is a graph showing editing efficiency at the SCAP locus in Huh7 cells treated with a tgRNA comprising a sgRNA (G021516) and a MS2-loop-linked 3’ extension (ST036058), a ngRNA (GO36183) and various mRNAs encoding fusion proteins comprising a MCP sequence, a Nme2Cas9 nickase moiety, a full length or a shortened polymerase Kappa variant moiety, and a HMGB1 moiety, with different linkers between the polymerase Kappa variant and Nme2Cas9 nickase moieties.Figures 9A-9D. Figure 9A is a graph showing editing efficiency at the SCAP locus in primary rat hepatocytes (PRH) with a single tgRNA (TG040203) and mRNAs encoding a variant Nme2nCas9 and either T5 polymerase or polymerase Kappa, encoded as either as a single polypeptide fusion protein or as two poly peptides (in trans) with intein moieties to promote polypeptide fusion, at the 200ng mRNA dose. Figure 9B is a graph showing editing efficiency at the SCAP locus in Huh7 cells with a single tgRNA (TG040203) and mRNAs encoding a variant Nme2nCas9 and either T5 polymerase or polymerase Kappa, encoded either as a singlepolypeptide fusion protein or as two polypeptides (in trans) with intein moieties to promote polypeptide fusion, at the 200ng mRNA dose. Figure 9C is a graph showing editing efficiency at the SCAP locus in PRH cells with a tgRNA comprising a sgRNA (G021516) and a MS2-loop-linked 3’ extension (ST039208) and mRNAs encoding an aptamer-binding (MCP) sequence fused to either T5 polymerase or polymerase Kappa; and an Nme2nCas9 variant, encoded either as a single polypeptide fusion protein or as two mRNA (in trans) with intein moieties to promote polypeptide fusion, at the 200ng dose. Figure 9D is a graph showing efficiency of editing at the SCAP locus in Huh7 cells with a tgRNA comprising a sgRNA (G021516) and a MS2-loop-linked 3’ extension (ST039208) and mRNAs encoding an aptamer-binding (MCP) sequence fused to either T5 polymerase or polymerase Kappa; and an Nme2nCas9 variant delivered either as a single polypeptide fusion protein or as two mRNA (in trans) with intein moieties to promote polypeptide fusion at the 200ng dose.Figure 10 is a graph showing editing efficiency at the EWSR1 locus in PRH cells treated with a tgRNA comprising a sgRNA (G039064) and a MS2-loop-linked 3’ extension (ST039177), and various mRNAs encoding an aptamer-binding (MCP) sequence, a polymerase, a Nme2Cas9 variant moiety. Polymerase-InteinN and InteinC-Nme2nCas9 were mixed 4:1, 1:1, 1:4 ratio to assess editing outcome.Figure 11 is a graph showing editing efficiency at the EWSR1 locus in PRH cells at the 300ng dose treated with a tgRNA comprising a sgRNA (G039064) and a MS2-loop-linked 3’ extension (ST040416), and mRNAs encoding a Nme2Cas9 nickase moiety and a full length or a shortened polymerase Kappa variant moiety comprising a MCP sequence, delivered in trans.Figure 12A-12C. Figure 12A is a graph showing editing efficiency at the SCAP locus in Huh7 cells treated with a tgRNA comprising a sgRNA (G021516) and a MS2-loop-linked 3’ extension (ST036058), ngRNA (GO36183), and a dilution series of a mRNA encoding a fusion protein comprising a MCP sequence, a PolK polymerase moiety, an Nme2Cas9 nickase moiety, and optionally a HMGB1 moiety. Figure 12B is a graph showing editing efficiency at the SCAP locus in Huh7 cells treated with a tgRNA comprising a sgRNA (G021516) and a MS2-loop-linked 3’ extension (ST036058), ngRNA (GO36183), and a dilution series of a mRNA encoding a fusion protein comprising a MCP sequence, a T5 polymerase moiety, an Nme2Cas9 nickase moiety, and optionally a HMGB1 moiety. Figure 12C is a graph showing editing efficiency withthe highest dose of mRNA encoding the polymerase-Cas fusion polypeptide for both PolK and T5 polymerases.Figure 13A is a schematic of an exemplary Nme2 Cas9 sgRNA with the nucleotide positions numbered as in this application. The color coding indicates bases amenable to single or pairwise deletion (open circles), bases amenable to substitution with a long linker (checked fill with solid outline), and bases amenable to substitution with a short linker (crosshatch fill with solid outline).Figure 13B shows an exemplary sgRNA of 101 nucleotides in length in a possible secondary structure. The unmodified nucleotides are shown in bold and methylation is shown in light fonts; phosphorothioate linkages are indicated by Watson- Crick base pairing is indicated by a —between nucleotides in duplex portions. Non- Watson-Crick base pairing is indicated by • between nucleotides. Figure discloses SEQ ID NO: 1845.Figure 13C shows an exemplary sgRNA of 105 nucleotides in length in a possible secondary structure. The unmodified nucleotides are shown in bold and methylation is shown in light fonts; phosphorothioate linkages are indicated by Watson- Crick base pairing is indicated by a —between nucleotides in duplex portions. Non- Watson-Crick base pairing is indicated by • between nucleotides. Figure discloses SEQ ID NO: 1846.Figures 14A-I show schematic representation of various Cas9 Nme2 template guide (tgRNA) formats.Figure 14A shows a single molecule Nme-nCas9 tgRNA with a sgRNA (spacer and scaffold) with a 3’ extension (template and DRS) attached directly to the 3’ end of the scaffold.Figure 14B shows a single molecule Nme-nCas9 tgRNA with a sgRNA (spacer and scaffold) with a 3’ extension (template and DRS) attached to the 3’ end of the scaffold with a linker, providing a structure wherein the template and DRS are not directly linked to the scaffold by a phosphodiester or phosphorothioate linkage.Figure 14C shows an Nme-nCas9 tgRNA with a hairpin 2 insertion. The first polynucleotide is an sgRNA (spacer and scaffold) wherein the scaffold sequence terminates at the end of the 5’ portion of hairpin2. The second polynucleotide is a 3’ extension (template and DRS) with a sequence 3’ of the DRS complementary to the 5’ portion of hairpin 2 in the scaffold polynucleotide. Annealing of the first and second polynucleotide provide a hairpin 2 structure with a 3’ extension extending from the portion of hairpin 2 where the loop would typically be.Figure 14D shows a schematic with exemplary first polynucleotide scaffold sequence and an exemplary second polynucleotide scaffold sequence wherein the 3 ’ extension sequences (template and DRS) are at the 3’ end of the hairpin 2 sequence. Figure 14E shows exemplary sequences to provide the structure in Figure 14C. In Figure 14D and 14E, the loops at the apex of the repeat-anti-repeat region and hairpin 1 represent internal linkers. In the Figure 14C-E structures, the template and DRS are linked to the scaffold by base pairing. In Figures 14D, 14E, and 14G, a “+” denotes 2'-0Me modification. Figure discloses SEQ ID NOS 1847-1850 and 1857-1860, respectively, in order of appearance.Figure 14F shows a schematic similar to Figure 14C except the 5’ end of the template is covalently linked to the 3’ end of the 5’ portion of hairpin 2 via linker.Figure 14G shows a schematic with exemplary nucleotide sequence for the structure provided in Figure 14F. In Figure 14G, the loops at the apex of the repeat-anti-repeat region and hairpin 1 represent internal linkers. depicts unconventional base pairings. Figure discloses SEQ ID NOS 1851-1855, respectively, in order of appearance.Figure 14H shows a schematic of an Nme2 Cas9 sgRNA with a 3’ extension including an aptamer at the 5’ end.Figure 141 shows a schematic with an exemplary sequence and chemical modification pattern for an MS2 hairpin attached to the 5’ end of a 3’ extension. Nucleotides depicted in bold are 2’-0Me modified. For Figure 141 only, circles indicate 2’-0Me modification. Nucleotides depicted in gray are dNTP (G at position 7 from the 5’ end; entire template region; and the first 5' end DRS (" C")). Figure discloses SEQ ID NO: 1856.Figure 15 is a graph showing editing efficiency at the SCAP locus in Huh7 cells treated with a mRNA encoding either one of a T5Pol-nCas9 or a nCas9-PolK(GE> RV) with template guide RNAs having various formats including a single molecule tgRNA with two tandem or one SI 8 linker, or a deoxyribose modification to create an abasic site; with a split hairpin tgRNA in which the 3’ extension template-DRS sequences extend from the stem loop position in hairpin 2 of the Cas9Nme2 guide RNA, optionally with an SI 8 tether sequences or a di deoxyribose modification between the guide scaffold and the extension comprising; and an sgRNA paired with a MS2-loop-linked 3 ’-extension.Figure 16 is a graph showing editing efficiency at the SCAP locus in Huh7 cells treated with a mRNA encoding MCP-T5-nCas9-HMGB1, an ngRNA, and an sgRNA paired with aMS2-loop-linked 3 ’-extension, a single molecule tgRNA or a split hairpin tgRNA, comprising one or two tandem S 18 tether sequences or a dideoxyribose modification between the guide scaffold (or the MS2 loop sequence in the case of the tgRNA with a separable 3’ extension) and the extension comprising, 5’ to 3’, the DNA template and the DRS sequence.Figure 17 is a graph showing editing efficiency at the SCAP locus in Hepal-6 cells treated with a tgRNA comprising a sgRNA and various MS2-loop-linked 3 ’-extension differing in the number and position of their MS2 loop sequences, along with mRNA constructs encoding a fusion protein comprising a MCP sequence, a T5 polymerase moiety or a Polymerase Kappa variant moiety, a Nme2Cas9 nickase moiety, and a HMGB1 moiety.Figures 18A-18B are graphs showing editing efficiency at the SCAP locus in Huh7 cells treated with a mRNA encoding one of (A) Nme2(E932R)-POLK(GE> RV, 1-526) of (B) POLK(GE> RV,l-526)-Nme2(E932R) or, and tgRNAs comprising a spacer targeting the SCAP site and DNA template and DRS were added at the 3’ of guide scaffold (TG040203), or inserted at the tip of hairpin2 flanked with a basic nucleotide (TG040199), S18-PEG linker (TG040200), or 2 base pair extension plus S18-PEG linker (TG040208).DETAILED DESCRIPTIONThe present disclosure provides, e.g., compositions, methods, and systems for templatebased genome editing. In some embodiments, the compositions, methods, and systems provide for generating templated insertions, deletions, or substitutions within the genome of a cell without the involvement of the HDR pathway.In some embodiments, the compositions, methods, and systems disclosed herein comprise a Neisseria meningitidis Cas9 nickase (Nme-nCas9), e.g., Nme2-nCas9, a DNA-dependent DNA polymerase (DDP), and template guide RNA (tgRNA).Without being bound by theory, an exemplary tgRNA according to the present disclosure may comprise an Nme-Cas guide RNA that is capable of binding to the Nme2 Cas9 nickase (Nme-nCas) (via a scaffold sequence) and a target region of a target strand of a DNA duplex target nucleic acid (via a spacer sequence) (see, e.g., Fig. 1 A). The Nme-Cas9 guide RNA thereby facilitates binding of the Nme2-nCas9 to the target region. The Nme2-nCas9 nickase preferably comprises a substitution in the HNH nuclease domain (e.g., a H588A substitution). Once bound to the target region, the Nme2-nCas9 nickase may generate a nick in a non-targetstrand of the DNA duplex target nucleic acid. The nicked strand of the DNA duplex target nucleic acid may comprise a flap 5’ of the nick (the 3’ end flap) and a flap 3’ of the nick (the 5’ end flap) (see Fig. 2, which show the 3’ end of the flap 5’ of the nick and the 5’ end of the flap 3’ of the nick).An exemplary tgRNA according to the present disclosure may further comprise a 3’ extension comprising (from 5’ to 3’) a template sequence and a DNA polymerase-recruiting sequence (DRS). The DRS may be designed to hybridize to the 3’ end of the flap 5’ of the nick in the non-target strand of the DNA duplex target nucleic acid, thereby forming a duplex (see, e.g., Figs. 1 and 2). Subsequently, the DNA-dependent DNA polymerase may bind to the duplex formed by the DRS and 3’ end of the flap 5’ of the nick. The 3’ end of the flap 5’ of the nick may serve as a primer for synthesis of a new DNA strand that is complementary to the template sequence. The template sequence may include one or more of an insertion, deletion, or substitution (e.g., a transition or a transversion) relative to an endogenous nucleotide sequence. For example, Fig. 2 show an exemplary template comprising a two-nucleotide substitution relative to the endogenous nucleotide sequence. Following DNA synthesis, the newly synthesized DNA strand may include one or more of an insertion, deletion, or substitution relative to the endogenous nucleotide sequence (see Fig. 1, which shows the newly synthesized DNA strand with an edit relative to the endogenous DNA sequence). As shown in Fig. IB, the newly synthesized DNA strand and the flap 3’ of the nick may competitively bind to the target strand. The flap 3’ of the nick may be excised, for example by FEN1 or EXO1, and the newly synthesized DNA strand may anneal to the target strand. Subsequent mismatch repair may result in either (1) repair of the unedited strand using the newly synthesized DNA strand, thereby incorporating the insertion, deletion, or substitution into the genomic sequence; or (2) repair of the edited strand using the unedited strand, thereby preserving the original sequence.The compositions and methods provided herein further may comprise one or more enhancers of template-based genome editing. In some embodiments, such enhancers may promote DNA synthesis by increasing the concentration of dNTPs within the cell, e.g., by inhibiting a deoxynucleotide triphosphohydrolase protein. In some embodiments, such enhancers may promote the hybridization of the newly synthesized DNA strand and the target strand. For example, DNA repair proteins may remove the flap 3 ’ of the nick. Removal of the flap 3 ’ of thenick may promote hybridization of the newly synthesized DNA strand to the target strand of the DNA duplex target nucleic acid.Compositions comprising (1) Nme2-nCas9, (2) an RNA-dependent DNA polymerase (e.g., a reverse transcriptase), and (3) a guide RNA comprising an RNA-based template sequence have previously been shown to install templated edits into genomic sequences. However, such compositions and methods can produce unintended genetic modifications. Thus, the utility of such compositions and methods is currently limited. For example, after synthesizing a new DNA strand that is complementary to the template sequence, RNA-dependent DNA polymerases may continue DNA synthesis, using the scaffold of the Nme-Cas9 guide RNA as a template and thereby creating unintended modifications whereby a portion of the scaffold sequence is inadvertently incorporated into the DNA. Accordingly, there is a need for compositions and methods that do not run the risk of incorporating the Nme-Cas9 guide RNA scaffold sequence into the newly sequenced DNA strand.Exemplary compositions according to the present disclosure comprise DNA-dependent DNA polymerases instead of RNA-dependent DNA polymerases. DNA-dependent DNA polymerases such as T5 polymerase and PolK polymerase have a strong preference for DNA templates, and may therefore exhibit a reduced propensity to continue DNA synthesis past a DNA-RNA boundary, such as the boundary between a template sequence comprising a plurality of DNA nucleotides and a Nme-Cas9 guide RNA scaffold sequence comprising RNA nucleotides.Additionally, there is a need for enzymes (e.g., Nme2-nCas9 and DNA-dependent DNA polymerases) with robust templated editing activity at physiological temperatures, e.g., 37°C.In some embodiments, the present disclosure provides for a system comprising a DNA-dependent DNA polymerase, an Nme2Cas9 nickase (Nme2-nCas9), and a template guide RNA (tgRNA), wherein the tgRNA comprises a first polynucleotide and a second polynucleotide, wherein: (a) the first polynucleotide comprises an Nme-Cas9 guide RNA comprising: (i) a spacer that is complementary to a target region of a target strand of a DNA duplex target nucleic acid; and (ii) a scaffold; and (b) the second polynucleotide is operably linked to the first polynucleotide and comprises: (i) a template sequence that is at least 10 nucleotides in length and complementary to at least a portion of a non-target strand of the DNA duplex target nucleic acid, wherein the template sequence comprises a 3’ end and a 5’ end; and wherein the templatecomprises DNA nucleotides; (ii) a DNA-dependent DNA polymerase recruiting sequence (DRS) that is 6-20 nucleotides in length, optionally 6-17 or 10-14 nucleotides in length and having a 3’ end and a 5’ end; wherein the 5’ end of the DRS is covalently attached to the 3’ end of the template sequence, and wherein the DRS comprises a sequence that is complementary to at least 6 nucleotides of a DRS-complementary region of the non-target strand of the DNA duplex target nucleic acid. In some embodiments, the DRS of the tgRNA comprises DNA nucleotides. In some embodiments, the DRS of the tgRNA comprises both RNA nucleotide(s) and DNA nucleotide(s).In some embodiments, the present disclosure provides for a system comprising a DNA-dependent DNA polymerase, an Nme2Cas9 nickase (nCas9), and a template guide RNA (tgRNA), wherein the tgRNA comprises a first polynucleotide and a second polynucleotide, wherein: (a) the first polynucleotide comprises an Nme-Cas9 guide RNA comprising: (i) a spacer that is complementary to a target region of a target strand of a DNA duplex target nucleic acid; and (ii) a scaffold; and (b) the second polynucleotide is operably linked to the first polynucleotide and comprises: (i) a template sequence that is at least 10 nucleotides in length and complementary to at least a portion of a non-target strand of the DNA duplex target nucleic acid, wherein the template sequence comprises a 3’ end and a 5’ end; and wherein the template comprises DNA nucleotides; (ii) a DNA-dependent DNA polymerase recruiting sequence (DRS) that is 6-20 nucleotides in length, optionally 6-17 or 10-14 nucleotides in length and having a 3’ end and a 5’ end; wherein the 5’ end of the DRS is covalently attached to the 3’ end of the template sequence wherein the covalent attachment is not a direct phosphorothioate or phosphodiester linkage, and wherein the DRS comprises a sequence that is complementary to at least 6 nucleotides of a DRS-complementary region of the non-target strand of the DNA duplex target nucleic acid, the DRS comprises DNA nucleotides; and wherein the DRS comprises at least one of: (1) a sequence not fully complementary to the DRS-complementary region of the non-target strand of the DNA duplex target nucleic acid; (2) a 1-5 nucleotide, optionally a 1-3 nucleotide 3’ terminal tail comprising a 3’ terminal modified uridine nucleotide; or (3) a 5’ terminal (DI) DNA nucleotide and a penultimate 5’ terminal (D2) RNA nucleotide wherein the 3’ end of the first polynucleotide is covalently linked to the 5’ end of the second polynucleotide by a phosphorothioate or phosphodiester linkage.In some embodiments, the present disclosure provides for a system comprising a DNA-dependent DNA polymerase, an Nme2-nCas9, and a template guide RNA (tgRNA), wherein thetgRNA comprises a first polynucleotide and a second polynucleotide, wherein: (a) the first polynucleotide comprises an Nme-Cas9 guide RNA comprising: (i) a spacer that is complementary to a target region of a target strand of a DNA duplex target nucleic acid; and (ii) a scaffold; and (b) the second polynucleotide is operably linked to the first polynucleotide and comprises: (i) a template sequence that is at least 10 nucleotides in length and complementary to at least a portion of a non-target strand of the DNA duplex target nucleic acid, wherein the template sequence comprises a 3’ end and a 5’ end; and wherein the template comprises DNA nucleotides; (ii) a DNA-dependent DNA polymerase recruiting sequence (DRS) that is 6-20 nucleotides in length, optionally 6-17 or 10-14 nucleotides in length and having a 3’ end and a 5’ end; wherein the 5’ end of the DRS is not covalently attached to the 3’ end of the template sequence, and wherein the DRS comprises a sequence that is complementary to at least 6 nucleotides of a DRS-complementary region of the non-target strand of the DNA duplex target nucleic acid, wherein the DRS comprises RNA nucleotides; and wherein the DRS comprises at least one of: (1) a sequence not fully complementary to the DRS-complementary region of the non-target strand of the DNA duplex target nucleic acid; (2) a 1-5 nucleotide, optionally a 1-3 nucleotide 3’ terminal tail comprising a 3’ terminal modified uridine nucleotide; or (3) a 5’ terminal (DI) DNA nucleotide and a penultimate 5’ terminal (D2) RNA nucleotide wherein the 3’ end of the first polynucleotide is covalently linked to the 5’ end of the second polynucleotide by a phosphorothioate or phosphodiester linkage.In some embodiments, the present disclosure provides for a system comprising a DNA polymerase kappa (polK), Nme2-nCas9, and a template guide RNA (tgRNA), wherein the tgRNA comprises a first polynucleotide and a second polynucleotide, wherein (a) the first polynucleotide comprises a Nme-Cas9 guide RNA comprising: (i) a spacer that is complementary to a target region of a target strand of a DNA duplex target nucleic acid; and (ii) a scaffold; and (b) the second polynucleotide is operably linked to the first polynucleotide and comprises: (i) a template sequence that is at least 10 nucleotides in length and complementary to at least a portion of a non-target strand of the DNA duplex target nucleic acid, wherein the template sequence comprises a 3’ end and a 5’ end; and wherein the template comprises DNA nucleotides; (ii) a DNA-dependent DNA polymerase recruiting sequence (DRS) that is about 6-18 nucleotides in length, optionally about 8-18 or 10-12 nucleotides in length and having a 3’ end and a 5’ end; wherein the 5’ end of the DRS is covalently attached to the 3’ end of thetemplate sequence, and wherein the DRS comprises a sequence that is complementary to at least 6 nucleotides of a DRS-complementary region of the non-target strand of the DNA duplex target nucleic acid. In some embodiments, the DRS of the tgRNA comprises DNA nucleotides. In some embodiments, the DRS of the tgRNA comprises both RNA nucleotide(s) and DNA nucleotide(s).In some embodiments, the present disclosure provides for a system comprising a DNA polymerase kappa (polK), an Nme2-nCas9, and a template guide RNA (tgRNA), wherein the tgRNA comprises a first polynucleotide and a second polynucleotide, wherein (a) the first polynucleotide comprises an Nme-Cas9 guide RNA comprising: (i) a spacer that is complementary to a target region of a target strand of a DNA duplex target nucleic acid; and (ii) a scaffold; and (b) the second polynucleotide is operably linked to the first polynucleotide and comprises: (i) a template sequence that is at least 10 nucleotides in length and complementary to at least a portion of a non-target strand of the DNA duplex target nucleic acid, wherein the template sequence comprises a 3’ end and a 5’ end; and wherein the template comprises DNA nucleotides; (ii) a DNA-dependent DNA polymerase recruiting sequence (DRS) that is about 6-18 nucleotides in length, optionally about 8-18 or 10-12 nucleotides in length and having a 3’ end and a 5’ end; wherein the 5’ end of the DRS is covalently attached to the 3’ end of the template sequence, and wherein the DRS comprises a sequence that is complementary to at least 6 nucleotides of a DRS-complementary region of the non-target strand of the DNA duplex target nucleic acid, wherein the DRS comprises RNA nucleotides.In some embodiments, the present disclosure provides for a system comprising a T5 DNA polymerase (T5 pol), an Nme2-nCas9, and a template guide RNA (tgRNA), wherein the tgRNA comprises a first polynucleotide and a second polynucleotide, wherein (a) the first polynucleotide comprises an Nme-Cas9 guide RNA comprising: (i) a spacer that is complementary to a target region of a target strand of a DNA duplex target nucleic acid; and (ii) a scaffold; and (b) the second polynucleotide is operably linked to the first polynucleotide and comprises: (i) a template sequence that is at least 10 nucleotides in length and complementary to at least a portion of a non-target strand of the DNA duplex target nucleic acid, wherein the template sequence comprises a 3’ end and a 5’ end; and wherein the template comprises DNA nucleotides; and (ii) a DNA-dependent DNA polymerase recruiting sequence (DRS) that is 6-20 nucleotides in length, optionally 6-17 or 10-14 nucleotides in length, and having a 3’ end and a 5’ end; wherein the 5’ end of the DRS is covalently attached to the 3’ end of the templatesequence, and wherein the DRS comprises a sequence that is complementary to at least 6 nucleotides of a DRS-complementary region of the non-target strand of the DNA duplex target nucleic acid comprising nucleotides 5-105’ of the PAM in the non-target strand of the DNA duplex target nucleic acid. In some embodiments, the DRS of the tgRNA comprises DNA nucleotides. In some embodiments, the DRS of the tgRNA comprises both RNA nucleotide(s) and DNA nucleotide(s).In some embodiments, the present disclosure provides for a system comprising a T5 DNA polymerase (T5 pol), an Nme2-nCas9, and a template guide RNA (tgRNA), wherein the tgRNA comprises a first polynucleotide and a second polynucleotide, wherein (a) the first polynucleotide comprises an Nme-Cas9 guide RNA comprising: (i) a spacer that is complementary to a target region of a target strand of a DNA duplex target nucleic acid; and (ii) a scaffold; and (b) the second polynucleotide is operably linked to the first polynucleotide and comprises: (i) a template sequence that is at least 10 nucleotides in length and complementary to at least a portion of a non-target strand of the DNA duplex target nucleic acid, wherein the template sequence comprises a 3’ end and a 5’ end; and wherein the template comprises DNA nucleotides; and (ii) a DNA-dependent DNA polymerase recruiting sequence (DRS) that is 6-20 nucleotides in length, optionally 6-17 or 10-14 nucleotides in length, and having a 3’ end and a 5’ end; wherein the 5’ end of the DRS is covalently attached to the 3’ end of the template sequence, and wherein the DRS comprises a sequence that is complementary to at least 6 nucleotides of a DRS-complementary region of the non-target strand of the DNA duplex target nucleic acid comprising nucleotides 5-105’ of the PAM in the non-target strand of the DNA duplex target nucleic acid, wherein the DRS comprises RNA nucleotides..In some embodiments, the first polynucleotide and the second polynucleotide are covalently linked wherein the covalent attachment is not a direct phosphorothioate or phosphodiester linkage. In some embodiments, the first polynucleotide and the second polynucleotide are not covalently linked. In some embodiments, the template guide RNA further comprises an affinity tag, wherein the first polynucleotide or the second polynucleotide are bound to a peptide or a peptide complex comprising an Nme2-nCas9, and a DNA-dependent DNA polymerase by the affinity tag.In some embodiments, the composition further comprises an Nme2-nCas9. In some embodiments, the scaffold of the Nme-Cas9 guide RNA binds to an Nme2-nCas9. In someembodiments, the Nme2-nCas9 generates a nick on the same strand of the DNA duplex target nucleic acid as a nickase comprising an H588A mutation, i.e., the Nme2-nCas9 cleaves the strand of the DNA duplex target nucleic acid opposite to the strand of the DNA duplex target nucleic acid that hybridizes to the spacer (i.e., the nickase cleaves the non-target strand of the DNA duplex target nucleic acid). In some embodiments, the Nme2-nCas9 generates a nick on the non-target strand of the DNA duplex target nucleic acid. In some embodiments, the Nme2-nCas9 comprises a catalytically inactive HNH domain. In some embodiments, the Nme2-nCas9 comprises an H588A or an H588S mutation within its HNH-like nuclease domain. In some embodiments, the Nme2-nCas9 comprises an H588A point mutation. Throughout the present disclosure, it is to be understood that, when the term “point mutation” is used in the context of an amino acid sequence, it refers to a substitution of a single amino acid residue in the amino acid sequence.In some embodiments, the composition further comprises a DNA-dependent DNA polymerase. In some embodiments, the DRS bound to the non-target strand of the DNA duplex target nucleic acid forms a binding site for DNA-dependent DNA polymerase. In some embodiments, the DNA-dependent DNA polymerase comprises a eukaryotic DNA-dependent DNA polymerase. In some embodiments, the DNA-dependent DNA polymerase comprises a mammalian DNA-dependent DNA polymerase. In some embodiments, the DNA-dependent DNA polymerase comprises a human DNA-dependent DNA polymerase. In some embodiments, the DNA-dependent DNA polymerase comprises a cynomolgus DNA-dependent DNA polymerase. In some embodiments, the DNA-dependent DNA polymerase comprises a mouse DNA-dependent DNA polymerase. In some embodiments, the DNA-dependent DNA polymerase comprises a bacterial DNA-dependent DNA polymerase. In some embodiments, the DNA-dependent DNA polymerase comprises an E. coli DNA polymerase. In some embodiments, the DNA-dependent DNA polymerase comprises a viral DNA-dependent DNA polymerase. In some embodiments, the DNA-dependent DNA polymerase comprises a phage DNA-dependent DNA polymerase. In some embodiments, the DNA-dependent DNA polymerase comprises human DNA polymerase K, cynomolgus DNA polymerase K, mouse DNA polymerase K, human DNA polymerase 0, human DNA polymerase N, E. coli DNA polymerase I, phage T5 DNA polymerase, or phage Phi29 DNA polymerase. In some embodiments, the DNA-dependent DNA polymerase comprises human DNA polymerase K. Insome embodiments, the DNA-dependent DNA polymerase comprises phage T5 DNA polymerase. In some embodiments, the DNA-dependent DNA polymerase does not comprise phage Phi29 DNA polymerase. In some embodiments, the DNA-dependent DNA polymerase comprises a point mutation(s) or deletion(s). In some embodiments, the DNA-dependent DNA polymerase comprises a point mutation(s) or deletion(s) within an exonuclease domain. In some embodiments, the point mutation(s) or deletion(s) within the exonuclease domain abolishes exonuclease activity.In some embodiments, the Nme2-Cas9 nickase (Nme2-nCas9) is operably linked to the DNA-dependent DNA polymerase. In some embodiments, the Nme2-nCas9 and DNA-dependent DNA polymerase comprise a single polypeptide. In some embodiments, the Nme2-nCas9 and DNA-dependent DNA polymerase comprise a single polypeptide expressed from a single open reading frame (ORF). In some embodiments, the Nme2-nCas9 and DNA-dependent DNA polymerase comprise a single polypeptide expressed from separate open reading frames (ORFs). In some embodiments, wherein the Nme2-nCas9 and DNA-dependent DNA polymerase comprise a single polypeptide expressed from separate open reading frames (ORFs), the ORF encoding the Nme2-nCas9 can further encode a first intein and the ORF encoding the DNA-dependent DNA polymerase can further encode a second intein capable of binding the first intein (i.e. participating in a trans-splicing reaction with the first intein). In some embodiments, the Nme2-nCas9 and DNA-dependent DNA polymerase are provided as separate polypeptides. In some embodiments, wherein the Nme2-nCas9 and DNA-dependent DNA polymerase comprise a single polypeptide expressed form separate open reading frames (ORFs), the ORF encoding the Nme2-nCas9 can further encode a first intein and the ORF encoding the DNA-dependent DNA polymerase can further encode a second intein capable of binding the first intein (i.e. participating in a trans-splicing reaction with the first intein). In some embodiments, the Nme2-nCas9 and DNA-dependent DNA polymerase are provided as separate polypeptides. In some embodiments, the Nme2-nCas9 and DNA-dependent DNA polymerase directly interact through non-covalent interactions. In some embodiments, the Nme2-nCas9 and DNA-dependent DNA polymerase do not directly interact. As a first example, in some embodiments, the Nme2-nCas9 and DNA-dependent DNA polymerase may both non-covalently bind a single polynucleotide such as a template guide RNA. As a second example, in some embodiments, the Nme2-nCas9 may bind a first polynucleotide comprising a guide RNA and the DNA-dependent DNApolymerase may bind a second polynucleotide comprising a separable 3’ extension, wherein the first and second polynucleotides target the Nme2-nCas9 and DNA-dependent DNA polymerase to proximal genomic loci.In some embodiments, the composition comprises (a) a single polypeptide comprising Nme2-nCas9 and a DNA-dependent DNA polymerase; and (b) a single polynucleotide comprising, from 5’ to 3’, (i) an Nme-Cas9 guide RNA comprising a spacer and a scaffold; and (ii) a template sequence and a DRS, wherein the scaffold is not covalently attached directly to template sequence and DRS by a phosphorothioate or phosphodiester linkage.In some embodiments, the composition comprises (a) a single polypeptide comprising an Nme2-nCas9 nickase and a DNA-dependent DNA polymerase; (b) a first polynucleotide comprising an Nme-Cas9 guide RNA comprising, from 5’ to 3’, a spacer and a scaffold; and (c) a second polynucleotide comprising, from 5’ to 3’, a template sequence and a DRS, wherein the first and second polynucleotide are provided as separate molecules, optionally wherein the second polynucleotide comprises an affinity tag, optionally an aptamer, for binding to the DNA-dependent DNA polymerase, wherein the affinity tag is preferably 5’ of the template sequence.In some embodiments, the composition comprises (a) a first polypeptide comprising an Nme2-nCas9; (b) a second polypeptide comprising a DNA-dependent DNA polymerase; and (c) a single polynucleotide comprising, from 5’ to 3’, (i) an Nme-Cas9 guide RNA comprising a spacer and a scaffold; and (ii) a template sequence and a DRS, wherein the first and second polynucleotide are provided as separate molecules, optionally wherein the second polynucleotide comprises an affinity tag, optionally an aptamer, for binding to a 3’ extension-recruiting domain on the DNA-dependent DNA polymerase. In some embodiments, the Nme2-nCas9 and DNA-dependent DNA polymerase directly interact through non-covalent interactions. In some embodiments, the Nme2-nCas9 and DNA-dependent DNA polymerase do not directly interact. In some embodiments, the Nme2-nCas9 and DNA-dependent DNA polymerase may both non-covalently bind a single polynucleotide such as a template guide RNA.In some embodiments, the composition comprises (a) a first polypeptide comprising an Nme2-nCas9; (b) a second polypeptide comprising a DNA-dependent DNA polymerase and a 3’ extension-recruiting domain; (c) a first polynucleotide comprising a Nme-Cas9 guide RNA comprising, from 5’ to 3’, a spacer and a scaffold; and (d) a second polynucleotide comprising, from 5’ to 3’, a template sequence and a DRS, and further comprising an affinity tag, preferably5’ of the template sequence; wherein the first and second polypeptide and first and second polynucleotide are provided as separate molecules. In some embodiments, the Nme2-nCas9 and DNA-dependent DNA polymerase directly interact through non-covalent interactions. In some embodiments, the Nme2-nCas9 and DNA-dependent DNA polymerase do not directly interact. In some embodiments, the Nme2-nCas9 may bind a first polynucleotide comprising a guide RNA and the DNA-dependent DNA polymerase may bind a second polynucleotide comprising a separable 3’ extension, wherein the first and second polynucleotides target the Nme2-nCas9 and DNA-dependent DNA polymerase to proximal genomic loci.In some embodiments, the composition further comprises a nicking guide RNA. The ngRNA comprises a spacer that hybridizes to a sequence such that the nick site of the ngRNA is within 200 nucleotides 5’ or 3’ from the nick site of the template guide RNA and on the target strand of the DNA duplex target nucleic acid, i.e., the strand to which the spacer of the tgRNA hybridizes. In other words, the ngRNA / Nme2Cas9 complex nicks the strand opposite to the strand nicked by the tgRNA / Nme2Cas9 complex. In some embodiments, the nick site of the ngRNA is about 20-200 nucleotides 5’ or 3’ from the nick site of the template guide RNA and on the target strand of the DNA duplex target nucleic acid. In some embodiments, the nick site of the ngRNA is within the genomic locus targeted by the spacer sequence of the template guide RNA. In some embodiments, the nick site of the ngRNA is preferably outside of the genomic locus targeted by the spacer sequence of the template guide RNA.In some embodiments, the composition further comprises an enhancer of template-based genome editing. In some embodiments, the enhancer is an inhibitor of deoxynucleotide triphosphohydrolase. In some embodiments, wherein the enhancer is an inhibitor of deoxynucleotide triphosphohydrolase, the deoxynucleotide triphosphohydrolase comprises SAM domain and HD domain-containing protein 1 (SAMHD1). In some embodiments, inhibiting SAMHD1 comprises contacting the SAMHD1 with a Vpx, BGLF4, M97, or KSHV ORF36 protein, or expressing the Vpx, BGLF4, M97, or KSHV ORF36 protein in a cell. In some embodiments, inhibiting SAMHD1 comprises contacting an mRNA encoding the SAMHD1 with a microRNA, shRNA, or siRNA that hybridizes to the mRNA, or expressing the microRNA, shRNA, or siRNA in a cell. In some embodiments, inhibiting SAMHD1 comprises contacting the SAMHD1 with a small molecule SAMHD1 inhibitor. In some embodiments, the enhancer is a DNA repair protein. In some embodiments, the DNA repair protein is a single-strandedendonuclease that removes flaps comprising a free 5’ end, i.e., flaps 3’ of a nick. In some embodiments, the DNA repair protein is a single-stranded endonuclease that removes flaps 5’ of a nick. In some embodiments, the DNA repair protein is flap structure-specific endonuclease 1 (FEN1) or a polynucleotide encoding FEN1. In some embodiments, the DNA repair protein is mutL homolog 1 (MLH1) or a polynucleotide encoding MLH1. In some embodiments, the enhancer comprises a dNTP synthetic enzyme. In some embodiments, the enhancer comprises a kinase. In some embodiments, the kinase comprises a nucleoside kinase, deoxynucleoside kinase, deoxynucleoside monophosphate kinase, or deoxynucleotide diphosphate. In some embodiments, the enhancer comprises Vpx, BGLF4, M97, KSHV1 ORF36, or FEN1. In some embodiments, the enhancer comprises Vpx and FEN1. In some embodiments, the enhancer comprises M97 and FEN 1. In some embodiments, the FEN 1 comprises a heterodimerization domain, e.g., a self-assembling coiled coil heterodimerization domain, for binding to a DNA-dependent DNA polymerase having the sequence of the other portion of the heterodimerization domain.In some embodiments, the composition comprises a lipid nanoparticle composition comprising (a) a first polynucleotide encoding Nme2-nCas9 and a DNA-dependent DNA polymerase; and (b) a second polynucleotide comprising, from 5’ to 3’, a spacer, a scaffold, a template sequence, and a DRS, wherein the scaffold is not covalently attached directly to template sequence and DRS by a phosphorothioate or phosphodiester linkage.In some embodiments, the composition comprises a lipid nanoparticle composition comprising (a) a first polynucleotide encoding an Nme2-nCas9 and a DNA-dependent DNA polymerase; (b) a second polynucleotide comprising, from 5’ to 3’, a spacer and a scaffold; and (c) a third polynucleotide comprising, from 5’ to 3’, a template sequence and a DRS, wherein the second and third polynucleotide are provided as separate molecules, optionally wherein the third polynucleotide comprises an affinity tag, optionally an aptamer, 5’ of the template sequence, for binding to the DNA-dependent DNA polymerase.In some embodiments, the composition comprises a lipid nanoparticle composition comprising (a) a first polynucleotide encoding an Nme2-nCas9; (b) a second polynucleotide encoding a DNA-dependent DNA polymerase; and (c) a third polynucleotide comprising, from 5’ to 3’, a spacer, a scaffold, a template sequence, and a DRS,, wherein the scaffold is not covalently attached directly to template sequence and DRS by a phosphorothioate orphosphodiester linkage; wherein the first and second polynucleotide are provided as separate molecules, optionally wherein the third polynucleotide comprises an affinity tag, optionally an aptamer, preferably 5’ of the template sequence for binding to the DNA-dependent DNA polymerase.In some embodiments, the composition comprises a lipid nanoparticle composition comprising (a) a first polynucleotide encoding an Nme2-nCas9; (b) a second polynucleotide encoding a DNA-dependent DNA polymerase; (c) a third polynucleotide comprising, from 5’ to 3’, a spacer and a scaffold; and (d) a fourth polynucleotide comprising, from 5’ to 3’, a template sequence and a DRS, wherein the first, second, third, and fourth polynucleotides are provided as separate molecules, optionally wherein the fourth polynucleotide comprises an affinity tag, optionally an aptamer, preferably 5’ of the template sequence, for binding to the DNA-dependent DNA polymerase.In some embodiments, use of the composition results in template-based genome editing. In some embodiments, template-based genome editing results in edits comprising an insertion or deletion in a nucleotide sequence. In some embodiments, template-based genome editing results in edits comprising a substitution in a nucleotide sequence. In some embodiments, templatebased genome editing results in at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, optionally at least 50%, 55%, 60%, 65%, optionally at least 70%, 75%, or 80%, optionally at least 85%, 90%, 95%, 99% or more templated edits as a percent of total edits in the target nucleic acid. It is understood that non-templated edits, may occur during template-based genome editing, either alone or in conjunction with a templated edit. Non-templated edits include byproduct edits (i.e., mismatches or indels at or near the target site of the tgRNA or the nicking guide RNA, within the sequence analyzed by NGS, that are not encoded in the template). In determining the percent of template-based edits, the number of sequence reads with templatebased edits, including byproduct edits, is determined as a percent of the total number of sequence reads. The number of template-based edits without byproduct edits, which are sometimes referred to herein as “perfect edits” or “templated edits” can be similarly determined. The percent of “perfect edits” or “templated edits” as a percent of total template-based edits can also be readily determined.In some embodiments, use of the composition results in template-based genome editing in a cell or population of cells. In some embodiments, the cell is in vitro. In some embodiments,the cell is ex vivo. In some embodiments, the cell is in vivo. In some embodiments, the cell is a quiescent cell. In some embodiments, the cell is a quiescent cell selected from a hepatocyte and an inactivated T-cell, a muscle cell, a neuronal cell, and a lung cell. In some embodiments, the cell is a typically non-dividing cell type, i.e., a cell type that in adults does not typically divide in the absence of injury or tissue damage, e.g., liver cell, nerve cell, muscle cell. In some embodiments, the cell is a liver cell, such as a hepatocyte. In some embodiments, the cell is an immune cell such as a T cell. In some embodiments, at least 5% of the cells in the cell population comprise a template-based edit in the target nucleic acid. In some embodiments, at least 50% of the cells in the cell population comprise a desired genome edit in the target nucleic acid. In some embodiments, the cell is in vivo and at least 5% of the cells in the cell population comprise a desired genome edit in the target nucleic acid. In some embodiments, the cell is a typically nondividing cell type in vivo and at least 5% of the cells in the cell population comprise a desired genome edit in the target nucleic acid. In some embodiments, the cell is a hepatocyte in vivo and at least 5% of the cells in the cell population comprise a desired genome edit in the target nucleic acid. In some embodiments, the cell is an immune cell and at least 50% of the cells in the cell population comprise a desired genome edit in the target nucleic acid. In some embodiments, the cell is a T cell and at least 50% of the cells in the cell population comprise a desired genome edit in the target nucleic acid.In some embodiments, a method of producing a cell or a population of cells is provided. In some embodiments, the method comprises an insertion, deletion, or substitution in the genome of the target cell or cells, the method comprising contacting the cell or cells with (a) an Nme2-nCas9 or a nucleic acid encoding the same, (b) a DNA-dependent DNA polymerase or a nucleic acid encoding the same, and (c) a template guide RNA for template-based genome editing.In some embodiments, the present disclosure provides, e.g., a system comprising a DNA-dependent DNA polymerase, an Nme2Cas9 nickase (Nme2-nCas9), and a template guide RNA (tgRNA), wherein the tgRNA comprises a first polynucleotide and a second polynucleotide, wherein: (a) the first polynucleotide comprises an Nme-Cas9 guide RNA comprising: (i) a spacer that is complementary to a target region of a target strand of a DNA duplex target nucleic acid; and (ii) a scaffold; and (b) the second polynucleotide is operably linked to the first polynucleotide and comprises: (i) a template sequence that is at least 10 nucleotides in length and complementary to at least a portion of a non-target strand of the DNA duplex target nucleic acid,wherein the template sequence comprises a 3’ end and a 5’ end; and wherein the template comprises DNA nucleotides; and (ii) a DNA-dependent DNA polymerase recruiting sequence (DRS) that is 6-20 nucleotides in length, and having a 3’ end and a 5’ end; wherein the 5’ end of the DRS is covalently attached to the 3’ end of the template sequence, wherein the scaffold is not covalently attached directly to template sequence and DRS by a phosphorothioate or phosphodiester linkage; and wherein the DRS comprises a sequence that is complementary to at least 6 nucleotides of a DRS-complementary region of the non-target strand of the DNA duplex target nucleic acid, wherein the DRS comprises DNA nucleotides; and wherein the DRS comprises at least one of: (1) a sequence not fully complementary to the DRS-complementary region of the non-target strand of the DNA duplex target nucleic acid; (2) a 1-5 nucleotide, optionally a 1-3 nucleotide 3’ terminal tail comprising a 3’ terminal modified uridine nucleotide; or (3) a 5’ terminal (DI) DNA nucleotide and a penultimate 5’ terminal (D2) RNA nucleotide wherein the 3’ end of the first polynucleotide is covalently linked to the 5’ end of the second polynucleotide by a phosphorothioate or phosphodiester linkage.In some embodiments, the present disclosure provides, e.g., a system comprising a DNA-dependent DNA polymerase, an Nme2Cas9 nickase (Nme2-nCas9), and a template guide RNA (tgRNA), wherein the tgRNA comprises a first polynucleotide and a second polynucleotide, wherein: (a) the first polynucleotide comprises an Nme-Cas9 guide RNA comprising: (i) a spacer that is complementary to a target region of a target strand of a DNA duplex target nucleic acid; and (ii) a scaffold; and (b) the second polynucleotide is operably linked to the first polynucleotide and comprises: (i) a template sequence that is at least 10 nucleotides in length and complementary to at least a portion of a non-target strand of the DNA duplex target nucleic acid, wherein the template sequence comprises a 3’ end and a 5’ end; and wherein the template comprises DNA nucleotides; and (ii) a DNA-dependent DNA polymerase recruiting sequence (DRS) that is 6-20 nucleotides in length, and having a 3’ end and a 5’ end; wherein the 5’ end of the DRS is covalently attached to the 3’ end of the template sequence, and wherein the DRS comprises a sequence that is complementary to at least 6 nucleotides of a DRS-complementary region of the non-target strand of the DNA duplex target nucleic acid, wherein the DRS comprises RNA nucleotides; and wherein the DRS comprises at least one of: (1) a sequence not fully complementary to the DRS-complementary region of the non-target strand of the DNA duplex target nucleic acid; (2) a 1-5 nucleotide, optionally a 1-3 nucleotide 3’ terminal tailcomprising a 3’ terminal modified uridine nucleotide; or (3) a 5’ terminal (DI) DNA nucleotide and a penultimate 5’ terminal (D2) RNA nucleotide wherein the 3’ end of the first polynucleotide is covalently linked to the 5’ end of the second polynucleotide by a phosphorothioate or phosphodiester linkage.In some embodiments, the template sequence is at least 5-10,000 nucleotides in length. In some embodiments, the template sequence is at least 5, 10, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, or 10,000 nucleotides in length. In some embodiments, the template sequence is at least 10-1000, 1000-2000, 2000-3000, 3000-4000, 4000-5000, 5000-6000, 6000-7000, 7000-8000, 8000-9000, or 9000-10,000 nucleotides in length. In some embodiments, the template sequence is at least 10-10,000, 1000-10,000, 2000-10,000, 3000-10,000, 4000-10,000, 5000-10,000, 6000-10,000, 7000-10,000, 8-10,000, or 9-10,000 nucleotides in length. In some embodiments, the template sequence is at least 10-1000, 10-2000, 10-3000, 10-4000, 10-5000, 10-6000, 10-7000, 10-8000, 10-9000, or 10-10,000 nucleotides in length.In some embodiments, the template sequence is about 10-10,000 nucleotides in length. In some embodiments, the template sequence is about 10, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, or 10,000 nucleotides in length. In some embodiments, the template sequence is about 10-1000, 1000-2000, 2000-3000, 3000-4000, 4000-5000, 5000-6000, 6000-7000, 7000-8000, 8000-9000, or 9000-10,000 nucleotides in length. In some embodiments, the template sequence is about 10-10,000, 1000-10,000, 2000-10,000, 3000-10,000, 4000-10,000, 5000-10,000, 6000-10,000, 7000-10,000, 8-10,000, or 9-10,000 nucleotides in length. In some embodiments, the template sequence is about 10-1000, 10-2000, 10-3000, 10-4000, 10-5000, 10-6000, 10-7000, 10-8000, 10-9000, or 10-10,000 nucleotides in length.In some embodiments, the template sequence comprises DNA nucleotides, wherein the plurality of nucleotides in the template sequence are DNA nucleotides. In some embodiments, 1-3 nucleotides at the 3’ end of the template (T1-T3), optionally only 1 RNA nucleotide at the 3’ end of the template (Tl) are RNA nucleotides. In some embodiments, the template sequence consists of DNA nucleotides.In some embodiments, the DRS comprises 6-20 nucleotides in length, the DRS is 6-17, 8-17, 10-12, 10-14, 10-16, or 12-14 nucleotides in length. In some embodiments, wherein the DRS comprises 6-17 nucleotides in length, the DRS is about 6-17, 8-17, 10-12, 10-14, 10-16, or 12-14nucleotides in length. In some embodiments, the DRS is 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides in length.In some embodiments, the DRS is 75-100% complementary to the DRS-complementary region of the non-target strand of the DNA duplex target nucleic acid. In some embodiments, the DRS is 100% complementary to the DRS-complementary region of the non-target strand of the DNA duplex target nucleic acid. In some embodiments, the DRS is fully complementary to the DRS-complementary region of the non-target strand of the DNA duplex target nucleic acid. In some embodiments, the DRS is not fully complementary to the DRS-complementary region of the non-target strand of the DNA duplex target nucleic acid. In some embodiments, the DRS has 0, 1, 2, 3, or 4 mismatches to the DRS-complementary region of the non-target strand of the DNA duplex target nucleic acid. In some embodiments, the DRS comprises 0, 1, 2, 3, or 4 mismatches to the DRS-complementary region of the non-target strand of the DNA duplex target nucleic acid. In some embodiments, the first 50% of nucleotides at the 5’ end of the DRS have 0 mismatches to the corresponding genomic sequence. In some embodiments, the first 50% of nucleotides at the 5’ end of the DRS have 1, 2, or 3 mismatches to the corresponding genomic sequence. In some embodiments, the first four nucleotides at the 5’ end of the DRS have 0, 1, 2, or 3 mismatches to the corresponding genomic sequence. In some embodiments, the first four nucleotides at the 5’ end of the DRS have 0 mismatches to the corresponding genomic sequence. In some embodiments, the first four nucleotides at the 5’ end of the DRS have 1 or 2 mismatches to the corresponding genomic sequence. In some embodiments, the first three nucleotides at the 5’ end of the DRS have 0 mismatches to the corresponding genomic sequence. In some embodiments, the first three nucleotides at the 5’ end of the DRS have 1 mismatch to the corresponding genomic sequence. In some embodiments, the first 6 nucleotides at the 5’ end of the DRS have 0, 1, or 2 mismatches to the corresponding genomic sequence. In some embodiments, the first 10 nucleotides at the 5’ end of the DRS have 0, 1, or 2 mismatches to the corresponding genomic sequence. In some embodiments, 70%-100% of the nucleotides in the first 10 nucleotides at the 5’ end of the DRS are complementary to the corresponding genomic sequence. In some embodiments, the DRS comprises, e.g., further comprises, one or more mismatches in the 3’ half of the DRS.In some embodiments, the DRS comprises a 1-5 nucleotide 3’ terminal tail comprising a 3’ terminal modified uridine nucleotide. In some embodiments, the DRS comprises a 1-3nucleotide 3’ terminal tail comprising a 3’ terminal modified uridine nucleotide. In some embodiments, the 3 ’ terminal tail is 1, 2, or 3 nucleotides in length.In some embodiments, the 5’ terminal nucleotide in the DRS (DI) is a DNA nucleotide. In some embodiments, up to 5 of the 5’ terminal nucleotides in the DRS (D1-D5) are DNA nucleotides. In some embodiments, up to 4 of the 5’ terminal nucleotides in the DRS (D1-D4) are DNA nucleotides. In some embodiments, the penultimate 5’ nucleotide (D2) in the DRS is an RNA nucleotide. In some embodiments, each nucleotide from the penultimate 5’ nucleotide (D2) to the 3’ end nucleotide in the DRS is an RNA nucleotide.The present disclosure also relates to manufacturing methods to prepare cells in vitro or ex vivo for subsequent therapeutic administration to a subject. In some embodiments, the platform relates to genome editing via simultaneous or sequential administration of lipid nanoparticles (LNPs) comprising (a) an Nme2Cas9 nickase (Nme2-nCas9) or a nucleic acid encoding the same, (b) a DNA-dependent DNA polymerase or a nucleic acid encoding the same, and (c) a template guide RNA for template-based genome editing. The systems and methods disclosed herein are relevant to any cell type but are particularly advantageous in preparing cells that require insertion, deletion, or substitution of a defined genomic sequence for full therapeutic applicability, e.g., in primary immune cells, e.g., T cells, B cells, NK cells; or stem cells including hematopoietic stem cells. As provided herein, the platform methods apply to “a cell” or to “a cell population” (or “population of cells”). When referring to delivery or gene editing methods for “a cell” herein, it is understood that the methods may be used for delivery or gene editing to “a cell population.”In some embodiments, provided herein is an engineered cell modified by the methods disclosed herein, and the engineered cell comprises at least one genomic modification, e.g., insertion, deletion, or substitution of nucleotides.In some embodiments, provided herein is a cell treated in vitro with any method or composition disclosed herein. In some embodiments, provided herein is a cell treated in vivo with any method or composition disclosed herein. In some embodiments herein, a cell treated in vivo is a liver cell. In some embodiments herein, a cell treated in vivo is not a liver cell. In some embodiments, provided herein is a population of cells comprising any cell disclosed herein.The section headings used herein are for organizational purposes only and are not to be construed as limiting the desired subject matter in any way. In the event that any materialincorporated by reference contradicts any term defined in this specification or any other express content of this specification, this specification controls. While the present teachings are described in conjunction with various embodiments, it is not intended that the present teachings be limited to such embodiments. On the contrary, the present teachings encompass various alternatives, modifications, and equivalents, as will be appreciated by those of skill in the art.DefinitionsUnless stated otherwise, the following terms and phrases as used herein are intended to have the following meanings:“Template-based genome editing”, “template-based editing”, “templated editing”, and the like, as used herein, is understood as a specific change to a nucleotide sequence, e.g., insertion, deletion, change in nucleotide sequence, dependent upon the sequence of an exogenous nucleotide template sequence and a polymerase delivered to the cell. As used herein, templatebased editing uses an exogenously provided polynucleotide template and a DNA-templated DNA polymerase delivered to the cell. The nucleotide sequence of the template, and a complement thereof, is integrated into the genome (See, e.g., Fig. 1).As used herein, “indel” refers to an insertion or deletion mutation consisting of a number of nucleotides that are either inserted, deleted, or inserted and deleted, e.g., at the site of a nick or double-strand break (DSB), in a target nucleic acid. As used herein, when indel formation results in an insertion, the insertion is a random insertion at the site of a nick or DSB and is not directed by or based on a template sequence.As used herein, the term “operably linked” is understood as a juxtaposition of at least two components, e.g., polypeptide chain components or polynucleotide chain components, in a manner to allow one component to exert an effect on the other, or to allow the components when operably linked to have an effect that the two components could not exert individually or as a mixture of the components. In certain embodiments, two components may be operably linked by a covalent linkage, e.g., a peptide bond between two polypeptide chains encoded by a single open reading frame. In certain embodiments, the linkage can be mediated by a linker, e.g., a peptide linker. In certain embodiments, the linker is covalently attached to at least one of the components. In certain embodiments, the linker is covalently attached to both components. In certain embodiments, e.g., polynucleotides, the components can be joined by one or morephosphodiester or phosphorothioate bonds, e.g., a single PO or PS bond, or a polynucleotide linker sequence, or by other types of linkages, or any combination thereof.In certain embodiments, components are joined by a linker not covalently attached to either component, e.g., two polypeptides bound to a single nucleic acid with binding sites for two distinct polypeptides, e.g., a guide RNA scaffold and an aptamer. In certain embodiments, polynucleotides, optionally polynucleotides bound to polypeptides, can be operably linked by being targeted to genomic loci with sufficient proximity to each other, typically on opposite strands of the DNA duplex target nucleic acid. For example, a nickase is recruited to a genomic locus by a first polynucleotide sequence comprising a spacer sequence 5’ of a guide scaffold sequence wherein the spacer sequence is complementary to the target strand of the DNA duplex target nucleic acid. Similarly, a polymerase is recruited to the non-target strand (opposite strand) of the DNA duplex target nucleic acid by a second polynucleotide sequence comprising a DNA polymerase recruiting sequence (DRS) complementary to the non-target strand of the DNA duplex target nucleic acid and a sequence to mediate binding of the second polynucleotide to the polymerase, e.g., an aptamer, 3’ of the DRS. The non-target strand of the DNA duplex target nucleic acid is available for hybridization to the DRS by the binding of the spacer sequence to the genomic locus and the nicking of the non-target strand by the nickase. The second polynucleotide further comprises a template sequence 5’ of the DRS.In certain embodiments, components are joined directly by a non-covalent linkage. For example, each of the components can include a domain, e.g., a heterodimerization domain (or heterodimer domain, which is interchangeably used herein with a heterodimerization domain), that mediates the binding of the components to each other. In some embodiments, each of the components is a polypeptide chain and each polypeptide chain comprises a fusion protein comprising the heterodimer domain. In some embodiments, the heterodimer domains comprise leucine zipper domains, PDZ domains, streptavidin and streptavidin binding protein domains, foldon domains, hydrophobic polypeptides, an antibody or one or more binding fragments thereof (e.g., scFv, VHH domain) on one component that binds an epitope, either naturally occurring or inserted, in the other component. The position of the heterodimer domain is selected independently for each component. In some embodiments, the heterodimerization domain comprises a coiled coil heterodimerization domain, e.g., a self-assembling coiled coil heterodimerization domain. In some embodiments, the heterodimerization domain comprises anEBV, El, KV, or KI domain, which may form a heterodimer with a corresponding selfassembling coiled coil heterodimerization domain. In some embodiments, the heterodimerization domain comprises an El or KI domain. In some embodiments, the heterodimerization domain comprises an El domain. In some embodiments, the heterodimerization domain comprises a KI domain. In some embodiments, the heterodimerization domain is SEQ ID NO: 1589, SEQ ID NO: 1593, or SEQ ID NO: 1595.In certain embodiments, two polynucleotide chain components are operably linked by polypeptide binding, e.g., by two polynucleotide chains binding to a single polypeptide or two polynucleotide chains binding to a heterodimer.As used herein, the term “system” refers to at least two operably linked elements, e.g., polypeptides or polynucleotides. In some embodiments, the system may comprise any two or more of a Nme2-Cas9 nickase (Nme2-nCas9), a DNA-dependent DNA polymerase, an Nme-Cas9 guide RNA, and a 3’ extension. In some embodiments, the Nme2Cas9 nickase and DNA-dependent DNA polymerase may be covalently linked in a fusion protein. In some embodiments, the Nme2-nCas9may be operably linked to a first split intein and the DNA-dependent DNA polymerase may be operably linked to a second split intein capable of participating in a transsplicing reaction with the first intein. In some embodiments, the Nme2-nCas9 operably linked to the first intein and the DNA-dependent DNA polymerase operably linked to the second intein may be present as two separate polypeptides (pre-splicing). In some embodiments, the Nme2-nCas9 operably linked to the first intein and the DNA-dependent DNA polymerase operably linked to the second intein are a fusion polypeptide (post-splicing). In some embodiments, the system may further comprise a nucleic acid encoding the Nme2-nCas9 or DNA-dependent DNA polymerase. In some embodiments, the Nme-Cas9 guide RNA is covalently linked to the 3 ’ extension, however the scaffold is not covalently attached directly to template sequence and DRS by a phosphorothioate or phosphodiester linkage. In some embodiments, the Nme-Cas9 guide RNA is not be covalently linked to the 3 ’ extension. In some embodiments, the system may further comprise one or more enhancers of genomic editing, or one or more nucleic acids encoding the one or more enhancers of genomic editing.As used herein, a “template guide”, “template guide RNA”, “tgRNA” or the like comprises a first polynucleotide sequence comprising a spacer sequence and a guide scaffold sequence, e.g., a guide RNA, wherein the spacer sequence is positioned 5’ of the guide scaffoldsequence, and wherein the spacer sequence is targeted to a target strand of a DNA duplex target nucleic acid at a genomic locus (See, e.g., Fig. 2). The first polynucleotide sequence is operably linked to a second polynucleotide sequence, referred to herein as a 3 ’ extension, comprising a template sequence and a DNA-polymerase recruiting sequence (DRS), wherein the template sequence is positioned 5’ to the DRS, wherein the DRS is complementary, e.g., 75-100% complementary, to the non-target (i.e., opposite) strand of the double-stranded DNA molecule for at least six consecutive nucleotides within the spacer genomic target sequence, e.g., complementary over 6 -20 consecutive nucleotides of the same genomic locus of the target locus of the spacer sequence. In certain embodiments, the DRS is less than 100% complementary to the non-target strand of the DNA duplex target nucleic acid. In certain embodiments, the DRS is 100% complementary to the genomic sequence across at least 3 base pairs, optionally at least 4 base pairs. In certain embodiments, the DRS has at least 6 base pairs with the genomic sequence across the length of the DRS. Mismatches between the DRS and the genomic sequence typically do not direct changes in the genomic sequence. Mismatches only at the 5’ end of the DRS can direct changes in the genomic sequence when the polymerase binds upstream of the mismatch(es) between the DRS and the genomic sequence such that the 5’ end of the DRS can act as a template. In certain embodiments, the DRS can direct a template-based edit at one or more of positions DI, D2, and D3, optionally at position DI. In certain embodiments, the DRS position directing an edit is a DNA nucleotide. In certain embodiments, an edit directed by a nucleotide in the DRS is less efficient than an edit directed by the template. In certain embodiments, the positions that are less than 100% complementary to the non-target strand of the DNA duplex target nucleic acid that can direct template-based edits do not introduce changes into the amino acid sequence of the corresponding protein after template-based genome editing, i.e., silent mutations. It is understood that reducing the complementarity of the DRS to the non-target strand of the DNA duplex target nucleic acid will similarly reduce the complementarity of the DRS to the spacer sequence of the guide RNA. In certain embodiments, one or more mismatches between the DRS and the genomic target sequence are at the 5’ end of the DRS, e.g., within the first three nucleotides of the DRS.In certain embodiments, the DRS further includes a 3’ tail that is not complementary to the genomic sequence, i.e., the mismatch is not flanked by nucleotides complementary to the genomic sequence. In certain embodiments, the 3’ tail of the DRS is 1-5 nucleotides in length,optionally 1, 2, or 3 nucleotides in length. In preferred embodiments, the most 3’ nucleotide in the 3’ tail is a uridine nucleotide. In certain embodiments, all of the nucleotides of the 3’ tail are uridine nucleotides. For the purpose of determining percent complementarity between the DRS and the genomic sequence, mismatches between the tail and the genomic sequence are not considered in percent identity.The template sequence is less than 100% complementary to the non-target strand of the DNA duplex target nucleic acid. After polymerase-mediated extension, the nucleotide mismatch within the template sequence is incorporated into the genomic sequence such that the genomic sequence contains at least one template-based edit as compared to the unedited genomic sequence. The DRS and template sequence can further include mismatches to the guide RNA spacer sequence that do not result in changes in the corresponding amino acid sequence following template-based editing. Such mismatches may reduce the formation of DNA-RNA duplexes between the DRS and template sequence, and the guide RNA spacer sequence, that can be susceptible to cleavage by RNaseH. Such mismatches may reduce nuclease recruitment by the spacer sequence to genomic target sequence after template-based editing by changing the nucleotide sequence in the genomic locus to which the spacer sequence is targeted.In certain embodiments, the first polynucleotide sequence, the guide RNA sequence having a spacer sequence and a scaffold sequence, and the second polynucleotide sequence, the 3’ extension, having a template sequence and a DRS sequence, are operably linked by being in a single molecule, however the scaffold sequence is not covalently attached directly to template and DRS sequences by a phosphorothioate or phosphodiester linkage. The first polynucleotide sequence is 5’ of the second polynucleotide sequence in the molecule. In certain embodiments, the first polynucleotide sequence is operably linked to the second polynucleotide sequence by a linker. In certain embodiments, the polynucleotide sequences are linked in the following orientation: 5 ’-first polynucleotide sequence-3 ’-linker-5 ’-second polynucleotide sequence-3’. In certain embodiments, the first polynucleotide and the second polynucleotide are non-covalently linked by base pairing between the 5’ portion of hairpin2 of the Nme gRNA scaffold and a nucleotide sequence 5’ of the template sequence capable of base pairing with the 5’ portion of hairpin 2. In certain embodiments, the 5’ portion of hairpin2 and the nucleotide sequence capable of base pairing with the hairpin 2 sequence form at least 8 base pairs, optionally at least 17 base pairs, optionally 8-17 base pairs, optionally 8-20 base pairs.In certain embodiments, the first polynucleotide sequence and the second polynucleotide sequence, optionally with the polynucleotide sequences bound to polypeptides, can be operably linked by being targeted to genomic loci with sufficient proximity to each other, typically on opposite strands of the DNA duplex target nucleic acid. In certain embodiments, the first polynucleotide sequence and the second polynucleotide sequence are in separate polynucleotide chains operably linked by being bound to a single polypeptide or a single polypeptide heterodimer. In certain embodiments, a first polynucleotide comprising the first polynucleotide sequence comprising the guide scaffold sequence is bound to an Nme2Cas9 enzyme portion of a polypeptide; and a second polynucleotide comprising the second polynucleotide sequence comprises an affinity tag polynucleotide sequence for binding to a corresponding polypeptide sequence in the polypeptide or polypeptide heterodimer. In preferred embodiments, the affinity tag is 5’ to the template sequence. In certain embodiments, there is more than one affinity tag in the second polynucleotide. In certain embodiments, there is only one affinity tag in the second polynucleotide. In certain embodiments, the affinity tag is operably linked to the template sequence or the DRS by a linker. In certain embodiments, the template sequence and affinity tag are linked in the following orientation: In certain embodiments, one or more linkers are present between the one or more of the DRS, affinity tag, and template. In certain embodiments, the corresponding polypeptide sequence for binding the affinity tag is present on a DNA dependent DNA polymerase or Nme2Cas9.“Guide RNA”, “gRNA”, and “guide” are used herein interchangeably to refer to either a crRNA (also known as CRISPR RNA), or the combination of a crRNA and a trRNA (also known as tracrRNA). The crRNA and trRNA may be associated as a single RNA molecule (single guide RNA, sgRNA) or in two separate RNA molecules (dual guide RNA, dgRNA). “Guide RNA” or “gRNA” refers to each type. The trRNA may be a naturally occurring sequence, or a trRNA sequence with modifications or variations compared to naturally occurring sequences.As used herein, a “nicking guide RNA” is a guide RNA, typically an sgRNA, that can bind to the same Cas9 enzyme, e.g., a Nme2Cas9 enzyme, as the template guide, but that does not contain a DRS or a template sequence. The target site for the spacer sequence in a nicking guide RNA is about 1-200 nucleotides, preferably about 1-100 nucleotides 5’ or 3’ from the nicking site for the template guide, on the opposite DNA strand in the genome i.e., the non-targetstrand of the DNA duplex target nucleic acid. In certain embodiments, the nicking guide RNA facilitates Nme2Cas9 nicking between 20-200 nucleotides 5’ or 3’ from the nicking site for the template guide on the opposite DNA strand of the DNA duplex target nucleic acid. In cases where the target site for the nicking guide RNA is within 20 nucleotides of the template guide RNA nicking site, the targeting sequence of the nicking guide RNA preferably already has the intended edits. In preferred embodiments, the nicking guide RNA does not promote editing at its target site.“Internal linker” as used herein describes a non-nucleotide segment joining two nucleotides within a guide RNA. If the guide RNA contains a spacer region, the internal linker is located outside of the spacer region (e.g., in the scaffold or conserved region of the guide RNA). Exemplary structures of guide RNA scaffolds with internal linkers are provided in WO2022261292, the content of which is incorporated by reference. In some embodiments, an internal linker may join two nucleotides within a template guide RNA. For example, an internal linker may join the guide RNA and 3’ extension, the template sequence and an affinity tag, or the DRS and an affinity tag. In some cases, the non-nucleotide linker having the same structure as an internal linker may be also used to join two nucleotides elsewhere and may be referred to as a non-nucleotide linker.As used herein, a “spacer,” “spacer sequence,” “guide sequence,” “guide region,” “targeting sequence” and the like refers to a sequence within a guide RNA that is complementary to a target sequence and functions to direct a guide RNA to a target sequence for binding or modification (e.g., nicking, cleavage) by an RNA-guided nickase. A guide sequence can be 24 nucleotides in length, e.g., in the case of Neisseria meningitidis (i.e., Nme2Cas9) and related Cas9 homologs / orthologs. Shorter or longer sequences can also be used as guides, e.g., 22-, 23-, or 25— nucleotides in length.Exemplary “scaffold” or “conserved region” of a N. meningitidis 2 Cas9 (“Nme2Cas9”) sgRNA” is shown in Figures 13A-13C and Tables 2A, and 2. Table 1 provides the scaffold numbering used in the instant application. The first row shows the numbering of the nucleotides; the second row shows the sequence (e.g., SEQ ID NO: 253); and the third row shows the regions. Various Nme-Cas9 guide RNA scaffold sequences and chemical modifications are known in the art including, but not limited to, those provided in WO2022261292 and WO2023081687 the contents of each of which are herein incorporated by reference.As used herein, a “3’ extension,” “3’ extension polynucleotide,” or the like is understood as a polynucleotide containing, at least a template sequence 5’ to a DNA-dependent DNA polymerase recruiting sequence (DRS), wherein thex 3’ extension is operably linked to a spacer sequence and a guide scaffold sequence, e.g., a guide RNA (See, e.g., Figs. 14A-14I). In certain embodiments, the 3’ extension is covalently linked to the 3’ end of the guide scaffold sequence, however the scaffold is not covalently attached directly to template sequence and DRS by a phosphorothioate or phosphodi ester linkage. That is, the molecule linking the 3 ’ end of the scaffold and the 5’ end of the template must include at least one along the length of the molecule that is not a phosphodi ester bond or a phosphorothioate bond, i.e., is a non- nucleotide linkage. In certain embodiments, the linkage is a non-covalent linkage, e.g., an operable linkage or formed by base pairing as provided herein. The 3 ’ extension does not need to be associated with the gRNA portion of the tgRNA and can be recruited to the site for template-based editing by base pairing with the flap adjacent to the nick directed by the Nme2Cas9. Such a 3’ extension may also include an affinity tag, e.g., an aptamer, for binding to the polymerase. As used herein, a 3’ extension that is not linked to a guide scaffold sequence may be referred to as a separable 3’ extension.In the context of the 3 ’ extension, the boundary between the template sequence and the DRS may be defined relative to the position of the nick generated by the Nme2-nCas9. The nucleotide at the 5’ end of the flap 3’ of the nick is complementary to the nucleotide at the 3’ end of the template (unless an edit is to be introduced at position Tl), while the nucleotide at the 3’ end of the flap 5’ of the nick is complementary to the nucleotide at the 5’ end of the DRS.Accordingly, the boundary between the template sequence and the DRS may be described relative to the extension activity of the DNA-dependent DNA polymerase, with the first nucleotide of the template (Tl; the nucleotide immediately 5’ of the boundary between the template sequence and the DRS) being complementary to the first nucleotide of the newly synthesized DNA strand.As used herein, the term “3’ extension-recruiting domain” (or “template- recruiting domain,” “aptamer-binding domain,” and the like) is understood as a polypeptide sequence or a polynucleotide sequence, a small molecule, or the like that binds to a cognate affinity tag covalently linked to a 3 ’ extension disclosed herein. In some embodiments, the 3 ’ extensionrecruiting domain is at the C-terminal of the DNA-dependent DNA polymerase. In someembodiments, the 3’ extension-recruiting domain is at the N-terminal of the DNA-dependent DNA polymerase.As used herein, a “chimeric DNA / RNA 3’ extension” or “chimeric DNA / RNA 3’ extension polynucleotide”, or “3’ extension”, is understood as a 3’ extension polynucleotide having a template portion with a sufficient number of DNA nucleotides (2’-H and 3 ’-OH) to permit extension by a DNA-dependent DNA polymerase when a DRS portion having independently at each position a DNA nucleotide, an RNA nucleotide or modified RNA nucleotide wherein the modification is tolerated in the scaffold of a guide RNA (e.g., 2’-OH, 2’-Ome, 2’F modified nucleotide) has formed a duplex region with the 3’ end of the flap formed by a nick in the genomic DNA (the flap 5’ of the nick). In certain embodiments, the template portion of the chimeric DNA / RNA 3’ extension includes all DNA nucleotides. In certain embodiments, the DRS portion of the chimeric DNA / RNA 3 ’ extension includes all DNA nucleotides. In certain embodiments, the 3’ end of the DRS includes all RNA nucleotides, e.g., modified RNA nucleotides, and the 5’ end of the DRS includes DNA nucleotides. In certain embodiments, 1-3 nucleotides on the 5’ end of the DRS (D1-D3) are DNA nucleotides. In certain embodiments, 0-7 nucleotides on the 5’ end of the DRS (DI - D7) are DNA nucleotides. In certain embodiments, the 3’ nucleotide of the DRS is an RNA nucleotide or modified RNA nucleotide and the remaining nucleotides are DNA nucleotides. In certain embodiments, the template portion of the chimeric DNA / RNA 3’ extension includes all DNA nucleotides and the 3’ end of the DRS includes all RNA including modified RNA nucleotides, and the 5’ end of the DRS includes DNA nucleotides. In certain embodiments, 1-3 nucleotides on the 3’ end of the DRS are modified nucleotides, e.g., 2’-0me modified nucleotides. In certain embodiments, the 3’ end of the DRS has 1-3 phosphorothioate modifications, preferably with a single phosphorothioate, e.g., between the most 3’ nucleotides. In certain embodiments, 1-3 nucleotides on the 3’ end of the DRS are modified nucleotides, e.g., independently 2’-0me and phosphorothioate modified nucleotides. In certain embodiments, the DRS has a 3’ tail. In certain embodiments, the 3’ tail of the DRS is 1-5 nucleotides in length, optionally 1, 2, or 3 nucleotides in length. In preferred embodiments, the most 3 ’ nucleotide in the 3 ’ tail is a uridine nucleotide. In certain embodiments, all of the nucleotides of the 3’ tail are uridine nucleotides. In certain embodiments, the most 3 ’ uridine nucleotide of the 3 ’ extension is a modified uridine nucleotide. In certain embodiments, all of the nucleotides of the 3’ tail are modified uridine nucleotides.“Template sequence” as used herein is a nucleotide sequence 5’ to the DRS, wherein the template sequence provides a nucleotide sequence different from the nucleotide sequence in the strand of genomic DNA prior to editing, wherein the template directs incorporation of at least one nucleotide sequence change into the genome, i.e., template-based genome editing. Such incorporations can come in the form of nucleotide substitutions, insertions, or deletions. In some embodiments, the template sequence is at least 5 nucleotides in length, preferably at least 10 nucleotides in length. In preferred embodiments, the template sequence is 100% complementary to the genomic sequence for at least 4 consecutive nucleotides prior to template-based genome editing. In certain embodiments, the 3’ portion of the template sequence includes the nucleotide sequence that is different from the nucleotide sequence in the strand of the genomic DNA prior to template-based genome editing. In certain embodiments, the most 3 ’ position of the template sequence is a nucleotide that is different from the nucleotide sequence of the strand of the DNA duplex target nucleic acid prior to template-based genome editing. In certain embodiments, the 5’ terminal portion of the template sequence is 100% complementary to the non-target strand of the DNA duplex target nucleic acid across four consecutive nucleotides. The template sequence preferably directs at least one change in the genomic sequence that alters the expression or sequence of an encoded polypeptide, e.g., a change in at least one encoded amino acid, or a change in a promoter or other regulatory element that alters expression of the sequence under control of the regulatory element. In certain embodiments, the positions of the template that are less than 100% complementary to the non-target strand of the DNA duplex target nucleic acid do not introduce changes into a protein sequence after template-based genome editing, i.e., silent mutations. In certain embodiments, the template sequence directs the incorporation of a change in the genomic sequence within the PAM, i.e., by altering the identity or position of one of the G nucleotides relative to the spacer binding site in the non-target strand. In certain embodiments, the incorporation of a change within the genomic sequence of the PAM is a silent mutation. In certain embodiments, the template sequence directs the incorporation of a change in the genomic sequence within the spacer sequence, e.g., within the seed sequence of the spacer, i.e., within the 3-7 nucleotides adjacent to the 5’ end of the PAM sequence in the non-target strand. In certain embodiments, the incorporation of a change within the genomic sequence of the spacer sequence is silent mutation. The introduction of silent mutations within the spacer or PAM sequence can be used to reduce nickase recruitment to the target site.As used herein, “a DNA polymerase- recruiting sequence” or “DRS” is located 3’ of a template sequence in a 3’ extension. In some embodiments, the DRS can be about 6-20 nucleotides in length, e.g., 6-17, 8-17, 10-12, 10-14, 10-16, or 12-14 nucleotides in length. In certain embodiments, the DRS is complementary or partially complementary to the flap 5’ of the nick, e.g., contains no more than one mismatch within the first 6 nucleotides at the 5’ end of the DRS in the genomic DNA 5’ to the site for nicking by the nickase. However, it is understood that the length and sequence to which the DRS is complementary is determined, in part, by the nucleotide sequence of the genomic locus to be edited and the availability of a PAM to permit nicking of the genomic DNA. In certain embodiments, the DRS is less than 100% complementary to the non-target strand of the genome. It is understood that reducing the complementarity of the DRS to the non-target strand of the DNA duplex target nucleic acid similarly reduces the complementarity of the DRS to the spacer sequence of the guide RNA. In certain embodiments, the DRS is 100% complementary to the genomic sequence across at least 3 base pairs, optionally at least 4 base pairs. In certain embodiments, the DRS has at least 6 base pairs with the genomic sequence across the length of the DRS. In certain embodiments, the DRS comprises 1 or 2 mismatches within the 5’ half of the DRS, i.e., the end closer to the DRS-template sequence junction. In certain embodiments, the DRS comprises 1 or 2 mismatches within the four most 5’ nucleotides in the DRS. In certain embodiments, the DRS comprises, e.g., further comprises, one or more mismatches in the 3’ half of the DRS. In certain embodiments, the DRS further includes a 3’ tail that is not complementary to the genomic sequence, i.e., the mismatch is not flanked by nucleotides complementary to the genomic sequence. In certain embodiments, the 3’ tail of the DRS is 1-5 nucleotides in length, optionally 1, 2, or 3 nucleotides in length. In preferred embodiments, the most 3’ nucleotide in the 3’ tail is a uridine nucleotide. In certain embodiments, all of the nucleotides of the 3 ’ tail are uridine nucleotides. For the purpose of determining percent complementarity between the DRS and the genomic sequence, mismatches between the tail and the genomic sequence are not considered in percent identity. In some embodiments, one to three consecutive nucleotides from the 5’ end of the DRS is a DNA nucleotide (2’-H). In other embodiments, the DRS contains entirely DNA nucleotides. In some embodiments, the DRS contains a mixture of DNA and RNA nucleotides. In some embodiments, the 3’ end of the DRS can include non-DNA nucleotides, RNAnucleotides including modified RNA nucleotides, e.g., 2’-OH, 2’-0me, 2’F, 3’-amine, abasic nucleotides, and 3 ’-PEG nucleotides; dideoxynucleotides and non-nucleotide linkers.As used herein, the term “affinity tag” is understood to refer to a structural element that binds to a polynucleotide sequence, polypeptide sequence, small molecule, or the like. In certain embodiments, affinity tags may be used to mediate binding of polynucleotides such as guide RNAs to a corresponding polypeptide. In certain embodiments, an affinity tag may be an aptamer. In certain embodiments, an affinity tag may be a small molecule such as biotin, desthiobiotin, or digoxigenin.As used herein, the term “aptamer” is understood to refer to a structural polynucleotide that binds to a polypeptide sequence, small molecule, or the like. In certain embodiments, aptamers may be used to mediate binding of polynucleotides such as guide RNAs to a corresponding polypeptide. Aptamers may be naturally occurring. For example, some viral nucleic acids bind viral proteins, e.g., the MS2 hairpin that binds to the bacteriophage MS2 coat protein (MCP). As an additional example, bacterial nucleic acids may bind portions of bacterial proteins, e.g., domains from CRISPR endonucleases that bind guide RNAs. Other aptamers may be designed or generated through molecular evolution using known methods in the art. As used herein, the term aptamer does not include the portion of a guide RNA scaffold that binds to a Nme2Cas9 enzyme.As used herein, aptamers may be single-stranded oligonucleotides that fold into well-defined three-dimensional shapes, allowing them to bind their targets, preferably with high affinity and specificity. Aptamers fold into defined three-dimensional shapes determined by their primary sequences that are usually about 10-80 nt long. Aptamer structures include binding pockets and clefts through which they bind their respective targets by a combination of van der Waals, hydrogen bonding, salt bridges, hydrophobic and electrostatic interactions for specific recognition, (see, e.g., Banerjee and Nilsen-Hamilton, 2013. Aptamers: multifunctional molecules for biomedical research. Journal of Molecular Medicine. 91:1333-1342.)In certain embodiments, an aptamer may be the MS2 hairpin (alternatively referred to herein as a MS2-loop, MS2 aptamer, or MS2 RNA loop), which binds the bacteriophage MS2 coat protein (MCP), both of which are well known in the art. The coat protein dimer of bacteriophage MS2 binds specifically to an RNA hairpin in the viral genome, thereby repressing the translation of the viral replicase. This hairpin / translational operator (TR) corresponds tonucleotide positions -15 to +4 relative to the start of the replicase gene and is 19 nt in length. The wild-type TR consists of a 7 base pair stem, interrupted by one unpaired residue between base pairs five and six, and is closed by a 4-nt loop. Various MS2 hairpin and MCP sequences are provided, for example, in Helgstrand et al., 2002. Investigating the structural basis of purine specificity in the structures of MS2 coat protein RNA translational operator hairpins NAR 30:2678-2685; and Lim et al., 1994. Altering the RNA binding specificity of a translational repressor. 269:9006-9010. Thus, the structures and requirements for binding of the MS2 hairpin and MCP are well known in the art.In certain embodiments, the aptamer may be a cognate RNA for binding the PP7 coat protein, which is well characterized. The structure of the cocrystal of the PP7 coat protein and its cognate RNA reveals the molecular basis of the interaction, and it demonstrates that the conserved beta-sheet surface is a flexible architecture that can evolve to recognize diverse RNA hairpins. Various sequences for the PP7 coat protein and cognate RNA and requirements for binding are known in the art. (see, e.g., Chao et al., 2008. Structural basis for the coevolution of a viral RNA-protein complex www.nature.com / doifinder / 10.1038 / nsmbl327).In certain embodiments, aptamers and their cognate binding peptides can be derived from bacterial proteins, including portions of CRISPR proteins and nucleic acids, e.g., polypeptide sequences from CRIPSR endonucleases that bind to portions of cognate guide RNAs sequences. Structural studies have defined these interactions between CRISPR endonucleases and guide RNAs see, e.g., Haurwitz etal., Science. 2010;329:1355-8. doi: 10.1126 / science.1192272 and Mulepati etal., Science. 2014;345:1479-84. doi: 10.1126 / science.1256996. Based on these studies, as well as others, those of skill in the art could identify RNA sequences for use as aptamers with their cognate protein binding sequences.“Polypeptide” as used herein refers to a multimeric compound comprising amino acid residues that can adopt a three-dimensional conformation. Polypeptides include but are not limited to enzymes, enzyme precursor proteins, regulatory proteins, structural proteins, receptors, nucleic acid binding proteins, antibodies, etc. Polypeptides may, but do not necessarily, comprise post-translational modifications, non-natural amino acids, prosthetic groups, and the like. In some embodiments, a polypeptide may comprise an amino acid sequence provided by a SEQ ID NO listed herein (e.g., in Table 6) that includes an N-terminal methionine. In some embodiments, such a polypeptide may comprise the SEQ ID NO comprising the N-terminalmethionine. In other embodiments, the polypeptide may comprise the SEQ ID NO as listed, but without the N-terminal methionine. For example, a SEQ ID NO provided herein may, in some embodiments, be operably linked to another moiety at the N-terminus (e.g., a nuclear localization signal, a second polypeptide, etc.). In such embodiments, a person of skill in the art will recognize that the N-terminal methionine is optional. Accordingly, in SEQ ID NOs provided herein that contain an N-terminal methionine residue, the N-terminal methionine residue should be considered an optional feature. Likewise, for nucleic acid sequences provided herein which encode a protein or polypeptide that comprises an N-terminal methionine residue, the nucleotides encoding the N-terminal methionine residue should be considered an optional feature.As used herein, “Cas nuclease”, also called “Cas protein” as used herein, encompasses Cas cleavases, Cas nickases (nCas), and dCas DNA binding agents. As used herein, a “Class 2 Cas nuclease” is a single-chain polypeptide with RNA-guided DNA binding activity. As used herein, “NmeCas9” or “Nme Cas9” is generic and encompasses any type of NmeCas9, including, NmelCas9 (e.g., SEQ ID NO: 2), Nme2Cas9 (e.g., SEQ ID NO: 1), and Nme3Cas9 (e.g., SEQ ID NO: 3). Several Cas9 orthologs have been obtained from N. meningitidis (Esvelt et al., NAT. METHODS, vol. 10, 2013, 1116 - 1121; Hou et al., PNAS, vol. 110, 2013, pages 15644 - 15649) (NmelCas9, Nme2Cas9, and Nme3Cas9). The Nme2Cas9 ortholog functions efficiently in mammalian cells, recognizes an N4CC PAM, and can be used for in vivo editing (Ran et al., NATURE, vol. 520, 2015, pages 186 - 191; Kim et al., NAT. COMMUN., vol. 8, 2017, pages 14500). Nme2Cas9 has been shown to be naturally resistant to off-target editing (Lee et al., MOL. THER., vol. 24, 2016, pages 645 - 654; Kim et al., 2017). See also e.g., WO / 2020081568 (e.g., pages 28 and 42), describing an Nme2Cas9 D16A nickase, the contents of which are hereby incorporated by reference in its entirety. Further, NmeCas9 variants are known in the art, see, e.g., Huang et al., Nature Biotech. 2022, doi.org / 10.1038 / s41587-022-01410-2, which describes Cas9 variants targeting single- nucleotide-pyrimidine PAMs. The sequence for wildtype NmelCas9 is set forth in SEQ ID NO: 2; the sequence for wild-type Nme2Cas9 is set forth in SEQ ID NO: 1; and the sequence for wildtype Nme3Cas9 is set forth in SEQ ID NO: 3.As used herein, a “nickase” is an enzyme that creates a single-strand break (also known as a “nick”) in double strand DNA, i.e., cuts one strand but not the other of the DNA double helix. As used herein, an “RNA-guided nickase” means a polypeptide or complex of polypeptides having DNA nickase activity, wherein the DNA nickase activity is sequence-specific and depends on the sequence of the RNA. Exemplary RNA-guided nickases include Cas nickases particularly Nme2Cas9 nickases (Nme2-nCas9). In some embodiments, a NmeCas9 may comprise an amino acid substitution in the RuvC or RuvC-like nuclease domain. Exemplary amino acid substitutions in the RuvC or RuvC-like nuclease domain include H588A (based on the N. meningitidis Cas9 protein).As used herein, a “DNA-dependent DNA polymerase” or “DNA-templated DNA polymerase” (DDP) synthesizes DNA opposite a nucleic acid template preferentially comprised of DNA over RNA. In some embodiments, the extension activity of a DDP on DNA templates consisting only of DNA nucleotides is at least 4-fold higher than the extension activity of the DDP on RNA templates consisting only of RNA nucleotides, as measured, for example using the method provided in the Examples below. Editing is compared between a template guide having a fully RNA DRS and a fully RNA template against a template guide having a fully RNA DRS and a fully DNA template. Consequently, editing by the editors disclosed herein (a complex comprising an Nme2-nCas9 operably linked to a DDP using a template guide RNA) is at least 10-fold, optionally 20-fold higher than editing with tgRNAs containing RNA template sequences. In some embodiments, repair DDPs such as human DNA polymerase K may tolerate a template in which fewer than 100% of the nucleotides are DNA nucleotides. For example, in some embodiments, repair DDPs such as human DNA polymerase K may tolerate a template in which 1, 2, or 3 of the nucleotides are RNA nucleotides.In certain embodiments, DNA-dependent DNA polymerases are prokaryotic DNA polymerases. In certain embodiments, DNA-dependent DNA polymerases are viral DNA polymerases. In certain embodiments, DNA-dependent DNA polymerases are eukaryotic DNA polymerases.In certain embodiments, DNA-dependent DNA polymerases are wild-type DNA polymerases. In certain embodiments, DNA-dependent DNA polymerases are variant DNA polymerases, i.e., not wild-type DNA polymerases. In certain embodiments, a variant DNA polymerase has altered activity as compared to the wild-type polymerase. For example, in certain embodiments, the processivity of the variant polymerase may be increased as compared to the wild-type polymerase. In certain embodiments, an exonuclease or certain exonuclease activity of the variant polymerase may be decreased or abolished as compared to the wild-type polymerase.As used herein, an “enhancer” or an “enhancer of template-based genome editing” is a nucleic acid, e.g., siRNA or shRNA, or protein for increasing the efficiency of template-based genome editing. In certain embodiments, one or more enhancers may be used to increase template-based genome editing.In certain embodiments, an enhancer of template-based genome editing is a DNA repair protein, e.g., an mRNA encoding a DNA repair protein or a DNA repair protein. In certain embodiments, the DNA repair protein is a single-strand endonuclease responsible for removing flaps generated at 3 ’ of a nick. In certain embodiments, removal of flaps 3 ’ of a nick includes expression of flap structure-specific endonuclease 1 (FEN1) protein (see, e.g., www.ncbi.nlm.nih.gov / gene / 2237 which is incorporated herein by reference in the version available as of the earliest filing date of this application). The FEN1 protein removes 5' overhanging flaps in DNA repair and processes the 5' ends of Okazaki fragments in lagging strand DNA synthesis. Direct physical interaction between this protein and AP endonuclease 1 during long-patch base excision repair provides coordinated loading of the proteins onto the substrate, thus passing the substrate from one enzyme to another. In certain embodiments, the DNA repair protein is mutL homolog 1 (MLH1) (see, e.g., www. ncbi.nlm.nih.gov / gene / 4292 / , incorporated herein by reference in the version available on the earliest filing date of the instant application). The MLH1 protein can heterodimerize with mismatch repair endonuclease PMS2 to form MutL alpha, part of the DNA mismatch repair system. When MutL alpha is bound by MutS beta and some accessory proteins, the PMS2 subunit of MutL alpha introduces a single-strand break near DNA mismatches, providing an entry point for exonuclease degradation. In certain embodiments, such an enhancer is used in a dividing cell, e.g., a T cell, e.g., an activated T cell. In certain embodiments, such enhancers are used in a cell that is typically a non-dividing cell, e.g., a liver cell, a monocyte, a neuron, a hematopoietic stem cell, or a muscle cell.In certain embodiments, an enhancer of template-based genome editing increases the availability of deoxynucleoside triphosphate (dNTP), e.g., the concentration of dNTP in the nucleus relative to a cell not contacted with such an enhancer, particularly in a cell that is typically a non-dividing cell, e.g., a liver cell. In certain embodiments, increasing the dNTP concentration in the cell comprises inhibiting a deoxynucleotide triphosphate triphosphohydrolase in the cell. In certain embodiments, the deoxynucleotide triphosphate triphosphohydrolase comprises SAM domain and HD domain-containing protein 1 (SAMHD1)(see, e.g., ncbi.nlm.nih.gov / gene / 25939, which is incorporated herein by reference in the version available as of the earliest filing date of this application). In certain embodiments, inhibiting SAMHD1 comprises contacting the SAMHD1 with a Vpx protein, or expressing the Vpx protein in the cell (see, e.g., www. ncbi.nlm.nih.gov / gene / 1724714, which is incorporated herein by reference in the version available as of the earliest filing date of this application). In various aspects, inhibiting SAMHD1 comprises contacting the SAMHD1 with a BGLF4 protein, or expressing the BGLF4 protein in the cell (see, e.g., www.ncbi.nlm.nih.gov / gene / 3783704, which is incorporated herein by reference in the version available as of the earliest filing date of this application). In various aspects, inhibiting SAMHD1 comprises contacting the SAMHD1 with an M97 protein, or expressing the M97 protein in a cell (see, e.g., www.ncbi.nlm.nih.gov / gene / 80532996, which is incorporated herein by reference in the version available as of the earliest filing date of this application). In various aspects, inhibiting SAMHD1 comprises contacting the SAMHD1 with an KSHV ORF36 protein, or expressing the KSHV ORF36 protein in a cell. In various aspects, inhibiting SAMHD1 comprises contacting an mRNA encoding the SAMHD1 with a microRNA, shRNA, or siRNA that hybridizes to the mRNA, or expressing the microRNA, shRNA or siRNA in the cell. In certain embodiments, inhibiting SAMHD1 comprises contacting the SAMHD1 with a small molecule SAMHD1 inhibitor. In certain embodiments, increasing the dNTP concentration in the cell comprises administering dNTPs to the cell. In certain embodiments, administering dNTPs to the cell comprises administering dNTPs to a subject comprising the cell. In various aspects, increasing the dNTP concentration in the cell comprises administering nucleosides or nucleotides to the cell. The nucleosides or nucleotides may include deoxynucleosides (dNs), deoxynucleoside monophosphates (dNMPs), or nucleoside triphosphates (NTPs). In certain embodiments, the nucleosides or nucleotides are not dNTPs, or do not include dNTPs. In certain embodiments, administering nucleosides or nucleotides to the cell comprises administering the nucleosides or nucleotides to a subject comprising the cell. In certain embodiments, increasing the dNTP concentration in the cell comprises delivering a dNTP synthetic enzyme to the cell. In various aspects, the dNTP synthetic enzyme comprises a kinase. In certain embodiments, the kinase comprises a nucleoside kinase, deoxynucleoside kinase, deoxynucleoside monophosphate kinase, or deoxynucleotide diphosphate kinase. Such enhancers to increase availability of dNTP in a cell are known in the art.In certain embodiments, a DNA repair protein-based enhancer is used in combination with an enhancer to increase the availability of dNTP in a cell.In some embodiments, the presence of one or more enhancers may increase the efficiency of template-based genome editing by at least five-fold, optionally by at least 10-fold.The term “chromatin remodeler,” as used herein, is a polypeptide that is capable of interacting with chromatin and mediating changes in chromatin. The chromatin remodeler may alter the interaction between DNA and DNA binding proteins, thereby increasing chromatin accessibility. In some embodiments, target genomic sequences located in a chromatin-dense region, in particular, may be less susceptible to genome editing. For example, it is known that Cas9 can exhibit reduced editing of targets whose protospacer adjacent motifs (PAMs) are located within nucleosomes. A system or fusion protein comprising a chromatin remodeler may therefore show increased editing efficiency at loci that are positioned within compacted chromatin.The term “High Mobility Group Box 1” or “HMGB1,” as used herein in the context of the HMGB 1 protein, refers to a non-histone, nuclear DNA-binding protein belonging to the High Mobility Group-Box superfamily, or a portion thereof. The wildtype HMGB1 protein is composed of 215 amino acids in three structural domains: a Box A DNA-binding domain (alternatively referred to as an HMGB1 Box A domain elsewhere herein), an Box B DNA-binding domain (alternatively referred to elsewhere herein as an HMGB1 Box B domain elsewhere herein), and an acidic tail domain. The wildtype HMGB1 protein comprising SEQ ID NO: 1783 may be understood to comprise, from N-terminus to C-terminus, a HMGB1 Box A DNA-binding domain comprising the sequence of amino acid residues 2-78 of SEQ ID NO: 1783, a HMGB1 Box B DNA-binding domain comprising the sequence of amino acid residues 89-162 of SEQ ID NO: 1783, a cryptic nuclear localization signal (NLS) comprising the sequence of amino acid residues 179-185 of SEQ ID NO: 1783, and an acidic tail corresponding to amino acid residues 186-215 of SEQ ID NO: 1783. The term “HMGB1 polypeptide” as used herein refers to a polypeptide comprising the amino acid sequence of HMGB 1, or a portion or fragment thereof. For example, in some embodiments, an HMGB1 polypeptide can comprise one or more HMGB1 domains (such as an HMGB1 Box B domain, an HMGB1 Box A domain, and an acidic tail domain). It is understood that, when an HMGB1 polypeptide is present as part of a fusion protein, the HMGB1 polypeptide may be referred as “HMGB1” (e.g., “a fusionprotein comprising, from N-terminus to C-terminus, deaminase-first linker-DNA-binding domain- heterologous NLS-second linker-HMGB1”). In some embodiments, the acidic tail may serve as a transcription stimulatory domain. “HMGB1” as used herein in the context of nucleic acids refers to a nucleic acid (e.g., DNA or mRNA) encoding an HMGB1 polypeptide. The human HMGB1 gene has accession number NC_000013.11 (30456704.30617597). It is understood that, when an HMGB1 polypeptide (e.g., an HMGB1 protein of SEQ ID NO: 1783) is present as part of a fusion protein, the N-terminal methionine residue of HMGB1 may be omitted.As used herein, in the context of the wildtype HMGB1 protein, the term “Box A” refers to an amino acid sequence comprising or consisting of SEQ ID NO: 1785. In some embodiments, the HMGB1 Box A domain may comprise or consist of amino acid residues 2-78 of SEQ ID NO: 1783. In some embodiments, the HMGB1 Box A domain may have DNA binding activity.As used herein, in the context of the wildtype HMGB1 protein, the term “Box B” refers to an amino acid sequence comprising or consisting of SEQ ID NO: 1786. In some embodiments, the HMGB1 Box B domain may comprise or consist of amino acid residues 89-162 of SEQ ID NO: 1783. In some embodiments, the HMGB1 Box B domain may have DNA binding activity.As used herein, in the context of the wildtype HMGB1 protein, the term “cryptic nuclear localization signal” or “cryptic NLS” refers to an amino acid sequence comprising or consisting of EKSKKKK (SEQ ID NO: 1787) or a variant thereof. In some embodiments, the cryptic NLS may comprise amino acid residues 179-185 of SEQ ID NO: 1783. In some embodiments, the cryptic NLS may comprise additional amino acid residues. In some embodiments, the cryptic NLS may comprise a part of or all of amino acid residues 166-185 of SEQ ID NO: 1783. In some embodiments, the cryptic NLS disclosed herein comprises a variant of EKSKKKK (SEQ ID NO: 1787) wherein one amino acid residue of SEQ ID NO: 1787 comprises a conservative substitution thereof. As used herein, a cryptic NLS, as provided by SEQ ID NO: 1787, or as a variant thereof, is not a heterologous NLS described herein.In some embodiments, the cryptic NLS may have constitutive NLS activity (that is, act as a signal fragment that mediates the nuclear import of the HMGB1 protein). In some embodiments, the cryptic NLS may not have constitutive NLS activity.As used herein, in the context of the wildtype HMGB1 protein, the term “receptor for advanced glycation end-products (RAGE) binding domain” or “RAGE binding domain” refers to an amino acid sequence comprising amino acid residues 150-183 of SEQ ID NO: 1783. In some embodiments, the HMGB1 polypeptide described herein comprises a RAGE binding domain, or portion thereof, C-terminal to the HMGB1 Box B domain. In some embodiments, the RAGE binding domain comprises the amino acid sequence of SEQ ID NO: 1803 C terminal to the Box B domain.As used herein, in the context of the wildtype HMGB1 protein, the term “acidic tail domain” of an amino acid sequence comprising or consisting of SEQ ID NO: 1788. In some embodiments, the acidic tail domain may comprise or consist of amino acid residues 186-215 of SEQ ID NO: 1783. In some embodiments, the acidic tail domain may have transcriptional stimulatory function.As used herein, the term “fusion protein” (or “fusion polypeptide”) refers to a hybrid polypeptide which comprises polypeptides from at least two different proteins or sources. One polypeptide may be located at the amino-terminal (N-terminal) portion of the fusion protein or at the carboxy-terminal (C- terminal) protein thus forming an “amino-terminal fusion protein” or a “carboxy-terminal fusion protein,” respectively. It is understood that, if one or more of the polypeptides includes an N-terminal methionine corresponding to a start codon, the methionine may be omitted from the fusion protein. For example, a polypeptide that is not located at the N-terminal portion in some cases may lack an N-terminal methionine and its coding sequence may similarly lack a start codon in its open reading frame that ordinarily would encode an N-terminal methionine. A fusion protein can be expressed from a single ORF for expression as a single polypeptide. A fusion protein can be expressed as two polypeptides each having a paired intein for trans-splicing to generate a fusion protein. Any of the proteins provided herein may be produced by any method known in the art.The term “linker,” as used herein, refers to a chemical group or a molecule linking two adjacent molecules or moieties. Typically, the linker is positioned between, or flanked by, two groups, molecules, or other moieties and connected to each one via a covalent bond. In some embodiments, the linker is a peptide linker comprising an amino acid or a plurality of amino acids (e.g., a peptide or protein) such as a 16-amino acid residue “XTEN” linker, or a variant thereof (See, e.g., the Examples; and Schellenberger et al. A recombinant polypeptide extendsthe in vivo half-life of peptides and proteins in a tunable manner. Nat. Biotechnol. 27, 1186-1190 (2009)). In some embodiments, the XTEN linker comprises the sequence SGSETPGTSESATPES (SEQ ID NO: 1601), SGSETPGTSESA (SEQ ID NO: 1602), SGSETPGTSESATPEGGSGGS (SEQ ID NO: 1603), or GAPESATESGGTSTESEGSAGPKKKRKVTSTESEGSAGSAGSTSGSSSG (SEQ ID NO: 1600).The term “intein,” as used herein refers to a protein domain capable of mediating a process known as protein splicing. After intein directed protein splicing, the resulting protein is a fusion protein. In certain instances, the intein may be one formed from two separate but complementary split inteins that are capable of ligating together to mediate a trans-protein splicing reaction. The term “split intein” refers to an intein that may exist as two separate polypeptide fragments - an N-split-intein (N-intein) and a C-split-intein (C-intein)- where the two polypeptide fragments are capable of ligating together and undergoing a protein transsplicing reaction culminating in the formation of a peptide bond between polypeptide sequences flanking each split intein providing a fusion protein. For example, a first split intein positioned at the C-terminus of a first polypeptide (the N-terminal intein or N-intein) and a second split intein positioned at the N-terminus of a second polypeptide (the C-terminal intein or C-intein) may undergo a chemical reaction culminating in the formation of a peptide bond between the first polypeptide and the second polypeptide and the excision of the first and second intein domains. Intein-mediated protein splicing is known in the art and represents a well-established technique for generating a single fusion protein from two separate polypeptides (see, e.g., Shah and Muir. Inteins: Nature’s Gift to Protein Chemists. Chem. Sci., 5(1), 446-461 (2014)).The term “heterodimerization domain” can include coiled coil polypeptides capable of self-assembling into stable heterodimers with other coiled coil polypeptides referred to herein as “coiled coil heterodimerization domains.” The coiled coil heterodimerization domain is a ubiquitous protein folding and assembly motif which has been identified in well over 200 natural proteins. Structurally, it is made of a-helices wrapping around each other forming a supercoil, either right- or left-handed. Such structures are well known in the art. In some embodiments, coiled coil heterodimerization domains may comprise EV, El, KV, and KI domains, where E, V, I, and K are aspartic acid, valine, isoleucine, and lysine, respectively. Exemplary coiled coil heterodimerization domains may comprise, from N-terminus to C-terminus, the sequenceEVSALEKEVSALEKENSALEWEVSALEK (EV domain, SEQ ID NO: 1590), I< VSALI< EI< VSALI< EI< NSALI< WI< VSALI< E (KV domain, SEQ ID NO: 1591), IAALEKEIAALEKENAALEWEIAALEK (El domain, SEQ ID NO: 1589), EIAALEKEIAALEKENAALEWEIAALEK (El domain, SEQ ID NO: 1593), or I< IAALI< EI< IAALI< EI< NAALI< WI< IAALI< E (KI domain, SEQ ID NO: 1595). Coiled coil heterodimerization domains are known in the art and associate with their binding domain (see, e.g., Aronsson C, Danmark S, Zhou F, Oberg P, Enander K, Su H, Aili D. Self-sorting heterodimeric coiled coil heterodimerization domains with defined and tuneable self-assembly properties. SciRep. 2015 Sep 15;5:14063. doi: 10.1038 / srepl4063). KI domains interact with El domains to form heterodimers, while KV domains interact with EV domains to form heterodimers.As used herein, the terms “nuclear localization signal” (NLS) or “nuclear localization sequence” refers to an amino acid sequence which induces transport of molecules comprising such sequences or linked to such sequences into the nucleus of eukaryotic cells. The nuclear localization signal may form part of the molecule to be transported. In some embodiments, the NLS may be fused to the molecule by a covalent bond, hydrogen bonds, or ionic interactions. In some embodiments, the NLS may be fused to the molecule via a linker.As used herein, a “target sequence” or “genomic target sequence” refers to a sequence of nucleic acid in a target genomic locus, in either the positive or the negative strand, that has complementarity to the guide sequence of the guide RNA, i.e., that is sufficiently complementary to the guide sequence of the guide RNA to permit specific binding of the guide to the target sequence. The interaction of the target sequence and the guide scaffold sequence directs an RNA-guided DNA binding agent, e.g., an Nme2-nCas9, to bind, and potentially nick or cleave (depending on the activity of the agent), within the target sequence. Target sequences for Nme2Cas proteins include both the positive and negative strands of genomic DNA (i.e., the sequence given and the sequence’s complement), as a nucleic acid substrate for a Cas protein is a double stranded nucleic acid. Accordingly, where a guide sequence is said to be “complementary to a target sequence,” it is to be understood that the guide sequence may direct Nme2-nCas9 to bind to the complement of a target sequence. Thus, in some embodiments, where the guide sequence binds the complement of a target sequence, the guide sequence is identical to certainnucleotides of the target sequence (e.g., the target sequence which does not include the PAM) except for the substitution of U for T in the guide sequence.In some embodiments, the target sequence is in a genomic locus or on a chromosome, for example, and is complementary to the guide sequence. For example, the guide sequence and the target sequence may contain 1, 2, 3, or 4 mismatches, where the total length of the duplex formed between the guide sequence and the target sequence in the genome is typically across 24 base pairs. In other embodiments, the guide sequence and the target sequence may contain at least one mismatch, i.e., one nucleotide that is not identical or not complementary, depending on the reference sequence.As used herein, a “target strand” refers to the strand (positive or negative) of the DNA duplex target nucleic acid that comprises the target sequence.As used herein, a “non-target strand” refers to the strand (positive or negative) of the DNA duplex target nucleic acid that comprises a sequence that is complementary to the target sequence.“Messenger RNA” or “mRNA” is used herein to refer to a polynucleotide that comprises an open reading frame that can be translated into a polypeptide (i.e., can serve as a substrate for translation by a ribosome and amino-acylated tRNAs). mRNA can comprise one or more chemically modified nucleosides such as 5-methyl-cytidine (5mC), 2-thio-uridine (2sU), Nl-methylpseudouridine (ml \| / U) and pseudo-uridine (\| / U), or a modified cap structure as provided below.“Polynucleotide” and “nucleic acid” are used herein to refer to a multimeric compound comprising nucleosides or nucleoside analogs which have nitrogenous heterocyclic bases or base analogs linked together along a backbone, including conventional RNA, DNA, mixed RNA-DNA, and polymers that are analogs thereof. A nucleic acid “backbone” can be made up of a variety of linkages, including one or more of sugar-phosphodiester linkages, peptide-nucleic acid bonds (“peptide nucleic acids” or PNA; PCT No. WO 95 / 32305), phosphorothioate linkages, methylphosphonate linkages, or combinations thereof. Sugar moieties of a nucleic acid can be ribose, deoxyribose, or similar compounds with substitutions, e.g., 2’ methoxy, 2’ halide, or 2’-O-(2-methoxy ethyl) (2’-O-moe) substitutions. Nitrogenous bases can be conventional bases (A, G, C, T, U), analogs thereof (e.g., modified uridines such as 5-methoxyuridine, pseudouridine, or N1 -methylpseudouridine, or others).As used herein, a “population of cells comprising edited cells” (or “population of cells comprising engineered cells”) or the like refers to a cell population that comprises edited cells (or engineered cells), however not all cells in the population must be edited.As used herein, a “control” is understood as an appropriate matched sample or subject for comparison. For example, a control can be a cell population treated in the same manner as the test population except that the treatment used for the control population lacks at least one active agent, e.g., a guide RNA, an mRNA encoding an Nme2-nCas9, an insertion construct, a lipid formulation. In certain embodiments, a control may be an internal control, e.g., a cell population prior to treatment.As used herein, the phrase “pharmaceutically acceptable” means that which is useful in preparing a pharmaceutical composition that is generally non-toxic and is not biologically undesirable and that are not otherwise unacceptable for pharmaceutical use. Pharmaceutically acceptable generally refers to substances that are non-pyrogenic. Pharmaceutically acceptable can refer to substances that are sterile, especially for pharmaceutical substances that are for injection or infusion.Before describing the present teachings in detail, it is to be understood that the disclosure is not limited to specific compositions or process steps, as such may vary. It should be noted that, as used in this specification and the appended claims, the singular form “a”, “an” and “the” include plural references unless the context clearly dictates otherwise. Thus, for example, reference to “a conjugate” includes a plurality of conjugates and reference to “a cell” includes a plurality of cells and the like.The term “about” or “approximately” means an acceptable error for a particular value as determined by one of ordinary skill in the art, which depends in part on how the value is measured or determined, or a degree of variation that does not substantially affect the properties of the described subject matter, or within the tolerances accepted in the art, e.g., within 10%, 5%, 2%, or 1% or within two standard deviations of a set of values. Accordingly, unless indicated to the contrary, the numerical parameters set forth in the following specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques.When “about” is present before the first value of a series, it is understood to modify each value in the series.Numeric ranges are inclusive of the numbers defining the range. Measured and measurable values are understood to be approximate, taking into account significant digits and the error associated with the measurement. Also, the use of “comprise”, “comprises”, “comprising”, “contain”, “contains”, “containing”, “include”, “includes”, and “including” are not intended to be limiting. It is to be understood that both the foregoing general description and detailed description are exemplary and explanatory only and are not restrictive of the teachings.Unless specifically noted in the specification, embodiments in the specification that recite “comprising” various components are also contemplated as “consisting of’ or “consisting essentially of’ the recited components; embodiments in the specification that recite “consisting of’ various components are also contemplated as “comprising” or “consisting essentially of’ the recited components; and embodiments in the specification that recite “consisting essentially of’ various components are also contemplated as “consisting of’ or “comprising” the recited components (this interchangeability does not apply to the use of these terms in the claims).The term “or” is used in an inclusive sense, i.e., equivalent to “and / or” unless the context clearly indicates otherwise.Ranges are understood to include the numbers at the end of the range and all logical values therebetween. For example, 5-10 nucleotides is understood as 5, 6, 7, 8, 9, or 10 nucleotides, whereas 5-10% is understood to contain 5% and all possible values through 10%.At least 21 nucleotides of a 24-nucleotide sequence is understood to include 21, 22, 23, or 24 nucleotides of the sequence provided, thereby providing a upper limit even if one is not specifically provided as it would be clearly understood. Similarly, up to 3 nucleotides would be understood to encompass 0, 1, 2, or 3 nucleotides, providing a lower limit even if one is not specifically provided. When “at least,” “up to,” or other similar language modifies a number, it is understood to modify each number in the series.As used herein, “no more than” or “less than” is understood as the value adjacent to the phrase and logical lower values or integers, as logical from context, to zero. For example, a duplex region of “no more than 2 nucleotide base pairs” has a 2, 1, or 0 nucleotide base pairs. When “no more than” or “less than” is present before a series of numbers or a range, it is understood that each of the numbers in the series or range is modified.As used herein, “detecting an analyte” and the like is understood as performing an assay in which the analyte can be detected, if present, wherein the analyte is present in an amount above the level of detection of the assay.As used herein, it is understood that when the maximum amount of a value is represented by 100% (e.g., 100% inhibition or 100% encapsulation) that the value is limited by the method of detection. For example, 100% inhibition is understood as inhibition to a level below the level of detection of the assay, and 100% encapsulation is understood as no material intended for encapsulation can be detected outside the vesicles.Reference will now be made in detail to certain embodiments of the invention, examples of which are illustrated in the accompanying drawings. While the invention is described in conjunction with the illustrated embodiments, it will be understood that they are not intended to limit the invention to those embodiments. On the contrary, the invention is intended to cover all alternatives, modifications, and equivalents, which may be included within the invention as defined by the appended claims and included embodiments.Template Guide RNAProvided here are a template guide RNA (tgRNA) comprising a first polynucleotide and a second polynucleotide, wherein: (a) the first polynucleotide comprises an Nme-Cas9 guide RNA comprising: (i) a spacer that is complementary to a target region of a target strand of a DNA duplex target nucleic acid; and (ii) an Nme2-Cas9 scaffold; and (b) the second polynucleotide (optionally operably linked to the first polynucleotide) comprises: (i) a template sequence that is at least 10 nucleotides in length and complementary to at least a portion of a non-target strand of the DNA duplex target nucleic acid, wherein the template sequence comprises a 3’ end and a 5’ end; and wherein the template comprises DNA nucleotides; and (ii) a DNA-dependent DNA polymerase recruiting sequence (DRS) having a 3’ end and a 5’ end; wherein the 5’ end of the DRS is covalently attached to the 3 ’ end of the template sequence, and wherein the DRS comprises a sequence that is reverse complementary to at least 6 nucleotides of a DRS-complementary region of the non-target strand of the DNA duplex target nucleic acid. In some embodiments, the DRS is 6-20 nucleotides in length, optionally 10-14 nucleotides in length. In some embodiments, the DRS comprises at least one of: (a) a sequence not fully complementary to the DRS-complementary region of the non-target strand of the DNA duplex target nucleicacid; (b) a 1-5 nucleotide, optionally a 1-3 nucleotide 3’ terminal tail comprising a 3’ terminal modified uridine nucleotide; or a terminal (DI) DNA nucleotide and a penultimate 5’ terminal (D2) RNA nucleotide wherein the 3’ end of the first polynucleotide is covalently linked to the 5’ end of the second polynucleotide by a phosphorothioate or phosphodiester linkage. In some embodiments, the DRS of the tgRNA comprises DNA nucleotides. In some embodiments, the DRS of the tgRNA comprises both RNA nucleotide(s) and DNA nucleotide(s).Provided here are systems comprising a template guide RNA (tgRNA) comprising a first polynucleotide and a second polynucleotide, wherein: (a) the first polynucleotide comprises an Nme2-Cas9 guide RNA comprising: (i) a spacer that is complementary to a target region of a target strand of a DNA duplex target nucleic acid; and (ii) an Nme2-Cas9 scaffold; and (b) the second polynucleotide (optionally operably linked to the first polynucleotide) comprises: (i) a template sequence that is at least 10 nucleotides in length and complementary to at least a portion of a non-target strand of the DNA duplex target nucleic acid, wherein the template sequence comprises a 3’ end and a 5’ end; and wherein the template comprises DNA nucleotides; and (ii) a DNA-dependent DNA polymerase recruiting sequence (DRS) having a 3’ end and a 5’ end; wherein the 5’ end of the DRS is covalently attached to the 3’ end of the template sequence, and wherein the DRS comprises a sequence that is reverse complementary to at least 6 nucleotides of a DRS-complementary region of the non-target strand of the DNA duplex target nucleic acid, wherein the DRS comprises RNA nucleotides.In some embodiments, the tgRNA comprises a first polynucleotide and a second polynucleotide, wherein: (a) the first polynucleotide comprises an Nme-Cas9 guide RNA comprising: (i) a spacer that is complementary to a target region of a target strand of a DNA duplex target nucleic acid; and (ii) an Nme2-Cas9 scaffold; and (b) the second polynucleotide (optionally operably linked to the first polynucleotide) comprises: (i) a template sequence that is at least 10 nucleotides in length and complementary to at least a portion of a non-target strand of the DNA duplex target nucleic acid, wherein the template sequence comprises a 3’ end and a 5’ end; and wherein the template comprises DNA nucleotides; (ii) a DNA-dependent DNA polymerase recruiting sequence (DRS) that is 6-20 nucleotides in length, optionally 6-17 or 10-14 nucleotides in length and having a 3’ end and a 5’ end; wherein the 5’ end of the DRS is covalently attached to the 3’ end of the template sequence, and wherein the DRS comprises a sequence that is complementary to at least 6 nucleotides of a DRS-complementary region of thenon-target strand of the DNA duplex target nucleic acid; and wherein the DRS comprises at least one of: (1) a sequence not fully complementary to the DRS-complementary region of the nontarget strand of the DNA duplex target nucleic acid; (2) a 1-5, optionally a 1-3 nucleotide 3’ terminal tail comprising a 3’ terminal modified uridine nucleotide; or (3) a 5’ terminal (DI) DNA nucleotide and a penultimate 5’ terminal (D2) RNA nucleotide wherein the 3’ end of the first polynucleotide is covalently linked to the 5’ end of the second polynucleotide by a phosphorothioate or phosphodiester linkage. In some embodiments, the DRS of the tgRNA comprises DNA nucleotides. In some embodiments, the DRS of the tgRNA comprises both RNA nucleotide(s) and DNA nucleotide(s).In some embodiments, the tgRNA comprises a first polynucleotide and a second polynucleotide, wherein: (a) the first polynucleotide comprises an Nme-Cas9 guide RNA comprising: (i) a spacer that is complementary to a target region of a target strand of a DNA duplex target nucleic acid; and (ii) an Nme2-Cas9 scaffold; and (b) the second polynucleotide (optionally operably linked to the first polynucleotide) comprises: (i) a template sequence that is at least 10 nucleotides in length and complementary to at least a portion of a non-target strand of the DNA duplex target nucleic acid, wherein the template sequence comprises a 3’ end and a 5’ end; and wherein the template comprises DNA nucleotides; (ii) a DNA-dependent DNA polymerase recruiting sequence (DRS) that is 6-20 nucleotides in length, optionally 6-17 or 10-14 nucleotides in length and having a 3’ end and a 5’ end; wherein the 5’ end of the DRS is covalently attached to the 3’ end of the template sequence, and wherein the DRS comprises a sequence that is complementary to at least 6 nucleotides of a DRS-complementary region of the non-target strand of the DNA duplex target nucleic acid, wherein the DRS comprises RNA nucleotides; and wherein the DRS comprises at least one of: (1) a sequence not fully complementary to the DRS-complementary region of the non-target strand of the DNA duplex target nucleic acid; (2) a 1-5, optionally a 1-3 nucleotide 3’ terminal tail comprising a 3’ terminal modified uridine nucleotide; or (3) a 5’ terminal (DI) DNA nucleotide and a penultimate 5’ terminal (D2) RNA nucleotide wherein the 3’ end of the first polynucleotide is covalently linked to the 5’ end of the second polynucleotide by a phosphorothioate or phosphodiester linkage.In some embodiments, the tgRNA comprises a first polynucleotide and a second polynucleotide, wherein (a) the first polynucleotide comprises an Nme-Cas9 guide RNA comprising: (i) a spacer that is complementary to a target region of a target strand of a DNAduplex target nucleic acid; and (ii) an Nme2-Cas9 scaffold; and (b) the second polynucleotide (optionally operably linked to the first polynucleotide) comprises: (i) a template sequence that is at least 10 nucleotides in length and complementary to at least a portion of a non-target strand of the DNA duplex target nucleic acid, wherein the template sequence comprises a 3’ end and a 5’ end; and wherein the template comprises DNA nucleotides; (ii) a DNA-dependent DNA polymerase recruiting sequence (DRS) that is about 6-18 nucleotides in length, optionally about 8-18 or 10-12 nucleotides in length and having a 3’ end and a 5’ end; wherein the 5’ end of the DRS is covalently attached to the 3 ’ end of the template sequence, and wherein the DRS comprises a sequence that is complementary to at least 6 nucleotides of a DRS-complementary region of the non-target strand of the DNA duplex target nucleic acid. In some embodiments, the DRS of the tgRNA comprises DNA nucleotides. In some embodiments, the DRS of the tgRNA comprises both RNA nucleotide(s) and DNA nucleotide(s).In some embodiments, the tgRNA comprises a first polynucleotide and a second polynucleotide, wherein (a) the first polynucleotide comprises an Nme-Cas9 guide RNA comprising: (i) a spacer that is complementary to a target region of a target strand of a DNA duplex target nucleic acid; and (ii) an Nme2-Cas9 scaffold; and (b) the second polynucleotide (optionally operably linked to the first polynucleotide) comprises: (i) a template sequence that is at least 10 nucleotides in length and complementary to at least a portion of a non-target strand of the DNA duplex target nucleic acid, wherein the template sequence comprises a 3’ end and a 5’ end; and wherein the template comprises DNA nucleotides; (ii) a DNA-dependent DNA polymerase recruiting sequence (DRS) that is about 6-18 nucleotides in length, optionally about 8-18 or 10-12 nucleotides in length and having a 3’ end and a 5’ end; wherein the 5’ end of the DRS is covalently attached to the 3 ’ end of the template sequence, and wherein the DRS comprises a sequence that is complementary to at least 6 nucleotides of a DRS-complementary region of the non-target strand of the DNA duplex target nucleic acid, wherein the DRS comprises RNA nucleotides.In some embodiments, the tgRNA comprises a first polynucleotide and a second polynucleotide, wherein (a) the first polynucleotide comprises an Nme-Cas9 guide RNA comprising: (i) a spacer that is complementary to a target region of a target strand of a DNA duplex target nucleic acid; and (ii) an Nme2-Cas9 scaffold; and (b) the second polynucleotide (optionally operably linked to the first polynucleotide) comprises: (i) a template sequence that isat least 10 nucleotides in length and complementary to at least a portion of a non-target strand of the DNA duplex target nucleic acid, wherein the template sequence comprises a 3’ end and a 5’ end; and wherein the template comprises DNA nucleotides; and (ii) a DNA-dependent DNA polymerase recruiting sequence (DRS) that is 6-20 nucleotides in length, optionally 6-17 or 10-14 nucleotides in length, and having a 3’ end and a 5’ end; wherein the 5’ end of the DRS is covalently attached to the 3’ end of the template sequence, and wherein the DRS comprises a sequence that is complementary to at least 6 nucleotides of a DRS-complementary region of the non-target strand of the DNA duplex target nucleic acid comprising nucleotides 5-105’ of the PAM in the non-target strand of the DNA duplex target nucleic acid. In some embodiments, the DRS of the tgRNA comprises DNA nucleotides. In some embodiments, the DRS of the tgRNA comprises both RNA nucleotide(s) and DNA nucleotide(s).In some embodiments, the tgRNA comprises a first polynucleotide and a second polynucleotide, wherein (a) the first polynucleotide comprises an Nme-Cas9 guide RNA comprising: (i) a spacer that is complementary to a target region of a target strand of a DNA duplex target nucleic acid; and (ii) an Nme2-Cas9 scaffold; and (b) the second polynucleotide (optionally operably linked to the first polynucleotide) comprises: (i) a template sequence that is at least 10 nucleotides in length and complementary to at least a portion of a non-target strand of the DNA duplex target nucleic acid, wherein the template sequence comprises a 3’ end and a 5’ end; and wherein the template comprises DNA nucleotides; and (ii) a DNA-dependent DNA polymerase recruiting sequence (DRS) that is 6-20 nucleotides in length, optionally 6-17 or 10-14 nucleotides in length, and having a 3’ end and a 5’ end; wherein the 5’ end of the DRS is covalently attached to the 3’ end of the template sequence, and wherein the DRS comprises a sequence that is complementary to at least 6 nucleotides of a DRS-complementary region of the non-target strand of the DNA duplex target nucleic acid comprising nucleotides 5-105’ of the PAM in the non-target strand of the DNA duplex target nucleic acid, wherein the DRS comprises RNA nucleotides.In some embodiments, the first region in the target strand and the second region in the non-target strand each base pair with a strand of the DNA duplex independently for 6-20 consecutive nucleotides within the spacer genomic target sequence. In some embodiments, the first region in the target strand and the second region in the non-target strand base pair with a strand of the DNA duplex independently for 6-16 consecutive nucleotides within the spacergenomic target sequence. In some embodiments, the first region in the target strand and the second region in the non-target strand base pair with a strand of the DNA duplex independently for 6-10 consecutive nucleotides within the spacer genomic target sequence. In some embodiments, the first region in the target strand and the second region in the non-target strand each base pair with a strand the DNA duplex independently for at least 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 consecutive nucleotides within the spacer genomic target sequence.In some embodiments, the first polynucleotide is covalently linked to the second polynucleotide. In some embodiments, the 3’ end of the first polynucleotide is covalently linked to the 5’ end of the second polynucleotide. In some embodiments, the 3’ end of the first polynucleotide is covalently linked to the 5’ end of the second polynucleotide by a phosphodiester bond or a phosphorothioate (PS) bond. In some embodiments, the 3’ end of the first polynucleotide is covalently linked to the 5’ end of the second polynucleotide by a phosphodiester bond. In some embodiments, the 3’ end of the first polynucleotide is covalently linked to the 5’ end of the second polynucleotide by a phosphorothioate bond. In some embodiments, the first polynucleotide is linked to the second polynucleotide by a non-nucleotide linker. In some embodiments, the first polynucleotide is linked to the second polynucleotide by an internal linker. In some embodiments, the 3’ end of the first polynucleotide is covalently linked to the 5’ end of the second polynucleotide by an internal linker.Provided herein are guide RNAs that in some embodiments include an operably linked 3 ’ extension sequence, referred to herein as template guides (tgRNA). As used herein, a guide RNA (gRNA) is understood to include at least a spacer (targeting) sequence that is complementary to a target sequence in a genomic locus; and a scaffold sequence for binding an Nme2Cas9 nickase. The spacer and scaffold can be in a single polynucleotide, i.e., a single guide RNA (sgRNA), or in two polynucleotides, i.e., a dual guide RNA (dgRNA) in which the crRNA and tracrRNA are separate polynucleotides.In certain embodiments, the guide RNA may be operably linked to a 3 ’-extension (i.e., a template guide RNA (tgRNA)). A 3’ extension includes, 5’ to 3’, a template and a DNA polymerase recruiting sequence (DRS). The template and DRS are covalently linked by a polynucleotide backbone linkage, e.g., a phosphodiester or phosphorothioate linkage, preferably a phosphorothioate linkage. When covalently attached, the 3’ extension is covalently attached, directly or indirectly, to the 3’ end of the scaffold. When the 3’ extension is not covalentlyattached to the 3’ end of the scaffold, it is referred to herein as a separable 3’ extension as it provides the same features at a site of template-based genome editing. When the 3’ extension is not covalently linked to the 3’ end of the scaffold, it can be retained at the site of template-based genome editing by binding to the polymerase, e.g., via an affinity tag to a 3’ extension-recruiting domain in the polymerase.It is understood that each the spacer and scaffold, the template, and the DRS have distinct functions. These distinct functions result in different tolerances for various nucleotides including chemically modified nucleotides and are provided herein. Therefore, as discussed herein, the terms “unmodified nucleotide” or “modified nucleotide” can be understood differently depending on the particular structure in which the nucleotide is present. Similarly, modified nucleotides for inclusion in an ORF or mRNA are different from those for inclusion in a guide RNA. Such considerations are well understood in the art.In some embodiments, the first polynucleotide sequence and the second polynucleotide sequence are provided as part of separate polynucleotide chains (i.e., the 3’ extension is a separable 3’ extension). In some embodiments, the separate polynucleotide chains comprising the first and second polynucleotide sequences, optionally with the first polynucleotide sequence complexed with Nme2Cas9 and the second polynucleotide sequence complexed with a DNA-dependent DNA polymerase, may be operably linked by being targeted to at least partially complementary sequences on opposite DNA strands of a genomic locus, i.e., nucleotide sequences that would base pair in the DNA duplex in the absence of disruption of the duplex, e.g., by a tgRNA. In some embodiments, the second polynucleotide sequence may be complexed to the DNA-dependent DNA polymerase through an affinity tag that binds to a corresponding domain on the DNA-dependent DNA polymerase.In some embodiments, the separate polynucleotide chains comprising the first and second polynucleotide sequences may be operably linked by forming a complex with a single polypeptide or a single polypeptide heterodimer, optionally wherein the polypeptide or single polypeptide heterodimer comprises Nme2Cas9 and a DNA-dependent DNA polymerase. In some embodiments, the first polynucleotide sequence may be complexed with Nme2Cas9 and the second polynucleotide sequence may be complexed with the DNA-dependent DNA polymerase. In some embodiments, the second sequence may be complexed with the DNA-dependent DNA polymerase through an affinity tag that binds to a corresponding 3’ extension recruiting domain on the single polypeptide or single polypeptide heterodimer.Guide RNAsIn some embodiments, the guide RNA disclosed herein is a Nme-Cas9 guide RNA.In some embodiments, the guide RNA is a Nme-Cas9 guide RNA that is a single guide RNA comprising a nucleotide sequence selected from SEQ ID NOs: 238-245, 248-255, 258-278, and 281-290, or a nucleotide sequence that is at least 85%, 90%, or 95% identical to SEQ ID NOs: 238-245, 248-255, 258-278, and 281-290. In some embodiments, the second guide comprises one or more internal polyethylene glycol (PEG) linker. In some embodiments, the Nme-Cas9 guide RNA comprising internal linkers comprise a sequence selected from SEQ ID NOs: 281-290.In certain embodiments, using SEQ ID NO: 253 (“Exemplary NmeCas9 sgRNA-1,” as shown in Figure 13A and provided in Figure 13A full length) as an example, the Exemplary NmeCas9 sgRNA-1 includes: (A) A guide RNA (gRNA) comprising a guide region and a conserved region, the conserved region comprising one or more of: (a) a shortened repeat / anti-repeat region, wherein the shortened repeat / anti-repeat region lacks 2-24 nucleotides within nucleotides 25-76 of SEQ ID NO: 253, wherein (i) one or more of nucleotides 37-48 and 53-64 is deleted and optionally one or more of nucleotides 37-64 is substituted relative to SEQ ID NO: 253; and (ii) nucleotide 36 is linked to nucleotide 65 by at least 2 nucleotides or by an internal linker; or (b) a shortened hairpin 1 region, wherein the shortened hairpin 1 lacks 2-10, optionally 2-8 nucleotides within nucleotides 78-100 of SEQ ID NO: 253, wherein (i) one or more of nucleotides 82-86 and 91-95 is deleted and optionally one or more of positions 82-96 is substituted relative to SEQ ID NO: 253; and (ii) nucleotide 81 is linked to nucleotide 96 by at least 4 nucleotides or by an internal linker; or (c) a shortened hairpin 2 region, wherein the shortened hairpin 2 lacks 2-18, optionally 2-16 nucleotides within nucleotides 102-143 of SEQ ID NO: 253, wherein (i) one or more of nucleotides 113-121 and 126-134 is deleted and optionally one or more of nucleotides 113-134 is substituted relative to SEQ ID NO: 253; and (ii) nucleotide 112 is optionally linked to nucleotide 135 by at least 4 nucleotides or by an internal linker; wherein one or both nucleotides 144-145 are optionally deleted relative to SEQ ID NO:253; wherein optionally at least 10 nucleotides are modified nucleotides. Internal linker structures are provided below.In certain embodiments, nt 112 is linked to nucleotide 135 of SEQ ID NO:253 by at least 4 nucleotides or an internal linker. In certain embodiments, at least nucleotides 102 to 112 is provided at the 3’ end of a first polynucleotide comprising a shortened repeat / anti-repeat region, and a shortened hairpin 1 region. At least nucleotides 135-143 of SEQ ID NO: 253 are provided on a second polynucleotide comprising a template sequence and DRS, optionally on the 3’ end of the second polynucleotide comprising the template and DRS (see, e.g., Figure 14D-14E). A duplex structure provided by hairpin 2 is formed by base pairing between the first polynucleotide and the second polynucleotide to provide a functional hairpin 2 structure.Exemplary unmodified conserved portion nucleotide sequences are provided in Table 2A.In the case of a sgRNA, the guide sequences may be integrated into one of the following exemplary modified conserved portion motifs as shown in Table 2B.In certain embodiments, the guide sequence is 20-25 nucleotides in length ((N)20-25), wherein each nucleotide may be independently modified. In certain embodiments, each of nucleotides 1-3 of the 5’ end of the guide is independently modified. In certain embodiments, each of nucleotides 1-3 of the 5’ end of the guide is independently modified with a 2’-0Me modification. In certain embodiments, each of nucleotides 1-3 of the 5’ end of the guide is independently modified with a phosphorothioate linkage to the adjacent nucleotide residue. In certain embodiments, each of nucleotides 1-3 of the 5’ end of the guide is independently modified with a 2’-0Me modification and a phosphorothioate linkage to the adjacent nucleotide residue.In the case of a sgRNA, modified guide sequences may be integrated into one of the following exemplary modified conserved portion motifs as shown in Table 2B.In some embodiments, the guide RNA comprises a sgRNA comprising a guide region and a conserved portion of an sgRNA, for example, the conserved portion of sgRNA shown as Exemplary NmeCas9 sgRNA- 1 or the conserved portions of the guide RNAs shown in Table 2A-3B and throughout the specification.In some embodiments, the sgRNA comprises Exemplary NmeCas9 sgRNA- 1 or the modified versions thereof provided herein, or a version as provided in Table 2B. Each N is independently modified or unmodified. In certain embodiments, in the absence of an indicationof a modification, the nucleotide is an unmodified RNA nucleotide residue, i.e., a ribose sugar and a phosphodiester backbone.Table 1. Exemplary Nme-Cas9 sgRNA (SEQ ID NO: 253)Table 2A. Exemplary Unmodified Nme-Cas9 Scaffold SequencesTable 2B. Exemplary Unmodified Nme-Cas9 Guide RNA SequencesTable 2C. Exemplary Modified Nme-Cas9 Scaffold Sequenceswherein “m” indicates a 2’-0-Me modification, and a indicates a phosphorothioate linkage between nucleotides, and no modification in the context of a modified sequence indicates an RNA (2 ’-OH) and a phosphorothioate linkage.Table 2D. Exemplary Modified Nme-Cas9 Guide RNA SequencesIn certain embodiments, the guide sequence is a chemically modified sequence. In certain embodiments, the chemically modified guide sequence is (mN* )3(N) 17-22. In certain embodiments, the guide sequence is (mN*)3(N)21, i.e., mN*mN*mN*NNNNNNNNNNNNNNNNNNNNN. In certain embodiments, each N of the (N)20-25 or the (N)21 is unmodified. In certain embodiments, the each N in the (N)20-25 or the (N)21 is independently modified, e.g. independently modified with a 2’-O-methyl modification.Linker containing guide RNAsIn certain embodiments, the guide RNA comprises one or more internal linkers. As used herein, “internal linker” describes a non-nucleotide segment joining two nucleotides within a guide RNA. If the guide RNA contains a spacer region, the internal linker is located outside of the spacer region (e.g., in the scaffold or conserved region of the guide RNA). Internal linkers and their use in the context of guide RNA are provided in WO2022261292, the contents of which are hereby incorporated by reference in its entirety. An “internal linker” is distinguished from a more generic linker by its position and not its chemical structure. The internal linker structures provided herein can be used, for example, as linkers for the attachment of a 3’ extension to an Nme guide scaffold.Guide RNAs disclosed herein may comprise an internal linker. In general, any internal linker compatible with the function of the guide RNA may be used. It may be desirable for the linker to have a degree of flexibility. In some embodiments, the internal linker comprises at least two, three, four, five, six, or more on-pathway single bonds. A bond is on-pathway if it is part of the shortest path of bonds between the two nucleotides whose 5’ and 3’ positions are connected to the linker.As used herein the length of the linker, e.g., the internal linker can be defined by its bridging length. The “bridging length” of a linker as used herein refers to the distance or number of atoms in the shortest chain of atoms on the pathway from the first atom of the linker (bound to a 3 ’ substituent, such as an oxygen or phosphate, of the preceding nucleotide to the last atom of the linker (bound to a 5’ substituent, such as an oxygen or phosphate) of the following nucleotide) (e.g., from ~ to # in the structure of Formula (I) described below). Approximate predicted bridging lengths for various linkers are provided in a table below.Exemplary predicted linker lengths by number of atoms, number of ethylene glycol units, approximate linker length in Angstroms on the assumption that an ethylene glycol monomer is about 3.7 Angstroms, and suitable location for substitution of at least the entire loop portion of a hairpin structure are provided in Table 3 below. Substitution of two nucleotides requires a linker length of at least about 11 Angstroms. Substitution of at least 3 nucleotides requires a linker length of at least about 16 Angstroms.In some embodiments, the internal linker has a bridging length of about 3 Angstroms to about 37 Angstroms. In some embodiments, the internal linker has a bridging length of about 6 Angstroms to about 37 Angstroms. In some embodiments, the internal linker has a bridging length of about 7 Angstroms to about 22 Angstroms.In some embodiments, the internal linker comprises 1-10 ethylene glycol subunits covalently linked to each other. In some embodiments, the internal linker comprises at least two ethylene glycol subunits covalently linked to each other. In some embodiments, the internal linker comprises at least six ethylene glycol subunits covalently linked to each other.In some embodiments, the internal linker comprises a polyethylene glycol (PEG) linker. In some embodiments, the internal linker comprises a PEG linker having from 1 to 10 ethylene glycol units. In some embodiments, the internal linker comprises a PEG linker having from 3 to 6 ethylene glycol units. In some embodiments, the internal linker comprises a PEG linker having3 ethylene glycol units. In some embodiments, the internal linker comprises a PEG linker having 6 ethylene glycol units.Table 3In some embodiments, the internal linker comprises a structure of formula (I):— L0-L1-L2-#(I)wherein:~ indicates a bond to a 3’ substituent of the preceding nucleotide;# indicates a bond to a 5’ substituent of the following nucleotide;L0 is null or C1-3 aliphatic;LI is -[E1-(R1)]m-5whereeach R1is independently a C1-5 aliphatic group, optionally substituted with 1 or 2E2,each E1and E2are independently a hydrogen bond acceptor, or are each independently chosen from cyclic hydrocarbons, and heterocyclic hydrocarbons, and each m is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; andL2 is null, C1-3 aliphatic, or is a hydrogen bond acceptor.In some embodiments, LI comprises one or more -CH2CH2O-,-CH2OCH2-, or -OCH2CH2- units (“ethylene glycol subunits”). In some embodiments, the number of -CH2CH2O-, -CH2OCH2-, or -OCH2CH2- units is in the range of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.In some embodiments, m is 1, 2, 3, 4 or 5. In some embodiments, m is 1, 2, or 3. In some embodiments, m is 6, 7, 8, 9, or 10.In some embodiments, L0 is null. In some embodiments, L0 is -CH2- or -CH2CH2-.In some embodiments, L2 is null. In some embodiments, L2 is -O-, -S-, or Cl -3 aliphatic. In some embodiments, L2 is -O-. In some embodiments, L2 is -S-. In some embodiments, L2 is -CH2- or -CH2CH2-.In the tables herein, LI and L2, are optionally, C9 and Cl 8, respectively as follows:In certain embodiments, the internal linker has a bridging length of about 3-30 atoms, optionally 12-21 atoms, and the linker substitutes for at least 2 nucleotides of the guide RNA. In certain embodiments, the internal linker has a bridging length of about 6-18 atoms, optionally about 6-12 atoms, and the linker substitutes for at least 2 nucleotides of the guide RNA. In certain embodiments, the internal linker substitutes for 2-12 nucleotides.In some embodiments, the guide RNA comprises a nucleic acid sequence of SEQ ID NO: 281-290 or other guide RNAs in Table 6, including modifications disclosed elsewhere herein.In certain embodiments, the internal linker is in a repeat-anti-repeat region of the guide RNA. In certain embodiments, the internal linker substitutes for at least 4 nucleotides of the repeat-anti-repeat region of the guide RNA (nucleotides 25-76 of SEQ ID NO: 253). In certain embodiments, the internal linker substitutes for up to 28 nucleotides in the repeat / anti-repeatregion of the guide RNA. In certain embodiments, the internal linker is in a hairpin between a first portion and a second portion of the repeat / anti-repeat region, wherein the first portion and the second portion together form a duplex portion. In certain embodiments, the internal linker substitutes for at least the loop in the repeat-anti-repeat region of an Nme Cas9 guide RNA, corresponding to nucleotides 49-52 of SEQ ID NO: 253.In certain embodiments, the internal linker is in a hairpin 1 region. In certain embodiments, the internal linker substitutes for at least 4 nucleotides of the hairpin 1 region of the guide RNA (nucleotides 78-100 of SEQ ID NO: 253). In certain embodiments, the internal linker substitutes for up to 14 nucleotides, or preferably up to 8 nucleotides in the hairpin 1 region of the guide RNA. In certain embodiments, the internal linker is in a hairpin between a first portion and a second portion of the hairpin 1 region, wherein the first portion and the second portion together form a duplex portion. In certain embodiments, the internal linker substitutes for at least the loop in the hairpin 1 region of an Nme-Cas9 guide RNA, corresponding to nucleotides 87-90 of SEQ ID NO: 253.In certain embodiments, the internal linker is in a hairpin 2 region. In certain embodiments, the internal linker substitutes for at least 4 nucleotides of the hairpin 2 region of the guide RNA (nucleotides 102- 143 of SEQ ID NO: 253). In certain embodiments, the internal linker substitutes for up to 22 nucleotides in the hairpin 2 region of the guide RNA. In certain embodiments, the internal linker is in a hairpin between a first portion and a second portion of the hairpin 2 region, wherein the first portion and the second portion together form a duplex portion. In certain embodiments, the internal linker substitutes for at least the loop in the hairpin 2 region of an Nme2Cas9 guide RNA, corresponding to nucleotides 122-125 of SEQ ID NO:253.The shortened Nme-Cas9 guide RNA may comprise internal linkers disclosed herein. In some embodiments, the internal linker comprises a polyethylene glycol (PEG) linker. The guide RNAs comprising an internal linker disclosed herein comprise one of the structures / modification patterns disclosed in WO2022 / 261292, the contents of which are hereby incorporated by reference in its entirety. Further exemplary Nme-Cas9 guide RNAs comprising linkers are provided in Table 4.In some embodiments, the shortened Nme-Cas9 guide RNA comprising internal linkers may be chemically modified as shown in Table 4. In certain embodiments, the guide sequence isa chemically modified sequence as shown in Table 4.Table 4. Exemplary Modified Nme-Cas9 Scaffold and Guide RNA SequencesIn certain embodiments, an sgRNA comprises an Nme2Cas9 sgRNA (e.g., SEQ ID NO: 253). In certain embodiments, the Nme2Cas9 sgRNA does not include a 3’ tail. In certain embodiments, the Nme2Cas9 sgRNA includes a 3’ tail, e.g., a 3’ tail of 1, 2, 3, 4 nucleotides, e.g., a tail of 1 nucleotide, e.g., a tail of 1 uridine nucleotide. It is understood that a 3’ tail is not a 3’ extension, which includes a template and a DRS, is distinct in structure and function from a 3’ tail. The nucleotides and nucleotide modifications discussed in relation to the Nme2Cas9 sgRNA spacer and scaffold may or may not be tolerated in a 3’ extension as discussed further below. In certain embodiments, the tail includes one or more modified nucleotides. In certain embodiments, the modified nucleotide is selected from a 2’-O-methyl (2’-0Me) modified nucleotide, a 2’-O-(2-methoxyethyl) (2’-O-moe) modified nucleotide, a 2’-fluoro (2’-F) modified nucleotide, a phosphorothioate (PS) linkage between nucleotides; or a combination thereof. In certain embodiments, the modified nucleotide includes a 2’-0Me modified nucleotide. In certain embodiments, the modified nucleotide includes a PS linkage between nucleotides. In certain embodiments, the modified nucleotide includes a 2’-0Me modified nucleotide and a PS linkage between nucleotides.In certain embodiments, the hairpin region includes one or more modified nucleotides. In certain embodiments, the modified nucleotide is selected from a 2’-O-methyl (2’-0Me) modified nucleotide, a 2’-O-(2-methoxyethyl) (2’-O-moe) modified nucleotide, a 2’-fluoro (2’-F) modified nucleotide, a phosphorothioate (PS) linkage between nucleotides; or a combination thereof. In certain embodiments, the modified nucleotide includes a 2’-0Me modified nucleotide.In certain embodiments, the upper stem region includes one or more modified nucleotides. In certain embodiments, the modified nucleotide selected from a 2’-O-methyl (2’-OMe) modified nucleotide, a 2’-O-(2-methoxyethyl) (2’-O-moe) modified nucleotide, a 2’-fluoro (2’-F) modified nucleotide, a phosphorothioate (PS) linkage between nucleotides; or a combination thereof. In certain embodiments, the modified nucleotide includes a 2’-0Me modified nucleotide.In certain embodiments, the Exemplary Nme2Cas9 sgRNA comprises one or more YA dinucleotides, wherein Y is a pyrimidine, wherein the YA dinucleotide includes a modified nucleotide.Guide RNAs Comprising Chemical ModificationsIn some embodiments, the Exemplary NmeCas9 sgRNA- 1 gRNA is chemically modified. An Exemplary NmeCas9 sgRNA- 1, NmeCas9 spacer and scaffold, or more simply guide RNA comprising one or more modified nucleosides or nucleotides is called a “modified” guide RNA or “chemically modified” guide RNA, to describe the presence of one or more non-naturally or naturally occurring components or configurations that are used instead of or in addition to the canonical A, G, C, and U residues. In some embodiments, a modified guide RNA that is produced or synthesized with a non-canonical nucleoside or nucleotide, is here called “modified.” Modified nucleosides and nucleotides can include one or more of: (i) alteration, e.g., replacement, of one or both of the non-linking phosphate oxygens or of one or more of the linking phosphate oxygens in the phosphodiester backbone linkage (an exemplary backbone modification); (ii) alteration, e.g., replacement, of a constituent of the ribose sugar, e.g., of the 2’ hydroxyl on the ribose sugar (an exemplary sugar modification); (iii) modification or replacement of a naturally occurring nucleobase, including with a non-canonical nucleobase (an exemplary base modification); and (iv) modification of nucleotides at the 3’ end or 5’ end of the oligonucleotide, e.g., to provide exonuclease stability, e.g., with 2’ 0-me, or 2’ halide substituted ribose; or inverted abasic terminal nucleotide, or replacement of phosphodiester with phosphorothioate. The RNA modification used depends, at least in part, to the type of the guide RNA (e.g., sgRNA, tgRNA) and the portion of the guide (e.g., spacer, scaffold, DRS, template when RNA is present in the template).Chemical modifications such as those listed above can be combined to provide modified guide RNAs comprising nucleosides and nucleotides (collectively “residues”) that can have two, three, four, or more modifications. For example, a modified residue can have a modified sugar and a modified nucleobase. In certain embodiments, phosphate groups of a guide RNA moleculeare replaced with phosphorothioate groups. In some embodiments, modified guide RNAs comprise at least one modified residue at or near the 5’ end of the RNA. In some embodiments, modified guide RNAs comprise at least one modified residue at or near the 3’ end of the RNA. In some embodiments, when the modified guide RNA comprises a 3 ’ extension that is covalently linked to the 3’ end of the scaffold sequence, the modified guide RNA does not comprise a modified residue at or near the 3’ end of the scaffold sequence.In some embodiments, the guide RNA disclosed herein comprises one, two, three or more modified residues. In some embodiments, at least 5% (e.g., at least 5%, 10%, 15%, preferably at least 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, or 85%) of the positions in a modified guide RNA are modified nucleosides or nucleotides. In some embodiments, 20-85% of the positions in the modified guide RNA spacer and scaffold are modified nucleotides.Unmodified nucleic acids can be prone to degradation by, e.g., intracellular nucleases or nucleases found in serum. For example, nucleases can hydrolyze nucleic acid phosphodiester bonds. Accordingly, in one aspect the guide RNAs described herein can contain one or more modified nucleosides or nucleotides, e.g., to introduce stability toward intracellular or serumbased nucleases. In some embodiments, the modified guide RNA molecules described herein can exhibit a reduced innate immune response when introduced into a population of cells, both in vivo and ex vivo. The term “innate immune response” includes a cellular response to exogenous nucleic acids, including single stranded nucleic acids, which involves the induction of cytokine expression and release, particularly interferons, and cell death.In some embodiments of a backbone modification, the phosphate group of a modified residue can be modified by replacing one or more of the oxygens with a different substituent. Further, the modified residue, e.g., modified residue present in a modified nucleic acid, can include the replacement of an unmodified phosphate moiety with a modified phosphate group as described herein. In some embodiments, the backbone modification of the phosphate backbone can include alterations that result in either an uncharged linker or a charged linker with unsymmetrical charge distribution.Examples of modified phosphate groups include, phosphorothioate, borano phosphate esters, methyl phosphonates, phosphoroamidates, phosphodithioate, alkyl or aryl phosphonates and phosphotriesters. In certain embodiments, the modified phosphate group is aphosphorothioate group. The phosphorous atom in an unmodified phosphate group is achiral. However, replacement of one of the non-bridging oxygens with one of the above atoms or groups of atoms can render the phosphorous atom chiral. The stereogenic phosphorous atom can possess either the “R” configuration (herein Rp) or the “S” configuration (herein Sp). The backbone can also be modified by replacement of a bridging oxygen, (i.e., the oxygen that links the phosphate to the nucleoside), with nitrogen (bridged phosphoroamidates), sulfur (bridged phosphorothioates) and carbon (bridged methylenephosphonates). The replacement can occur at either linking oxygen or at both of the linking oxygens.The phosphate group can be replaced by non-phosphorus containing connectors in certain backbone modifications, e.g., an amide linkage. In some embodiments, the charged phosphate group can be replaced by a neutral moiety. Examples of moieties which can replace the phosphate group can include, without limitation, e.g., methyl phosphonate, carboxymethyl, carbamate, amide, and thioether. Further examples of moieties which can replace the phosphate group can Include, without limitation, e.g., ethylene oxide linker, sulfonate, sulfonamide, thioformacetal, formacetal, methyleneimino, methylenemethylimino, methylenehydrazo, methylenedimethylhydrazo, and methyleneoxymethylimino.Scaffolds that can mimic nucleic acids can also be constructed wherein the phosphate linker and ribose sugar are replaced by nuclease resistant nucleoside or nucleotide surrogates. Such modifications may comprise backbone and sugar modifications. In some embodiments, the nucleobases can be tethered by a surrogate backbone. Examples can include, without limitation, the morpholino, cyclobutyl, pyrrolidine, and peptide nucleic acid (PNA) nucleoside surrogates.The modified nucleosides and modified nucleotides can include one or more modifications to the sugar group, i.e., a sugar modification. For example, the 2’ hydroxyl group (OH) can be modified, e.g., replaced with a number of different “oxy” substituents. In some embodiments, modifications to the 2’ hydroxyl group can enhance the stability of the nucleic acid since the hydroxyl can no longer be deprotonated to form a 2’ -alkoxide ion. Such 2’ modifications and their structures are well known in the art.Examples of 2’ hydroxyl group modifications can include alkoxy or aryloxy (OR, wherein “R” can be, e.g., alkyl, cycloalkyl, aryl, aralkyl, heteroaryl or a sugar); polyethyleneglycols (PEG), O(CH2CH2O)nCH2CH2OR wherein, in scaffold embodiments, R can be, e.g., H or optionally substituted alkyl, and n can be an integer from 0 to 20 (e.g., from 0to 4, from 0 to 8, from 0 to 10, from 0 to 16, from 1 to 4, from 1 to 8, from 1 to 10, from 1 to 16, from 1 to 20, from 2 to 4, from 2 to 8, from 2 to 10, from 2 to 16, from 2 to 20, from 4 to 8, from 4 to 10, from 4 to 16, and from 4 to 20). In some embodiments, the 2’ hydroxyl group modification can be 2’-0-Me. In some embodiments, the 2’ hydroxyl group modification can be a 2’-fluoro modification, which replaces the 2’ hydroxyl group with a fluoride. In some embodiments, the 2’ hydroxyl group modification can include “locked” nucleic acids (LNA) in which the 2’ hydroxyl can be connected, e.g., by a Cl-6 alkylene or Cl-6 heteroalkylene bridge, to the 4’ carbon of the same ribose sugar, where exemplary bridges can include methylene, propylene, ether, or amino bridges; 0-amino (wherein amino can be, e.g., NH2; alkylamino, dialkylamino, heterocyclyl, arylamino, diarylamino, heteroarylamino, or diheteroarylamino, ethylenediamine, or polyamino) and aminoalkoxy, O(CH2)n-amino, (wherein amino can be, e.g., NH2; alkylamino, dialkylamino, heterocyclyl, arylamino, diarylamino, heteroarylamino, or diheteroarylamino, ethylenediamine, or polyamino).Locked nucleic acids are known in the art and can be depicted as follows:In some embodiments, the 2’ hydroxyl group modification can include “unlocked” nucleic acids (UNA) in which the ribose ring lacks the C2’-C3’ bond. Such modifications are known in the art.The sugar modification can comprise a sugar group which may also contain one or more carbons that possess the opposite stereochemical configuration than that of the corresponding carbon in ribose. Thus, a modified nucleic acid can include nucleotides containing e.g., arabinose, as the sugar. The modified nucleic acids can also include abasic sugars. These abasic sugars can also be further modified at one or more of the constituent sugar atoms. The modifiednucleic acids can also include one or more sugars that are in the L form, e.g., L- nucleosides. As used herein, a single abasic sugar is not understood to result in a discontinuity of a duplex.In certain embodiments, 2’ modifications include, for example, 2’-0me, 2’-F, LNA, optionally 2’-0-Me.The modified nucleosides and modified nucleotides described herein, which can be incorporated into a modified nucleic acid, can include a modified base, also called a modified nucleobase. Examples of nucleobases include, but are not limited to, adenine (A), guanine (G), cytosine (C), and uridine (U). These nucleobases can be modified or wholly replaced to provide modified residues that can be incorporated into modified nucleic acids. The nucleobase of the nucleotide can be independently selected from a purine, a pyrimidine, a purine analog, or a pyrimidine analog. In some embodiments, the nucleobase can include, for example, naturally-occurring and synthetic derivatives of a base.In embodiments employing a guide RNA having two separate polynucleotide strands such that each strand has a 5’ terminus not covalently linked to another molecule and a 3’ end not covalently linked to another molecule, each of the polynucleotides can contain modifications, e.g., terminal modifications. Such modifications may be at one or both ends of the each of the polynucleotide strands. In some embodiments, when the first polynucleotide comprises a 3’ extension that is covalently linked to the 3’ end of the scaffold sequence, the modified first polynucleotide may not comprise a modified residue at or near the 3’ end of the scaffold sequence. In embodiments comprising an sgRNA, one or more residues at one or both ends of the sgRNA may be chemically modified, or internal nucleosides may be modified, or the sgRNA may be chemically modified throughout. Certain embodiments comprise a 5’ end modification.Certain embodiments comprise a 3’ end modification. Certain embodiments comprise a 5’ end modification and a 3’ end modification. In some embodiments, when the modified sgRNA comprises a 3’ extension that is covalently linked to the 3’ end of the scaffold sequence, the modified sgRNA optionally comprises a modified residue at or near the 3’ end of the scaffold sequence.In some embodiments, the guide RNAs, spacer and scaffold, disclosed herein comprise one of the modification patterns disclosed in WO2022 / 261292 or WO2023 / 081687, the contents of each of which are hereby incorporated by reference in their entirety.Any of the modifications described below may be present in the guide RNAs and mRNAs described herein.In the context of chemically modified sequences, “A,” “C,” “G,” “N,” and “U” denote an RNA nucleotide, i.e., 2’-OH with a phosphodiesterase linkage to the 3’ nucleotide.The terms “mA,” “mC,” “mU,” or “mG” are used to denote an adenine, cytosine, uridine, or guanidine nucleotide, respectively, that has been modified with 2’-0-Me.Modification of 2’-O-methyl can be depicted as follows:In some embodiments, the modification may be 2’-O-(2-methoxyethyl) (2’-O-moeThe terms “moeA,” “moeC,” “moeU,” or “moeG” may be used to denote an adenine, cytosine, uridine, or guanidine nucleotide, respectively, that has been modified with 2’-O-moe.Another chemical modification that has been shown to influence nucleotide sugar rings is halogen substitution. For example, 2’-fluoro (2’-F) substitution on nucleotide sugar rings can increase oligonucleotide binding affinity and nuclease stability.In this application, the terms “fA,” “fC,” “fU,” or “fG” are used to denote an adenine, cytosine, uridine, or guanidine nucleotide, respectively, that has been substituted with 2’-F.Phosphorothioate (PS) linkage or bond refers to a bond where a sulfur is substituted for one non-bridging phosphate oxygen in a phosphodiester linkage, for example in the bonds between nucleotide bases. When phosphorothioates are used to generate oligonucleotides, the modified oligonucleotides may also be referred to as S-oligos.A is used to denote a PS modification. In this application, the terms A*, C*, U*, or G* may be used to denote an adenine, cytosine, uridine, or guanidine nucleotide, respectively, that is linked to the next (e.g., 3’) nucleotide with a PS bond.In this application, the terms “mA*,” “mC*,” “mU*,” or “mG*” are used to denote an adenine, cytosine, uridine, or guanidine nucleotide, respectively, that has been substituted with 2’-0-Me and that is linked to the next (e.g., 3’) nucleotide with a PS bond.The diagram below shows the substitution of S- into a non-bridging phosphate oxygen, generating a PS bond in lieu of a phosphodiester bond:Natural phosphodiester Modified phosphorothioatelinkage of RNA (PS) bondIn some embodiments, guide RNAs are modified with sequence substitutions that do not comprise chemical modifications. In some embodiments, modified guide RNAs are engineered with G-C pairings (e.g., in lower or upper stem regions) that are not found in the parental guide RNA sequence. In some embodiments, modified guide RNAs are engineered with G-U mismatches (“GU wobbles” or mismatch pairings) that are not found in the parental guide RNA sequence.Abasic nucleotides refer to those which lack nitrogenous bases. The figure below depicts an oligonucleotide with an abasic (also known as apurinic) site that lacks a base. As used herein, the presence of a single abasic site is not considered to disrupt a duplex, e.g., a duplex formed between the targeting sequence of a guide RNA and a target site in the genome.Inverted bases refer to those with linkages that are inverted from the normal 5’ to 3’ linkage (i.e., either a 5’ to 5’ linkage or a 3’ to 3’ linkage). Such inverted bases can only be present as a terminal nucleotide. In chemical synthesis methods performed 3’ to 5’, inverted bases do not have 5’ hydroxy available to grow the chain.An abasic nucleotide can be attached with an inverted linkage. For example, an abasic nucleotide may be attached to the terminal 5’ nucleotide via a 5’ to 5’ linkage, or an abasic nucleotide may be attached to the terminal 3’ nucleotide via a 3’ to 3’ linkage. An inverted abasic nucleotide at either the terminal 5’ or 3’ nucleotide may also be called an inverted abasic end cap.Exemplary bicyclic ribose analogs include locked nucleic acid (LNA), ENA, bridged nucleic acid (BNA), or another LNA-like modifications. In some instances, a bicyclic ribose analog has 2’ and 4’ positions connected through a linker.An ENA modification refers to a nucleotide comprising a 2'-O,4'-C-ethylene modification. An exemplary structure of an ENA nucleotide is shown below, in which wavy lines indicate connections to the adjacent nucleotides (or terminal positions as the case may be, with the understanding that if the 3’ terminal nucleotide is an ENA nucleotide, the 3’ position may comprise a hydroxyl rather than phosphate).A UNA or unlocked nucleic acid modification refers to a nucleotide comprising a 2', 3'-seco-RNA modification, in which the 2’ and 3’ carbons are not bonded directly to each otherA base modification is any modification that alters the structure of a nucleobase or its bond to the backbone, including isomerization (as in pseudouridine). In some embodiments, a base modification includes inosine.The above modifications and their equivalents are included within the scope of the embodiments described herein.A modification at a YA site (also referred to as a YA modification) can be a modification of the internucleoside linkage, a modification of the base (pyrimidine or adenine), e.g. by chemical modification, substitution, or otherwise, or a modification of the sugar (e.g. at the 2’ position, such as 2’-O-alkyl, 2’-F, 2’-moe, 2’-F arabinose, (deoxyribose), and the like). In some embodiments, a “YA modification” is any modification that alters the structure of the dinucleotide motif to reduce RNA endonuclease activity, e.g., by interfering with recognition or cleavage of a YA site by an Rnase or by stabilizing an RNA structure (e.g., secondary structure) that decreases accessibility of a cleavage site to an RNase.The above modifications and their equivalents are included within the scope of the embodiments described herein.In some embodiments, one or more of the first three, four, or five nucleotides at the 5’ terminus, and one or more of the last three, four, or five nucleotides at the 3 ’ terminus are modified. In some embodiments, the modification is a 2’-O-Me, 2’-F, inverted abasic nucleotide, PS bond, or other nucleotide modification known in the art to increase stability or performance.In some embodiments, the first four nucleotides at the 5’ terminus, and the last four nucleotides at the 3’ terminus are linked with phosphorothioate (PS) bonds.In some embodiments, the first three nucleotides at the 5’ terminus, and the last three nucleotides at the 3’ terminus comprise a 2’-O-methyl (2’-0-Me) modified nucleotide. In some embodiments, the first three nucleotides at the 5’ terminus, and the last three nucleotides at the 3’ terminus comprise a 2’-fluoro (2’-F) modified nucleotide. In some embodiments, the first three nucleotides at the 5’ terminus, and the last three nucleotides at the 3’ terminus comprise an inverted abasic nucleotide.Modifications to Spacer SequenceIn some embodiments, the spacer sequence of a guide RNA is modified.In some embodiments, the spacer sequence of a guide RNA comprises a 2’-O-methyl (2’-O-Me) modified nucleotide. In some embodiments, the spacer of the tgRNA comprises at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten 2’0-Me modifications. In some embodiments, the spacer of the tgRNA comprises one, two, three, four, five, six, seven, eight, nine, ten, or eleven 2’0-Me modifications. In some embodiments, the spacer of the tgRNA comprises a 2’0-Me modification at one or more positions SI, S2, S3, S5, S8, S9, Sil, S13, S18, and S22. In some embodiments, the spacer of the tgRNA comprises a 2’0-Me modification at one or more positions SI, S2, S3, and further modifications at one or more positions selected from S5, S8, S9, Sil, SI 3, SI 8, and S22. In some embodiments, the spacer of the tgRNA comprises a 2’0-Me modification at one or more positions SI, S2, S3, and further modifications at four or more positions selected from S5, S8, S9, Sil, S13, S18, and S22.In some embodiments, the spacer sequence is 24 nucleotides in length. In some embodiments, the spacer of the guide RNA comprises a modified nucleotide. In some embodiments, the spacer of the guide RNA comprises a phosphorothioate (PS) modification, a 2’-O-methyl (2’-0-Me) modified nucleotide, or a 2’-F modified nucleotide. In someembodiments, the spacer of the guide RNA comprises a phosphorothioate (PS) modification. In some embodiments, the spacer of the guide RNA comprises a 2’-O-methyl (2’-0-Me) modified nucleotide. In some embodiments, the spacer of the guide RNA comprises a phosphorothioate (PS) modification, and a 2’-F modified nucleotide.In some embodiments, the spacer of the tgRNA comprises both DNA nucleotides and RNA nucleotides. In some embodiments, the spacer of the tgRNA comprises at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten DNA nucleotides. In some embodiments, the spacer of the tgRNA comprises one, two, three, four, five, six, seven, eight, nine, ten, or eleven DNA nucleotides. In some embodiments, the spacer of the tgRNA comprises a DNA nucleotide at one or more of positions S5, S8, S9, Sil, S13, S18, and S22. In some embodiments, the spacer sequence comprises at least 3 alternating pairs of DNA-RNA nucleotides.In some embodiments, the spacer of the guide RNA (or tgRNA) comprises DNA nucleotides. Without wishing to be bound by theory, the inclusion of DNA nucleotides in the spacer can prevent tgRNA degradation by RNAse H, in embodiments where the DRS region comprises DNA nucleotides. In some embodiments, the spacer of the guide RNA (or tgRNA) comprises a DNA nucleotide at at least 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides. In some embodiments, the spacer of the guide RNA (or tgRNA) comprises a DNA nucleotide at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 nucleotides. In some embodiments, the spacer of the guide RNA (or tgRNA) comprises a DNA nucleotide at one or more, two or more, three or more, or four or more of positions SI, S2, S3, S5, S8, S9, Sil, S13, S18, and S22. In some embodiments, the spacer of the guide RNA (or tgRNA) does not comprise DNA nucleotides. In some embodiments, the spacer of the tgRNA comprises one or more (e.g., one, two, three, four, five, six, seven, eight, nine, ten, or eleven) DNA nucleotides, and in addition comprises one or more 2’0Me or 2’F modifications. For example, a spacer containing DNA nucleotides as described herein can additionally contain 2’0Me or 2’F modifications at one or more of positions. In certain embodiments of the foregoing aspects, the spacer can be present in a tgRNA in which the DRS region contains DNA nucleotides. For example, in some embodiments, the DRS region can contain 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, 13 or more, 14 or more, 15 or more, 16 or more, 17 or more, 18 or more, 19 or more, or 20 or more DNA nucleotides. In some embodiments, each nucleotide in the DRSregion contains a DNA nucleotide. In some embodiments, the nucleotides in the DRS region contain primarily DNA nucleotides, with 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 RNA nucleotides, optionally wherein the RNA nucleotides in the DRS region comprise a 2’0Me modification.In some embodiments, the spacer of the guide RNA (e.g., tgRNA or ngRNA) comprises a modified nucleotide at one or more of the first five nucleotides at the 5’ end. In some embodiments, the spacer of the guide RNA (e.g., tgRNA or ngRNA) comprises a modified nucleotide at one or more of the first three nucleotides at the 5’ end of the spacer. Spacer modifications in Nme guide RNAs are known in the art and taught, for example, in WO2023 / 081687.Modifications to Terminal NucleotidesIn some embodiments, the 5’ or 3’ terminus region of a guide RNA is modified. In some embodiments, the terminus region of a polynucleotide strand of a guide RNA, including when a guide RNA is formed of two separate polynucleotide strands, the 5’ or 3’ terminus region of one or both polynucleotide strands is modified. In certain embodiments, each 5’ and 3’ terminus region of each strand of a polynucleotide of a guide RNA is modified. Terminal modifications in Nme gRNAs are known in the art and taught, for example, in WO2023 / 081687.3’ Terminus Region ModificationsIn some embodiments, the terminal (i.e., last) 1, 2, 3, or 4 nucleotides in the 3’ terminus region are modified. Throughout, this modification may be referred to as a “3 ’ end modification”. In some embodiments, the terminal (i.e., last) 1, 2, 3, or 4 nucleotides in the 3’ terminus region comprise more than one modification. In some embodiments, at least one of the terminal (i.e., last) 1, 2, 3, or 4 nucleotides in the 3’ terminus region are modified. In some embodiments, at least two of the terminal (i.e., last) 1, 2, 3, or 4 nucleotides in the 3’ terminus region are modified. In some embodiments, when the scaffold terminates at or 5’ of nucleotide 120 relative to SEQ ID NO:253 such that the complementary portion of hairpin 2, corresponding to at least nucleotides 135 -143, preferably at least nucleotides 132-143 of the guide scaffold, is provided in a polynucleotide not covalently attached to the scaffold portion providing the portion 5’ of nucleotide 120, the 3’ end of the scaffold can include 3’ end modification.In some embodiments, the 3 ’ end modification comprises a modified nucleotide selected from 2’-O-methyl (2’-O-Me) modified nucleotide, 2’-O-(2-methoxyethyl) (2’-O-moe) modified nucleotide, a 2’-fluoro (2’-F) modified nucleotide, a phosphorothioate (PS) linkage between nucleotides, an inverted abasic modified nucleotide, or combinations thereof.In some embodiments, the 3’ end modification comprises or further comprises a 2’-O-methyl (2’-0-Me) modified nucleotide.In some embodiments, the 3 ’ end modification comprises or further comprises a phosphorothioate (PS) linkage between nucleotides.3’ TailIn some embodiments, the guide RNA comprising a 3’ end modification comprises or further comprises a 3’ tail, wherein the 3’ tail comprises a modification of any one or more of the nucleotides present in the 3’ tail. In some embodiments, the 3’ tail is fully modified. In some embodiments, the 3’ tail comprises 1, 2, 3, 1-2, or 1-4 nucleotides, optionally where any one or more of these nucleotides are modified. 3’ tails on gRNAs are well known in the art and can be used to provide functional benefits or to facilitate synthesis of the gRNA. 3’ tails on Nme gRNA are known in the art and are provided, for example, in WO2023 / 081687.A 3’ tail can also be present at the 3’ end of a 3’ extension. A tail is characterized and distinguished from the DRS in that it is a terminal sequence that does not base pair with the genomic sequence.In some embodiments, the 3’ tail comprising 1-4 nucleotides, e.g., 1-2 nucleotides, is at the 3’ end of the conserved portion of a guide RNA. In some embodiments, the 3’ tail comprises 1-4 nucleotides, e.g., 1-2 nucleotides is at the 3’ end of the 3’ extension.In some embodiments, the 3 ’ tail comprises or further comprises a protective end modification selected from a phosphorothioate (PS) linkage between nucleotides, a 2’-0me modified nucleotide, a 2’-O-moe modified nucleotide, a 2’-F modified nucleotide, an inverted abasic modified nucleotide as a terminal nucleotide.In some embodiments, the 3 ’ tail comprises or further comprises a phosphorothioate (PS) linkages between nucleotides. In some embodiments, the 3’ tail comprises or further comprises a 2’-0me modified nucleotide. In some embodiments, the 3’ tail comprises or further comprises a combination of a phosphorothioate (PS) linkage between nucleotides, and a 2’-0me modified nucleotide.In some embodiments, the guide RNA does not comprise a 3’ tail. In some embodiments, the 3’ extension does not comprise a 3’ tail.5’ Terminus Region ModificationIn some embodiments, the 5’ terminus region is modified, for example, the first 1, 2, 3, or 4 nucleotides of the guide RNA are modified. Throughout, this modification may be referred to as a “5’ end modification”. In some embodiments, one or more of the first 1, 2, 3, or 4 nucleotides of the 5’ terminus region comprise more than one modification. In some embodiments, the first nucleotide at the 5’ terminus comprises more than one chemical modification. In some embodiments, the 5’ end modification is a 5’ protective end modification. In some embodiments, the 3’ tail comprises or further comprises a protective end modification selected from a phosphorothioate (PS) linkage between nucleotides, a 2’-0me modified nucleotide, a 2’-O-moe modified nucleotide, a 2’-F modified nucleotide, an inverted abasic modified nucleotide as a terminal nucleotide. In some embodiments, the 3’ tail comprises or further comprises a phosphorothioate (PS) linkages between nucleotides. In some embodiments, the 3’ tail comprises or further comprises a 2’-0me modified nucleotide. In some embodiments, the 3’ tail comprises or further comprises a combination of a phosphorothioate (PS) linkage between nucleotides, and a 2’-0me modified nucleotide. 5’ terminus region modifications of Nme gRNA are known in the art and are provided, for example, in WO2023 / 081687, and are discussed above as an aspect of spacer region modification.Repeat- Anti-Repeat Region ModificationsIn some embodiments, a guide RNA is provided comprising a repeat-anti-repeat region modification, wherein the repeat-anti-repeat region modification comprises modification of at least 8, 9, 10, 11, 12, 13, 14, or 15 nucleotides, optionally 12-18 nucleotides in the repeat-anti-repeat region. In some embodiments, the repeat-anti-repeat modification comprises a modified nucleotide selected from 2’-O-methyl (2’-0-Me) modified nucleotide, 2’-O-(2-methoxyethyl) (2’-O-moe) modified nucleotide, a 2’-fluoro (2’-F) modified nucleotide, optionally a 2’-0-Me or a 2’-F modification. Repeat-anti-repeat region modifications of Nme gRNA are known in the art and are provided, for example, in WO2023 / 081687.Hairpin ModificationsIn some embodiments, the guide RNA comprises a modification in the hairpin region. In some embodiments, the hairpin region modification comprises at least one modified nucleotide selected from a 2’-O-methyl (2’-0me) modified nucleotide, a 2’-fluoro (2’-F) modified nucleotide.In some embodiments, the hairpin region modification is in the hairpin 1 region. In some embodiments, the hairpin region modification is in the hairpin 2 region. In some embodiments, the hairpin region modification is only in the hairpin 2 region. In some embodiments, the hairpin region modification is in the hairpin 2 region at positions that could be characterized a 3 ’ end modification. In some embodiments, when the scaffold terminates at or 5’ of nucleotide 120 such that the complementary portion of hairpin 2, corresponding to at least nucleotides 135 -143 relative to SEQ ID NO: 253, preferably at least nucleotides 132-143 of the guide scaffold, is provided in a polynucleotide not covalently attached to the scaffold portion providing the portion 5’ of nucleotide 120, the 3’ end of the scaffold can include 3’ end modification. In some embodiments, modifications are within the hairpin 1 and hairpin 2 regions, optionally wherein the nucleotide 5’ of hairpin 1 or between hairpin 1 and 2 is also modified.In some embodiments, the hairpin modification comprises or further comprises a 2’-O-methyl (2’-0me) modified nucleotide.In some embodiments, the hairpin modification comprises or further comprises a PS modified nucleotide.In some embodiments, the guide RNA comprises a hairpin 2 region modification at positions that could be characterized a 3’ end modification. Modifications of hairpin regions of Nme gRNA are known in the art and are provided, for example, in WO2023 / 081687.3’ ExtensionIn some embodiments, the second polynucleotide of the template guide RNA is a 3 ’ extension. In some embodiments, the second polynucleotide is attached to the first polynucleotide. In some embodiments, the first polynucleotide and the second polynucleotide are covalently linked, e.g., covalently linked by a linker, e.g., by a flexible linker. In some embodiments, the first polynucleotide and the second polynucleotide are not linked to each other exclusively by phosphorothioate or phosphodiester bonds. In certain embodiments, the firstpolynucleotide and the second polynucleotide are non-covalently linked, e.g., joined by base pairing.In some embodiments, the second polynucleotide is not attached to the first polynucleotide. In some embodiments, the second polynucleotide is attached to an affinity tag, e.g., an aptamer, e.g., an MS polynucleotide. In some embodiments, the second polynucleotide is attached to the aptamer by a linker, e.g., by a flexible linker.In some embodiments, the second polynucleotide of the template guide RNA is a chimeric DNA / RNA 3’ extension polynucleotide. In some embodiments, all of the nucleotides constituting the template sequence are DNA nucleotides and the DRS comprise a plurality of RNA nucleotides. In some embodiments, all of the nucleotides constituting the template sequence are DNA nucleotides and the DRS comprise a single DNA nucleotide at its 5’ end. In some embodiments all of the nucleotides constituting the template sequence are DNA nucleotides and all of the nucleotides constituting the DRS are RNA nucleotides. In some embodiments, 1-3 nucleotides at the 3’ end of the template (T1-T3), optionally only 1 nucleotide at the 3’ end of the template (Tl) are RNA nucleotides, with the remaining nucleotides in the template being DNA nucleotides. In some embodiments, 1-7 nucleotides at the 5’ end of the DRS (nucleotides D1-D7) are DNA nucleotides, with the remaining nucleotides in the DRS being RNA nucleotides.In some embodiments, the template sequence comprises a modified nucleotide; or the DRS comprises a modified nucleotide. In some embodiments, the one or more modified nucleotides for use at an RNA position is selected from the group: 2’-0-Me; 2’-F; an amine; an alkoxy; an LNA; methoxyethyl; a halo; PS linkages; or an amine. In certain embodiments, the modified nucleotide is a 2’-0-Me modified nucleotide.Provided herein are 3’ extensions comprising a template sequence for the DNA-dependent DNA polymerase, a DNA-dependent DNA polymerase recruiting sequence (DRS), and, optionally, one or more affinity tags such as a small molecule or an aptamer. In some embodiments, the 3’ extension comprises a template sequence positioned 5’ of a DRS. In some embodiments, the 3 ’ extension comprises an affinity tag in addition to the template sequence positioned 5’ of a DRS. In some embodiments, the template sequence, DRS, and affinity tag are linked in the following orientation: 5 ’-affinity tag-template sequence-DRS-3’. In some embodiments, the 3’ extension has a single affinity tag. In some embodiments, the 3’ extensioncomprises two affinity tags and the template sequence. In some embodiments, the first and second affinity tags are the same. In some embodiments, the first and second affinity tags are different.Template SequenceIn some embodiments, the present disclosure provides for a 3’ extension comprising a template sequence. The template sequence provides a nucleotide sequence that is different from an endogenous nucleotide sequence prior to template-based genome editing. That is, the template sequence may comprise one or more of an insertion, deletion, or substitution (e.g., a transition or transversion) relative to the endogenous nucleotide sequence prior to template-based genome editing. After template-based genome editing and subsequent DNA repair, the endogenous nucleotide sequence may include the insertion, deletion, or substitution encoded by the template sequence.Because of their ability to facilitate precise, templated editing at a target sequence in a genomic locus, template sequences are of great interest for correcting mutations associated with genetic diseases. In some embodiments, the template can direct single nucleotide insertions, (e.g., insertions of 1 nucleotide), small insertions (e.g., insertions of 1-5 nucleotides), large insertions (e.g, insertions of 5 or more nucleotides), single nucleotide deletions (e.g., deletion of 1 nucleotide), small deletions (e.g., deletion of 1-5 nucleotides), or large deletions (e.g., deletion of 5 or more nucleotides). In other embodiments, the template can direct the specific substitution of one or more nucleotides. For example, the template can, in some embodiments, direct the substitution of 1 nucleotide, 1-5 nucleotides, or 5 or more nucleotides with a desired sequence. In some embodiments, the template encodes a transition (i.e., replacement of a purine with another purine, or replacement of a pyrimidine with another pyrimidine). In some embodiments, the template encodes a transversion (i.e., replacement of a purine with a pyrimidine, or replacement of a pyrimidine with a purine).The ability to introduce precise edits into a genomic sequence has numerous applications, non-limiting examples of which are described herein. For example, in certain embodiments, a template sequence comprising a single nucleotide insertion or deletion relative to the target sequence may be used to restore an open reading frame in an allele of a protein-coding gene harboring a frameshift mutation. In certain embodiments, a template sequence comprising a single nucleotide insertion, deletion, or substitution relative to a target sequence may be used tocorrect a disease-causing mutation. For example, a non-sense mutation can be corrected by removing a premature stop codon. A point mutation can be corrected by substituting a correct nucleotide for an altered or mutant nucleotide, thereby restoring the correct coding sequence of a gene of interest, or to restore a wildtype start or stop codon in a protein- coding gene. In certain embodiments, template sequences comprising an insertion relative to a target sequence may be used to restore the full-length coding sequence in an allele of a protein- coding gene comprising a large deletion. In certain embodiments, template sequences comprising a deletion relative to a target sequence may be used to restore the full-length coding sequence in an allele of a proteincoding gene comprising a repeat expansion. In certain embodiments, template sequences comprising one or more substitutions relative to a target sequence may be used to make one or more nonsynonymous substitutions in an allele of a protein-coding gene. In all of these exemplary cases, correction of the disease-associated mutation may lead to partial or full restoration of wildtype protein expression and activity.In other embodiments, the template may be used to introduce a stop codon at a precise location within a genomic sequence.In certain embodiments, template sequences comprising one or more insertions, deletions, or substitutions relative to a target sequence may be used to make one or more edits in a noncoding region of the genome. In certain non-limiting embodiments, the template sequence may comprise one or more insertions, deletions, or substitutions relative to one or more DNA or RNA regulatory elements, e.g., an enhancer, promoter, silencer, DNA boundary element, splicing enhancer, splicing silencer, or polyadenylation signal.It is to be understood that the design of the template sequence, including but not limited to features such as the length, relative position of the edit within the template sequence, and number and position of DNA nucleotides varies based on the target sequence and desired edit. For example, the distance between the PAM and the site of the desired insertion, deletion, or substitution influences the position of the insertion, deletion, or substitution (relative to the genomic DNA sequence) within the template sequence. For example, if the desired edit falls between the nick site and the PAM (i.e., within the 3 nucleotides 5’ of the PAM), then the template sequence can comprise an insertion, deletion, or substitution within the last 3 nucleotides at its 3’ end (i.e., the last three nucleotides before the boundary between the template sequence and the DRS). Alternatively, if the desired edit falls downstream of the PAM, then theinsertion, deletion, or substitution can be positioned farther away from the boundary between the template and the DRS. In addition, the number of nucleotides at the 5’ end of the template sequence that are complementary to the genomic DNA sequence can be varied based on factors including but not limited to the number of edited nucleotides (e.g., the number of substituted nucleotides or the length of an insertion or deletion) and the G / C and A / T content of the genomic DNA.The template sequence comprises DNA nucleotides wherein the plurality of nucleotides in the template sequence are DNA nucleotides. In some embodiments, all nucleotides of the template are preferably DNA nucleotides (dNTPs). In some embodiments, the template of the tgRNA comprises both DNA nucleotides and RNA nucleotides. In some embodiments, 1-3 nucleotides at the 3’ end of the template (T1-T3), optionally only 1 RNA nucleotide at the 3’ end of the template (Tl) are RNA nucleotides. In some embodiments, 1-3 nucleotides at the 3’ end of the template (T1-T3), optionally two nucleotides (e.g., at positions Tl and T2) or only one nucleotide at the 3’ end of the template (Tl) are RNA nucleotides. In some embodiments, 1-3 nucleotides at the 3’ end of the template (T1-T3) are RNA nucleotides. In some embodiments, two nucleotides at the 3’ end of the template (e.g., at positions Tl and T2, at positions Tl and T3, or at positions T2 and T3). In some embodiments, only one nucleotide at the 3’ end of the template (e.g., Tl) is a RNA nucleotide.In some embodiments, the template sequence comprises one or more modified nucleotides. In some embodiments, the modified nucleotide is selected from the group: 2’-0-Me; 2’-F; an amine; an alkoxy; an LNA; methoxy ethyl; a halo; PS linkages; or an amine. In some embodiments, the modified nucleotide is 2’-0-Me. In some embodiments, the modification in the template comprises a PS modification.In some embodiments, the template sequence is at least 5 nucleotides in length. In some embodiments, the template sequence is at least 10 nucleotides in length. In some embodiments, the template sequence is 5-100 nucleotides in length. In some embodiments, the template sequence is 10-100 nucleotides in length. In some embodiments, the template sequence is 10-500 nucleotides in length. In some embodiments, the template sequence is 10-80 nucleotides in length. In some embodiments, the template sequence is at least 6, 7, 8, 9, or 10 nucleotides in length. In some embodiments, the template sequence is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 nucleotides in length. In some embodiments, thetemplate sequence is at least 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 nucleotides in length.In some embodiments, the template sequence is 10-20 nucleotides in length. In some embodiments, the template sequence is 12-20 nucleotides in length. In some embodiments, the template sequence is 14, 15, 16, 17, or 18 nucleotides in length. In some embodiments, the template sequence is 14 nucleotides in length. In some embodiments, the template sequence is 15 nucleotides in length. In some embodiments, the template sequence is 16 nucleotides in length. In some embodiments, the template sequence is 17 nucleotides in length.In some embodiments, the template sequence is 5-10,000 nucleotides in length. In some embodiments, the template sequence is at least 5, 10, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, or 10,000 nucleotides in length. In some embodiments, the template sequence is at least 10-1000, 1000-2000, 2000-3000, 3000-4000, 4000-5000, 5000-6000, 6000-7000, 7000-8000, 8000-9000, or 9000-10,000 nucleotides in length. In some embodiments, the template sequence is at least 10-10,000, 1000-10,000, 2000-10,000, 3000-10,000, 4000-10,000, 5000-10,000, 6000-10,000, 7000-10,000, 8-10,000, or 9-10,000 nucleotides in length. In some embodiments, the template sequence is at least 10-1000, 10-2000, 10-3000, 10-4000, 10-5000, 10-6000, 10-7000, 10-8000, 10-9000, or 10-10,000 nucleotides in length.In some embodiments, the template sequence comprises a mismatch relative to the genomic DNA sequence. In some embodiments, the mismatch directs a template-based edit in the genomic DNA within nucleotides T1-T25, optionally within nucleotides T1-T15 of the template. In some embodiments, the mismatch directs a template-based edit in the genomic DNA within nucleotides T1-T10 of the template. In some embodiments, the template sequence comprises a mismatch to the genomic sequence at at least one of positions T1-T6, optionally at at least one of positions T5-T65’ of the template junction with the DRS, wherein the template introduces a change in the amino acid sequence encoded by the genomic sequence.In some embodiments, the template sequence further comprises at least 10 nucleotides 5’ of a sequence to be edited by template-based genome editing, wherein the at least 10 nucleotides are complementary to the second region of the target nucleic acid. In some embodiments, the template sequence comprises a sequence of at least 10 nucleotides in length that is complementary to the second region of the target nucleic acid. In some embodiments, the template sequence comprises at least 10 nucleotides that are complementary to the second regionof the target nucleic acid. In some embodiments, at least 3 consecutive nucleotides in the template sequence are fully complementary to the corresponding genomic sequence of a second region of the target nucleic acid. In some embodiments, the template sequence comprises at least 5, 10, 15, or 20 nucleotides that are fully complementary to the second region of the target nucleic acid.In some embodiments, the nucleotides that are complementary to the second region of the DNA duplex target nucleic acid are positioned 5’ of a templated insertion or deletion. In some embodiments, the nucleotides that are complementary to the second region of the DNA-duplex target nucleic acid are positioned 5’ of a substitution. In some embodiments, the nucleotides that are complementary to the second region of the target nucleic acid are fully complementary to the second region of the target nucleic acid.The template sequence provides a nucleotide sequence that is different from an endogenous nucleotide sequence prior to template-based genome editing. In some embodiments, the template sequence comprises a sequence for directing a template-based insertion, deletion, or substitution relative to an endogenous nucleotide sequence prior to template-based genome editing. In some embodiments, the template sequence comprises an insertion and a substitution. In some embodiments, the template sequence comprises a deletion and a substitution. In some embodiments, the template sequence comprises an insertion and a deletion. In some embodiments, the template sequence comprises an insertion relative to an endogenous nucleotide sequence prior to template-based genome editing. In some embodiments, the template sequence comprises a deletion relative to an endogenous nucleotide sequence prior to template-based genome editing. In some embodiments, the template sequence comprises a substitution relative to an endogenous nucleotide sequence prior to template-based genome editing. In some embodiments, the substitution is a transition. In some embodiments, the substitution is a transversion.In some embodiments, the template sequence comprises an insertion sequence relative to the corresponding genomic sequence. In some embodiments, the template sequence comprises an insertion sequence of at least one nucleotide. In some embodiments, the template sequence comprises a sequence for directing at least two non-adjacent insertions relative to the corresponding genomic sequence, further wherein each insertion comprises at least one nucleotide.In some embodiments, the template sequence comprises an insertion sequence of 1-5, 1-10, 1-15, 1-20, 1-30, 1-40, 1-50, 1-60, 1-70, 1-80, 1-90, or 1-100 nucleotides in length. In some embodiments, the template sequence comprises an insertion sequence of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides in length. In some embodiments, the template sequence comprises an insertion sequence of at least 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 nucleotides in length. In some embodiments, the template sequence comprises an insertion sequence of 1-100, 25-75, 5-100, 50-100, or 100-200 nucleotides in length.In some embodiments, the template sequence comprises an insertion sequence of at least 3, 10, 15, 20, 30, 40, or 50 nucleotides in length. In some embodiments, the template sequence comprises an insertion sequence of up to 500, 1000, 3500, or 5000 nucleotides in length, optionally up to 10,000 nucleotides in length. In some embodiments, the template sequence comprises a nucleotide sequence 5’ of the insertion sequence that is at least 5 nucleotides, optionally at least 10, 20, 30, 40, or 50 nucleotides complementary to the genomic sequence of the non-target strand of the DNA duplex target nucleic acid.In some embodiments, the template sequence comprises an insertion sequence of at least 100 nucleotides in length. In some embodiments, the template sequence comprises an insertion sequence of at least 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 nucleotides in length. In some embodiments, the template sequence comprises an insertion sequence of 1-1000 nucleotides in length. In some embodiments, the template sequence comprises an insertion sequence of 1-10,000, 10-5,000, or 10-1000 nucleotides in length.In some embodiments, the template region 5’ of the insertion, substitution, or deletion can comprise at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50 or more nucleotides complementary to the genomic DNA sequence. In some embodiments, the template region 5’ of the insertion, substitution, or deletion can comprise 5-40 nucleotides complementary to the genomic DNA sequence.In some embodiments, the insertion or at least two non-adjacent insertions are positioned at or near the 5’ end of the template. In some embodiments, the 5’ terminal nucleotide of the template sequence does not comprise one or more inserted nucleotides. In some embodiments, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 consecutive nucleotides at the 5’ end of the template sequence do not comprise one or more inserted nucleotides. In some embodiments, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 consecutive nucleotides atthe 5’ end of the template sequence do not comprise one or more inserted nucleotides. In some embodiments, the insertion or at least two non-adjacent insertions are positioned at or near the 3’ end of the template (i.e., the boundary between the template and the DRS). In some embodiments, one or more of the last 1, 2, or 3 nucleotides at the 3’ end of the template comprise an insertion or at least two non-adjacent insertions. In some embodiments, the 3’ terminal nucleotide of the template comprises one or more inserted nucleotide. In some embodiments, the 3’ terminal nucleotide of the template sequence does not comprise one or more inserted nucleotides. In some embodiments, the insertion or at least two non-adjacent insertions are positioned near the middle of the template (i.e., the template comprises similar numbers of noninserted nucleotides 5’ and 3’ of the insertion or at least two non-adjacent insertions).In some embodiments, the template sequence can comprise an insertion of one or more nucleotides relative to the corresponding genomic sequence. In some embodiments, the inserted nucleotide or nucleotides is within positions T1-T100 (see, e.g., Fig. 2). In some embodiments, the inserted nucleotide or nucleotides is within positions T1-T50, for example, within positions T1-T5, T5-T10, T10-15, T15-T20, T20-T25, T25-T30, T30-T35, T35-T40, T40-T45, or T45-T50.In some embodiments, the template sequence comprises a sequence for directing a deletion relative to the corresponding genomic sequence. In some embodiments, the template sequence comprises a sequence for directing a deletion of at least one nucleotide. In some embodiments, the template sequence comprises a sequence for directing at least two non-adjacent deletions relative to the corresponding genomic sequence, further wherein each deletion comprises at least one nucleotide.In some embodiments, the template sequence comprises a sequence for directing a deletion of 1-40 nucleotides in length. In some embodiments, the template sequence comprises a sequence for directing a deletion of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides in length. In some embodiments, the template sequence comprises a sequence for directing a deletion of at least 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 nucleotides in length. In some embodiments, the template sequence comprises a sequence for directing a deletion of at least 100 nucleotides in length. In some embodiments, the template sequence comprises a sequence for directing a deletion of at least 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 nucleotides in length.In some embodiments, the template sequence comprises a sequence to direct a deletion of at least 3, 10, 15, 20, 30, 40, or 50 nucleotides in length. In some embodiments, the template sequence comprises the template sequence comprises a sequence to direct a deletion of up to 3500 nucleotides in length, optionally up to 10,000 nucleotides in length. In some embodiments, the template sequence comprises a nucleotide sequence 5’ of the sequence to direct a deletion that is at least 10 nucleotides, optionally at least 20, 30, 40, or 50 nucleotides complementary to the genomic sequence of the non-target strand of the DNA duplex target nucleic acid.In some embodiments, the template sequence comprises a sequence for directing a deletion of up to 3500 nucleotides in length, optionally up to 10,000 nucleotides in length. In some embodiments, the template sequence comprises a sequence for directing a deletion of 1-10,000 nucleotides in length.In some embodiments, the deletion or at least two non-adjacent deletions are positioned at or near the 5’ end of the template. In some embodiments, the 5’ terminal nucleotide of the template sequence does not comprise one or more deleted nucleotides. In some embodiments, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 consecutive nucleotides at the 5’ end of the template sequence do not comprise a deleted nucleotide. In some embodiments, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 consecutive nucleotides at the 5’ end of the template sequence do not comprise a deleted nucleotide. In some embodiments, the deletion or at least two non-adjacent deletions are positioned at or near the 3’ end of the template (i.e., the boundary between the template and the DRS). In some embodiments, one or more of the last 1, 2, or 3 nucleotides at the 3’ end of the template comprise a deletion or at least two non-adjacent deletions. In some embodiments, the 3’ terminal nucleotide of the template comprises one or more deleted nucleotide. In some embodiments, the 3’ terminal nucleotide of the template sequence does not comprise one or more deleted nucleotides. In some embodiments, the deletion or at least two non-adjacent deletions are positioned near the middle of the template (i.e., the template comprises similar numbers of non-deleted nucleotides 5’ and 3’ of the deletion or at least two non-adjacent deletions).In some embodiments, the template sequence can comprise a deletion of one or more nucleotides relative to the corresponding genomic sequence. In some embodiments, (1) the nucleotide position that corresponds to the nucleotide immediately 5’ of the genomic sequence that is to be deleted and (2) the nucleotide position that corresponds to the nucleotideimmediately 3’ of the genomic sequence that is to be deleted are within positions T1-T50 (see, e.g., Figs. 2A-2B). In some embodiments, (1) the nucleotide position that corresponds to the nucleotide immediately 5’ of the genomic sequence that is to be deleted and (2) the nucleotide position that corresponds to the nucleotide immediately 3 ’ of the genomic sequence that is to be deleted are within positions T1-T5, T5-T10, T10-15, T15-T20, T20-T25, T25-T30, T30-T35, T35-T40, T40-T45, or T45-T50.In some embodiments, the insertion sequence or sequence for directing a deletion in the template sequence provides the template sequence for template-based genome editing comprising an insertion or deletion. In some embodiments, the insertion or deletion disrupts the spacing between a target sequence and a PAM.In some embodiments, the template sequence comprises a sequence for directing a substitution relative to the corresponding genomic sequence. In some embodiments, the substitution is a transition. In some embodiments, the substitution is a transversion. In some embodiments, the template sequence comprises a sequence for directing a substitution of a single nucleotide. In some embodiments, the template sequence comprises a sequence for directing a substitution of at least two nucleotides. In some embodiments, wherein the template sequence comprises a sequence for directing a substitution of at least two nucleotides, the at least two nucleotides are consecutive. In some embodiments, wherein the template sequence comprises a sequence for directing a substitution of at least two nucleotides, the at least two nucleotides are non-consecutive. In some embodiments, the substituted nucleotide or nucleotides are positioned at or near the 5’ end of the template. In some embodiments, the 5’ terminal nucleotide of the template sequence does not comprise a substituted nucleotide. In some embodiments, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 consecutive nucleotides at the 5’ end of the template sequence do not comprise a substituted nucleotide. In some embodiments, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 consecutive nucleotides at the 5’ end of the template sequence do not comprise a substituted nucleotide. In some embodiments, the substituted nucleotide or nucleotides are positioned at or near the 3’ end of the template (i.e., the boundary between the template and the DRS). In some embodiments, one or more of the last 1, 2, or 3 nucleotides at the 3’ end of the template comprise a substituted nucleotide. In some embodiments, the 3 ’ terminal nucleotide of the template comprises a substituted nucleotide. In some embodiments, the 3’ terminal nucleotide of the template sequence does not comprise asubstituted nucleotide. In some embodiments, the substituted nucleotide or nucleotides are positioned near the middle of the template (i.e., the template comprises similar numbers of nonsubstituted nucleotides 5’ and 3’ of the substituted nucleotide or nucleotides).In some embodiments, the template sequence can comprise a substitution of one or more nucleotides relative to the corresponding genomic sequence. In some embodiments, the substituted nucleotide or nucleotides is within positions T1-T50 (see, e.g., Figure 2). In some embodiments, the substituted nucleotide or nucleotides is within positions T1-T5, T5-T10, T10-15, T15-T20, T20-T25, T25-T30, T30-T35, T35-T40, T40-T45, or T45-T50.In some embodiments, the template sequence comprises at least one mismatch relative to the corresponding genomic sequence, wherein the mismatches provide the template sequence for template-based genome editing comprising a substitution. In some embodiments, the template sequence comprises at least three mismatches relative to the corresponding genomic sequence, wherein the mismatches provide the template sequence for template-based genome editing comprising a substitution. In some embodiments, the template further comprises an insertion sequence or a sequence for directing a deletion. In some embodiments, the mismatches introduce a mutation into the PAM of the edited DNA sequence. In some embodiments, the mismatches introduce a mutation into a region of the target nucleic acid adjacent to the PAM.In some embodiments, the template contains one or more silent mutation(s), in addition to the desired edit(s). Such silent mutations create alternations in the genomic sequence (e.g., substitutions) which do not alter the amino acid sequence of an encoded protein. In some embodiments, the template sequence comprises a silent mutation immediately adjacent to a desired edit. In some embodiments, the template sequence comprises two silent mutations immediately adjacent to a desired edit. In some embodiments, the template sequence comprises up to three, up to four, up to five, or more silent mutations within 10, within 20, or within 30 nucleotides of the desired edit(s). In one embodiment, the template sequence comprises up to three silent mutations within 10 nucleotides of the desired edit(s). In some embodiments, the silent mutation is a G> C mutation.In some embodiments, the template comprises a mismatch to the genomic sequence, optionally 1-4 mismatches to the genomic sequence. In some embodiments, the mismatch that directs a template-based edit in the genomic DNA is within nucleotides T1-T25, optionally within nucleotides T1-T15 of the template. In some embodiments, the template-based edit in thegenomic DNA comprises a substitution. In some embodiments, the template-based edit in the genomic DNA comprises an insertion of a nucleotide in the genomic sequence. In some embodiments, the template-based edit in the genomic DNA comprises a deletion of a nucleotide in the genomic sequence. In some embodiments, the template-based edit in the genomic sequence results in a change in an amino acid sequence encoded by a locus in which the genomic sequence is present. In some embodiments, the template-based edit in the genomic sequence does not result in a change in an amino acid sequence encoded by a locus in which the genomic sequence is present.In some embodiments, the template comprises DNA nucleotides. In some embodiments, the 3’ terminal nucleotide of the template is a DNA nucleotide. In some embodiments, the template consists of DNA nucleotides from nucleotide 4 (T4) from the 3’ end of the template to the 5’ end of the template. In some embodiments, the template consists of DNA nucleotides. In some embodiments, the template comprises RNA nucleotides. In some embodiments, the template comprises 0-1 RNA nucleotides, optionally 1 RNA nucleotide, at the 3’ end of the template. In some embodiments, the template comprises 1-3 RNA nucleotides, optionally only 1 RNA nucleotide, at the 3 ’ end of the template.DNA-Dependent DNA Polymerase Recruiting SequenceIn some embodiments, the present disclosure provides for a 3’ extension comprising a DNA-dependent DNA polymerase recruiting sequence (DRS). The DRS is complementary to a second region of a non-target strand of a target nucleic acid and forms a duplex with the 3’ end of the flap 5’ of the nick in the genomic DNA (see, e.g., Fig. 2). When the DRS is base-paired to the 3’ end of the flap 5’ of the nick, this flap-DRS duplex can serve as a primer for synthesis of a new DNA strand that is complementary to the template sequence 5’ of the DRS.It is to be understood that the DRS is partially or fully complementary to the spacer of the Nme-Cas9 guide RNA of the tgRNA. On account of this complementary sequence, in certain embodiments, the DRS may form a duplex with the spacer region. One of ordinary skill in the art would appreciate that RNA sequences within DNA-RNA duplexes, e.g., a spacer hybridized to a DRS comprising or consisting of DNA nucleotides, are susceptible to cleavage by RNAse H. Thus, there can be a need for both DRS and spacer sequences that minimize the likelihood of RNAse H cleavage following hybridization of the DRS to the spacer. The present disclosuretherefore provides for DRS sequences that lead to enhanced tgRNA stability when paired with a corresponding spacer sequence. Such DRS sequences can reduce or minimize the hybridization of the DRS to the spacer sequence, and / or reduce or minimize RNAse H-mediated cleavage of the tgRNA, should such hybridization occur.In certain embodiments, the DRS comprises DNA nucleotides. In certain embodiments, the plurality of nucleotides in the DRS are DNA nucleotides. In certain embodiments, the DRS comprises both DNA and RNA nucleotides. In certain embodiments, the DRS comprises an RNA nucleotide at its 3’ end and consecutive DNA nucleotides at its 5’ end. In certain embodiments, the DRS consists of DNA nucleotides. For example, Fig. 2 shows an exemplary DRS comprising DNA nucleotides at every position within the DRS. In such embodiments, the DRS or the spacer may further comprise chemical modifications that reduce the susceptibility of the resulting DRS-spacer duplex to cleavage by RNAse H.In certain embodiments, the DRS comprises RNA nucleotides. In some embodiments, the DRS comprises modified RNA nucleotides. In some embodiments, the plurality of nucleotides in the DRS are RNA nucleotides. In some embodiments, the DRS of the tgRNA comprises both DNA nucleotides and RNA nucleotides. In some embodiments, the DRS comprises consecutive RNA nucleotides at its 3’ end and consecutive DNA nucleotides at its 5’ end. For example, Fig.2 shows an exemplary DRS comprising a single DNA nucleotide at its 5’ end and consecutive RNA nucleotides from the penultimate 5’ terminal nucleotide of the DRS (D2) through the end of the DRS. In some embodiments, the DRS consists of RNA nucleotides. In embodiments in which the plurality of nucleotides in the DRS are RNA nucleotides or in which the DRS consists of RNA nucleotides, hybridization between the DRS and the spacer results in an RNA-RNA duplex, which is not susceptible to cleavage by RNAse H.In some embodiments, 1-7 nucleotides (e.g., 1-7, 1-6, 1-5, 1-4, 1-3, 1-2 nucleotides) at the 5’ end of the DRS (nucleotides D1-D7) are DNA nucleotides. In some embodiments, 1-7 nucleotides at the 5’ end of the DRS (nucleotides D1-D7) are DNA nucleotides, with the remaining nucleotides in the DRS being RNA nucleotides.In some embodiments, the 3 ’ nucleotide of the DRS is an RNA nucleotide and the remaining nucleotides in the DRS are DNA nucleotides.In some embodiments, 1-5 nucleotides (e.g., 1-5, 1-4, 1-3, 1-2 nucleotides) at the 5’ end of the DRS (nucleotides D1-D5) are DNA nucleotides. In some embodiments, 1-5 nucleotides atthe 5’ end of the DRS (nucleotides D1-D5) are DNA nucleotides, with the remaining nucleotides in the DRS being RNA nucleotides.In some embodiments, 1-3 nucleotides (e.g., 1-3, 1-2 nucleotides) at the 5’ end of the DRS (nucleotides D1-D3) are DNA nucleotides. In some embodiments, 1-3 nucleotides at the 5’ end of the DRS (nucleotides D1-D3) are DNA nucleotides, with the remaining nucleotides in the DRS being RNA nucleotides.In some embodiments, at least one nucleotide at positions D1-D5 of the DRS is a DNA nucleotide. In some embodiments, at least two nucleotides at positions D1-D5 of the DRS are DNA nucleotides. In some embodiments, at least three nucleotides at positions D1-D5 of the DRS are DNA nucleotides. In some embodiments, at least four nucleotides at positions D1-D5 of the DRS are DNA nucleotides. In some embodiments, one nucleotide at positions D1-D5 of the DRS is a DNA nucleotide. In some embodiments, two nucleotides at positions D1-D5 of the DRS are DNA nucleotides. In some embodiments, three nucleotides at positions D1-D5 of the DRS are DNA nucleotides. In some embodiments, four nucleotides at positions D1-D5 of the DRS are DNA nucleotides. In some embodiments, all five nucleotides at positions D1-D5 of the DRS are DNA nucleotides.In some embodiments, the nucleotide at the 5’ end of the DRS (nucleotide DI) is a DNA nucleotide. In some embodiments, the nucleotide at the 5’ end of the DRS (nucleotide DI) is a DNA nucleotide, with the remaining nucleotides in the DRS being RNA nucleotides. In some embodiments, the penultimate 5’ terminal nucleotide of the DRS (nucleotide D2) is an RNA nucleotide. In some embodiments, positions DI and D3 of the DRS are DNA nucleotides. In some embodiments, positions DI and D3 of the DRS are DNA nucleotides, with the remaining nucleotides in the DRS being RNA nucleotides. In some embodiments, positions DI, D3, and D5 of the DRS are DNA nucleotides. In some embodiments, positions DI, D3, and D5 of the DRS are DNA nucleotides, with the remaining nucleotides in the DRS being RNA nucleotides.In some embodiments, the 5’ terminal and penultimate 5’ terminal nucleotides of the DRS are DNA nucleotides. In some embodiments, 1-7 consecutive 5’ terminal nucleotides of the DRS are DNA nucleotides. In some embodiments, 1, 2, 3, 4, 5, 6, or 7 consecutive 5’ terminal nucleotides of the DRS are DNA nucleotides. In some embodiments, at least 3 consecutive 5’ terminal nucleotides of the DRS are DNA nucleotides. In some embodiments, 3 consecutive 5’ terminal nucleotides of the DRS are DNA nucleotides.In some embodiments, at least one nucleotide in the 3’ region of the DRS (e.g., a nucleotide at any one of positions one, two, three, four, five, six, or all seven of D6-D13) is a DNA nucleotide. In some embodiments, position D6, D7, D8, D9, D10, DI 1, DI 2, or DI 3 of the DRS is a DNA nucleotide. In some embodiments, at least one, at least two, at least three, at least four, at least five, at least six, at least seven, or at all eight nucleotides at positions D6-D13 of the DRS is a DNA nucleotide. In some embodiments, one, two, three, four, five, six, seven, or all eight nucleotides at positions D6-D13 of the DRS is a DNA nucleotide. In some embodiments, one to three nucleotides at positions D6-D13 of the DRS is a DNA nucleotide. In some embodiments, position D9 of the DRS is a DNA nucleotide. In some embodiments, one or both of positions D8 and DI 1 of the DRS are DNA nucleotides. In some embodiments, one, two, or three of positions D7, D9, and DI 1 of the DRS are DNA nucleotides. In some embodiments, one, two, or three of positions D6, D9 and DI 2 of the DRS are DNA nucleotides.In some embodiments, the DRS consists of DNA nucleotides. In some embodiments, the spacer may comprise one or more modifications that reduce its susceptibility to degradation by RNAse H following binding to the DRS. For example, spacer nucleotides whose 2’-hydroxyl group does not interact with Cas9 may be modified with a 2’-O-methyl (2’-0-me) or a 2’-fluoro (2’-F) modification. In some embodiments, the spacer of the guide RNA (or tgRNA) comprises a modified nucleotide. In some embodiments, the spacer of the guide RNA comprises a phosphorothioate (PS) modification. In some embodiments, the spacer of the guide RNA comprises a modified nucleotide selected from a 2’-O-methyl (2’-0-Me) modified nucleotide, or a 2’-fluoro (2’-F) modified nucleotide. In some embodiments, the spacer of the guide RNA comprises a 2’-O-methyl (2’-0-Me) modified nucleotide. In some embodiments, the spacer of the guide RNA comprises a 2’ -fluoro (2’-F) modified nucleotide. In some embodiments, the spacer of the guide RNA comprises DNA nucleotides. In some embodiments, the spacer of the guide RNA comprises a DNA nucleotide at at least 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides. In some embodiments, the spacer of the guide RNA comprises a DNA nucleotide at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 nucleotides. In some embodiments, the spacer of the guide RNA comprises a DNA nucleotide at one or more of positions Sil, SI 2, and SI 8, optionally at each of positions Sil, SI 2, and SI 8. In some embodiments, the spacer of the guide RNA comprises a DNA nucleotide at each of position Sil. In some embodiments, the spacer of the guide RNA comprises a DNA nucleotide at position SI 2. In some embodiments, the spacer of the guideRNA comprises a DNA nucleotide at position SI 8. In some embodiments, the spacer of the guide RNA comprises a DNA nucleotide at each of positions SI 1 and SI 2. In some embodiments, the spacer of the guide RNA comprises a DNA nucleotide at each of positions Sil and SI 8. In some embodiments, the spacer of the guide RNA comprises a DNA nucleotide at each of positions S12 and SI 8. In some embodiments, the spacer of the guide RNA comprises a DNA nucleotide at each of positions Sil, SI 2, and SI 8. In some embodiments, the spacer of the guide RNA does not comprise DNA nucleotides.In some embodiments, the spacer of the guide RNA comprises a modified nucleotide at one or more positions as provided above.In some embodiments, where the DRS consists of DNA nucleotides. In some embodiments, the 3 ’ terminal nucleotide in the DRS is an RNA nucleotide and the remaining nucleotides in the DRS are DNA nucleotides. Accordingly, the spacer may comprise one or more modifications that reduce its susceptibility to degradation by RNAse H following binding to the DRS. In some embodiments, the spacer of the guide RNA comprises a modified nucleotide at one or more positions as provided above.In some embodiments, the DRS consists of RNA nucleotides. In some embodiments, the DRS consisting of RNA nucleotides comprises of modified RNA nucleotides.In some embodiments, the DRS comprises a modified nucleotide. In some embodiments, the modified nucleotide is selected from the group: 2’-0-Me modified nucleotide; a 2’-F modified nucleotide; an amine modified nucleotide; an alkoxy modified nucleotide; an LNA modified nucleotide; a methoxyethyl modified nucleotide; a halo modified nucleotide; or a PS linkage modified nucleotide. In some embodiments, the modified nucleotide is 2’-0-Me or a PS linkage modified nucleotide. In some embodiments, 1 -3 nucleotides at the 3 ’ end of the DRS are modified nucleotides. In some embodiments, 1, 2, or 3 nucleotides at the 3’ end of the DRS are modified nucleotides. In some embodiments, the 3’ end of the DRS comprises 1-3 phosphorothioate (PS) linkages, optionally wherein at least one PS linkage is between the last two nucleotides at the 3’ terminus. In some embodiments, the 3’ end of the DRS comprises 1, 2, or 3 phosphorothioate (PS) linkages, optionally wherein at least one PS linkage is between the last two nucleotides at the 3’ terminus. In some embodiments, wherein the 3’ end of the DRS is at least 9 nucleotides in length, the 3’ end of the DRS comprises 2 phosphorothioate linkages between the last three nucleotides at the 3’ terminus.In some embodiments, the modification in the DRS comprises a phosphorothioate modification. In some embodiments, wherein the modification in the DRS comprises a phosphorothioate modification, the DRS comprises a phosphorothioate modification at or 3’ of position DIO in the DRS sequence. In some embodiments, the DRS comprises PS linkages between 2, 3, 4, 5, or 6 consecutive 3’ terminal nucleotides of the DRS. In some embodiments, the DRS comprises a PS linkage between the 3’ terminal and penultimate 3’ terminal nucleotides of the DRS. In some embodiments, the DRS comprises 3 PS linkages between the 4 consecutive nucleotides at the 3’ end of the DRS. In some embodiments, the DRS comprises a PS linkage between 2 nucleotides other than the 3’ terminal and penultimate 3’ terminal nucleotides of the DRS. In some embodiments, wherein the modification in the DRS comprises a phosphorothioate modification, the DRS does not comprise a phosphorothioate modification at position D1-D9 in the DRS sequence.In some embodiments, the modification in the DRS comprises a 2’-0-Me modification. In some embodiments, wherein the modification in the DRS comprises a 2’-0-Me modification, the DRS comprises a 2’-0-Me modification at or 3’ of position D4 in the DRS sequence. In some embodiments, wherein the modification in the DRS comprises a 2’-0-Me modification, the DRS does not comprise a 2’-0-Me modification at position D1-D3 in the DRS sequence. In some embodiments, the DRS comprises a 2’-0-Me modification at a nucleotide other than the 5’ terminal and 3’ terminal nucleotides of the DRS. In some embodiments, the 3’ terminal nucleotide of the DRS comprises a 2’-0-Me modification.In some embodiments, the DRS is at least 6 nucleotides in length. In some embodiments, the DRS is about 6-20 nucleotides in length, e.g., 6-17, 8-17, 10-12, 10-14, 10-16, or 12-14 nucleotides in length. In some embodiments, the DRS is 6-17 nucleotides in length. In some embodiments, the DRS is 10-16 nucleotides in length. In some embodiments, the DRS is 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides in length.In some embodiments, the DRS comprises a 3’ tail. In some embodiments, the 3’ tail comprises a 1-5 nucleotide tail. In some embodiments, the 3’ tail comprises a 1, 2, or 3 nucleotide tail. In some embodiments, the 3’ tail comprises a terminal uridine nucleotide. In some embodiments, the 3’ tail consists of uridine nucleotides. In some embodiments, the 3’ tail comprises a modified nucleotide, e.g., a modified uridine nucleotide.In some embodiments, the DRS has 0, 1, 2, 3, or 4 mismatches to the corresponding genomic sequence. In some embodiments, the DRS comprises 0 mismatches to the corresponding genomic sequence. In some embodiments, the DRS comprises 1-4 mismatches to the corresponding genomic sequence. In some embodiments, the first 50% of nucleotides at the 5’ end of the DRS have 0, 1, 2, or 3 mismatches to the corresponding genomic sequence. In some embodiments, the first 50% of nucleotides at the 5’ end of the DRS have 0 mismatches to the corresponding genomic sequence. In some embodiments, the first 50% of nucleotides at the 5’ end of the DRS have 1, 2, or 3 mismatches to the corresponding genomic sequence. In some embodiments, the first four nucleotides at the 5’ end of the DRS have 0, 1, 2, or 3 mismatches to the corresponding genomic sequence. In some embodiments, the first four nucleotides at the 5’ end of the DRS have 0 mismatches to the corresponding genomic sequence. In some embodiments, the first four nucleotides at the 5’ end of the DRS have 1 or 2 mismatches to the corresponding genomic sequence. In some embodiments, the first three nucleotides at the 5’ end of the DRS have 0 mismatches to the corresponding genomic sequence. In some embodiments, the first three nucleotides at the 5’ end of the DRS have 1 mismatch to the corresponding genomic sequence. In some embodiments, the first 6 nucleotides at the 5’ end of the DRS have 0, 1, or 2 mismatches to the corresponding genomic sequence. In some embodiments, the first 10 nucleotides at the 5’ end of the DRS have 0, 1, or 2 mismatches to the corresponding genomic sequence. In some embodiments, 70%-100% of the nucleotides in the first 10 nucleotides at the 5’ end of the DRS are complementary to the corresponding genomic sequence. In some embodiments, the DRS comprises, e.g., further comprises, one or more mismatches in the 3’ half of the DRS.In some embodiments, the sequence of the DRS that is complementary to the DRS-complementary region of the non-target strand of the DNA duplex target nucleic acid comprises nucleotides D2-D9 of the DRS, optionally D2-D8 or D3-D9 of the DRS.In some embodiments, when the DRS is less than 100% complementary to the corresponding genomic sequence, the positions that are less than 100% complementary to the corresponding genomic sequence do not introduce changes into a genomic sequence after template-based editing. In some embodiments, a mismatch between the DRS and the genomic sequence is at position DI, D2, or D3, optionally at position DI or D2, can introduce a templatebased edit into the genomic sequence. However, the template-based edit may be less efficientthan a template-based edit directed by the template. In certain embodiments, the protein sequence after template- based genome editing may not result in an amino acid change, i.e., silent mutations. That is, due to the degeneracy of the genetic code, most amino acids are specified by more than one codon so that a change in the nucleotide sequence does not necessarily give rise to a change in the sequence that is encoded. It is understood that reducing the complementarity of the DRS to the corresponding genomic sequence similarly reduces the complementarity of the DRS to the spacer sequence of the guide RNA.In some embodiments, the DRS is 6-18 nucleotides in length, optionally 8-18 or 10-12 nucleotides in length. In some embodiments, the DRS is 10-16 or 12-14 nucleotides in length. In some embodiments, the sequence of the DRS that is complementary to the DRS-complementary region of the non-target strand of the DNA duplex target nucleic acid comprises nucleotides 5-10 5’ of the PAM in the non-target strand of the DNA duplex target nucleic acid. In some embodiments, the DRS comprises a sequence that is complementary to at least 6 nucleotides of the DRS-complementary region of the non-target strand of the DNA duplex target nucleic acid comprising nucleotides D2-D9 of the DRS, optionally D2-D8 or D3-D9 of the DRS.In some embodiments, the DRS comprises a sequence that is complementary to a DRS-complementary region of a non-target strand of the DNA duplex target nucleic acid comprising nucleotides D6-D13 of the DRS, optionally wherein 1, 2, 3, 4, 5, 6, 7, or 8 of nucleotides D6-D13 are DNA nucleotides. In some embodiments, the DRS comprises a sequence that is not fully complementary to the DRS-complementary region of the non-target strand of the DNA duplex target nuclei acid. In some embodiments, the DRS comprises RNA nucleotides. In some embodiments, the penultimate 5’ terminal nucleotide of the DRS (D2) is an RNA nucleotide. In some embodiments, each nucleotide from the penultimate 5’ nucleotide (D2) to the 3’ end nucleotide in the DRS is an RNA nucleotide. In some embodiments, the 3’ terminal nucleotide of the DRS is an RNA nucleotide. In some embodiments, the DRS consists of RNA nucleotides. In some embodiments, the DRS comprises DNA nucleotides. In some embodiments, the 5’ terminal nucleotide of the DRS (DI) is a DNA nucleotide. In some embodiments, the DRS comprises a 3’ end and a 5’ end, wherein 0-7 nucleotides at the 5’ end of the DRS (nucleotides D1-D7) are DNA nucleotides. In some embodiments, one or more of nucleotides 1-7 nucleotides at the 5’ end of the DRS (nucleotides D1-D7) are DNA nucleotides. In some embodiments, one or more of nucleotides 1-5 at the 5’ end of the DRS (nucleotides D1-D5) are DNA nucleotides, optionallywherein the remaining nucleotides in the DRS are RNA nucleotides. In some embodiments, one or more of nucleotides 1-3 at the 5’ end of the DRS (nucleotides D1-D3), optionally the 5’ terminal nucleotide in the DRS (nucleotide DI), is a DNA nucleotide. In some embodiments, nucleotides 1 and 3 at the 5’ end of the DRS (nucleotides DI and D3) are DNA nucleotides, optionally wherein the remaining nucleotides in the DRS are RNA nucleotides. In some embodiments, nucleotides 1, 3, and 5 at the 5’ end of the DRS (nucleotides DI, D3, and D5) are DNA nucleotides, optionally wherein the remaining nucleotides in the DRS are RNA nucleotides. In some embodiments, the 3’ terminal nucleotide of the template and the 5’ terminal nucleotide of the DRS are DNA nucleotides, and the penultimate 5’ terminal nucleotide of the DRS is an RNA nucleotide. In some embodiments, the 3’ terminal nucleotide in the DRS is an RNA nucleotide and the remaining nucleotides in the DRS are DNA nucleotides.In some embodiments, the DRS consists of DNA nucleotides. In some embodiments, the spacer of the guide RNA comprises a modified nucleotide at one or more positions as provided above.In some embodiments, the DRS comprises a 3’ tail at the 3’ end of the DRS, wherein the tail is 1-5 nucleotides, optionally 1-3 nucleotides in length. In some embodiments, the 3’ tail of the DRS comprises an RNA nucleotide. In some embodiments, the 3’ tail comprises a uridine nucleotide, optionally wherein the 3 ’ terminal nucleotide is a modified uridine nucleotide. In some embodiments, the DRS comprises a modified nucleotide. In some embodiments, the DRS comprises a modified nucleotide selected from: (a) 2’-O-methyl (2’-0-Me) modified nucleotide; (b) 2’-fluoro (2’-F) modified nucleotide; (c) an amine modified nucleotide; (d) an alkoxy modified nucleotide; (e) an LNA modified nucleotide; (f) methoxyethyl modified nucleotide; (g) a halo modified nucleotide; or (h) phosphorothioate (PS) linkage modified nucleotide; optionally, wherein the modified nucleotide is a 2’-O-methyl (2’-0-Me) modified nucleotide or a phosphorothioate (PS) linkage modified nucleotide. In some embodiments, the modification in the DRS comprises a phosphorothioate modification, and the DRS does not comprise a phosphorothioate modification at position D1-D9 in the DRS sequence. In some embodiments, the modification in the DRS comprises a phosphorothioate modification, and the DRS comprises a phosphorothioate modification at or 3’ of position DIO in the DRS sequence. In some embodiments, the modification in the DRS comprises a 2’-0-Me modification, and the DRS does not comprise a 2’-0-Me modification at position D1-D3 in the DRS sequence. In someembodiments, the modification in the DRS comprises a 2’-O-Me modification, and the DRS does not comprise a 2’-O-Me modification at the 5’ terminal and 3’ terminal nucleotides of the DRS. In some embodiments, the modification in the DRS comprises a 2’-O-Me modification, and the DRS comprises a 2’-O-Me modification at or 3’ of position D4 in the DRS sequence. In some embodiments, the modification in the DRS comprises a 2’-O-Me or a 2’-F modification, and the DRS comprises a 2’-0-Me or 2’-F modification at the 3’ terminal nucleotide in the DRS. In some embodiments, the DRS comprises PS linkages between 2, 3, 4, 5, or 6 consecutive 3’ terminal nucleotides of the DRS. In some embodiments, the DRS comprises a PS linkage between the 3’ terminal and penultimate 3’ terminal nucleotides of the DRS. In some embodiments, the DRS comprises 3 PS linkages between the 4 consecutive 3’ terminal nucleotides of the DRS. In some embodiments, the DRS comprises a PS linkage between 2 nucleotides other than the 3’ terminal and penultimate 3’ terminal nucleotides of the DRS. In some embodiments, the DRS comprises a phosphorothioate modification, and wherein the DRS does not comprise a phosphorothioate modification at position D1-D9 in the DRS sequence. In some embodiments, the DRS comprises a phosphorothioate modification at or 3’ of position DIO in the DRS sequence.Affinity TagIn some embodiments, the template guide RNA further comprises an affinity tag, wherein the first polynucleotide or the second polynucleotide are bound to a peptide or a peptide complex comprising an Nme2-nCas9 and a DNA-dependent DNA polymerase by the affinity tag. In some embodiments, the affinity tag mediates binding of the 3’ extension to a corresponding 3’ extension-recruiting domain on a DNA-dependent DNA polymerase or Nme2-nCas9. In some embodiments, the affinity tag recruits a DNA-dependent DNA polymerase to an RNA: DNA duplex comprising the DRS and a flap with an available 3’ end, 5’ of a nick generated as a result of a single-strand break (i.e., a nick) in the DNA, thereby allowing the DNA-dependent DNA polymerase to initiate DNA synthesis from the 3’ end of the flap with an available 3’ end, 5’ of the nick, with the template sequence that is 5’ of the DRS serving as a template sequence for DNA synthesis.In some embodiments, an affinity tag is located on the second polynucleotide. In some embodiments, the affinity tag is located 5’ of the template sequence. In some embodiments, theaffinity tag is located 3’ of the DRS. In some embodiments, no affinity tag is present 3’ of the DRS. In some embodiments, the second polynucleotide has only one affinity tag, and preferably the single affinity tag is 5’ of the DRS. In some embodiments, the template guide RNA further comprises two affinity tags. In some embodiments, the first and second affinity tags are the same. In some embodiments, the first and second affinity tags are different.In some embodiments, the tgRNA comprises only one affinity tag located 5’ of the template and has a 5’ terminus, wherein the affinity tag is an aptamer comprising one or more modified nucleotide at the 5’ end thereof.In some embodiments, wherein the template guide RNA comprises two affinity tags, both affinity tags are located 5’ of the template sequence.In some embodiments, the affinity tag comprises an aptamer. In some embodiments, the aptamer is attached to the 3’ extension by a linker, e.g., by a flexible linker. In some embodiments, the aptamer comprises a DNA aptamer. In some embodiments, the aptamer comprises an RNA aptamer. In some embodiments, the aptamer is naturally occurring. In some embodiments, the aptamer is a viral nucleic acid and the 3’ extension-recruiting domain is a viral protein. In some embodiments, the aptamer comprises an MS2 aptamer sequence, a PP7 aptamer sequence, or a sequence from a guide RNA that does not bind to an Nme2Cas9 nickase. In some embodiments, the aptamer comprises an MS2 aptamer sequence (alternatively referred to herein as a MS2-loop, MS2 aptamer, or MS2 RNA loop). In some embodiments, the aptamer comprises an MS2 aptamer sequence comprising a nucleotide sequence that has at least 90%, 93%, 95%, or 100% identity to SEQ ID NO: 291. In some embodiments, the aptamer comprises a PP7 aptamer sequence. In some embodiments, the aptamer comprises a sequence from a guide RNA that does not bind to an Nme2-nCas9. In some embodiments, the aptamer is not naturally occurring, i.e., synthetic.In some embodiments, the affinity tag is an aptamer comprising one or more modified nucleotides. In some embodiments, the aptamer sequence is modified. In some embodiments, wherein the aptamer sequence comprises a modified nucleotide selected from 2’-O-methyl (2’-O-Me), 2’-fluoro (2’-F), a phosphorothioate (PS) linkage, an amine, an abasic nucleotide, a dideoxynucleotide, or a non-nucleotide linker such as a PEG. In some embodiments, wherein the aptamer sequence is modified, the modification comprises a 2’-O-Me modified nucleotide or a phosphorothioate PS linkage. In some embodiments, the modified nucleotide comprises a 2’-O-Me modified nucleotide. In some embodiments, the modified nucleotide comprises a PS linkage. It is understood that the tolerance for inclusion of modified nucleotides in an aptamer will be aptamer dependent.In some embodiments, the aptamer comprises a stem-loop. In some embodiments, wherein the aptamer comprises a stem-loop, the aptamer comprises 2’-O-Me modified nucleotides at each nucleotide in the stem of the stem-loop. In some embodiments, wherein the aptamer comprises a stem-loop, the aptamer comprises 2’-O-Me modified nucleotides at each nucleotide.In some embodiments, the aptamer is located 5’ of the template sequence. In some embodiments, wherein the aptamer is located 5’ of the template sequence and has a 5’ terminus, one or more modified nucleotides is at the 5’ end of the aptamer. In some embodiments, wherein the aptamer is located 5’ of the template sequence, the aptamer comprises a 5’ end modification. In some embodiments, the 5’ end modification comprises a 2’-O-Me modified nucleotide or PS linkage. In some embodiments, wherein the aptamer is located 5’ of the template sequence, the aptamer comprises a PS linkage between each of the first three nucleotides at the 5’ end. In some embodiments, wherein the aptamer is located 5’ of the template sequence, the aptamer comprises 2’-0-Me modified nucleotides at each of the first two nucleotides at the 5’ end. In some embodiments, wherein the aptamer is located 5’ of the template sequence, the aptamer comprises 2’-0-Me modified nucleotides at each of the first two nucleotides at the 5’ end and a PS linkage between each of the first three nucleotides at the 5’ end. In some embodiments, wherein the aptamer is located 5’ of the template sequence and comprises a stem-loop, the aptamer comprises 2’-0-Me modified nucleotides at each nucleotide in the stem of the stem-loop and a PS linkage between each of the first three nucleotides at the 5’ end.In some embodiments, the template guide RNA comprises two aptamers. In some embodiments, the first or second aptamer has the modification pattern of SEQ ID NO: 291. In some embodiments, the first and second aptamers are the same. In some embodiments, the first and second aptamers are different.In some embodiments, the aptamer, the template sequence, and the DRS are linked in the orientation 5 ’-aptamer-template sequence-DRS-3’. In some embodiments, the template guide RNA comprises one aptamer and the aptamer, the template sequence, and the DRS are linked in the following orientation: 5 ’-aptamer-template sequence-DRS-3’. In some embodiments, theaptamer is linked to the template sequence or the DRS by an internal linker. In some embodiments, a 3’ extension-recruiting domain (i.e., an aptamer binding domain) for binding the aptamer is present on the DNA-dependent DNA polymerase.In some embodiments, the affinity tag comprises a small molecule.Exemplary Template Guide RNAsIn some embodiments, the present disclosure provides for exemplary tgRNAs comprising a first polynucleotide and a second polynucleotide described herein.Provided herein is also a template guide RNA (tgRNA), wherein the tgRNA comprises a first polynucleotide and a second polynucleotide, wherein: (a) the first polynucleotide comprises an Nme2 Cas9 guide RNA comprising, from 5’ to 3’: (i) a spacer that is complementary to a target region of a target strand of a DNA duplex target nucleic acid; and (ii) an Nme2-Cas9 scaffold; and the second polynucleotide (optionally operably linked to the first polynucleotide) comprises, from 5’ to 3’: (i) a template sequence that is at least 10 nucleotides in length and complementary to at least a portion of a non-target strand of the DNA duplex target nucleic acid, wherein the template sequence comprises a 3’ end and a 5’ end; and wherein the template comprises DNA nucleotides; and (ii) a DNA-dependent DNA polymerase recruiting sequence (DRS) having a 3’ end and a 5’ end; wherein the 5’ end of the DRS is covalently attached to the 3’ end of the template sequence, and wherein the DRS comprises a sequence that is complementary to at least 6 nucleotides of a DRS-complementary region of the non-target strand of the DNA duplex target nucleic acid, optionally wherein the DRS is 6-20 nucleotides in length, further optionally 10-14 nucleotides in length. In some embodiments, the DRS comprises at least one of: (a) a sequence not fully complementary to the DRS-complementary region of the non-target strand of the DNA duplex target nucleic acid; (b) a 1-5 nucleotide, optionally a 1-3 nucleotide 3’ terminal tail comprising a 3’ terminal modified uridine nucleotide; or a terminal (DI) DNA nucleotide and a penultimate 5’ terminal (D2) RNA nucleotide wherein the 3’ end of the first polynucleotide is covalently linked to the 5’ end of the second polynucleotide..In some embodiments, the first polynucleotide is covalently linked to the second polynucleotide. In some embodiments, the 3’ end of the first polynucleotide is covalently linked to the 5’ end of the second polynucleotide. In some embodiments, the first polynucleotide is linked to the second polynucleotide by a non-nucleotide linker, e.g., a flexible linker. In someembodiments, the first polynucleotide is linked to the second polynucleotide by a phosphodiester bond or a phosphorothioate bond. In some embodiments, the first polynucleotide is linked to the second polynucleotide by at least one bond that is not a phosphodiester bond or a phosphorothioate bond.In some embodiments, the first polynucleotide is not covalently linked to the second polynucleotide. In some embodiments, 1-7 consecutive 5’ terminal nucleotides of the DRS are DNA nucleotides. In some embodiments, the 5’ terminal and penultimate 5’ terminal nucleotides of the DRS are DNA nucleotides. In some embodiments, at least 3 consecutive 5’ terminal nucleotides of the DRS are DNA nucleotides. In some embodiments, 3 consecutive 5’ terminal nucleotides of the DRS are DNA nucleotides.In certain embodiments, the second polynucleotide comprises (a) a template sequence that is at least 10 nucleotides in length and complementary to at least a portion of a non-target strand of the DNA duplex target nucleic acid, wherein the template sequence comprises a 3’ end and a 5’ end; and wherein the template comprises DNA nucleotides; and (b) a DNA-dependent DNA polymerase recruiting sequence (DRS) that is 6-20 nucleotides in length, optionally 10-14 nucleotides in length and having a 3’ end and a 5’ end; wherein the 5’ end of the DRS is covalently attached to the 3’ end of the template sequence, and wherein the DRS comprises a sequence that is complementary to at least 6 nucleotides of a DRS-complementary region of the non-target strand of the DNA duplex target nucleic acid. In some embodiments, the DRS of the tgRNA comprises RNA nucleotides. In some embodiments, the DRS of the tgRNA comprises DNA nucleotides. In some embodiments, the DRS of the tgRNA comprises RNA nucleotide(s) and DNA nucleotide(s). In some embodiments, the DRS comprises at least one of: (a) a sequence not fully complementary to the DRS-complementary region of the non-target strand of the DNA duplex target nucleic acid; (b) a 1-5 nucleotide, optionally a 1-3 nucleotide 3’ terminal tail comprising a 3’ terminal modified uridine nucleotide; or (c) a 5’ terminal (DI) DNA nucleotide and a penultimate 5’ terminal (D2) RNA nucleotide wherein the 3’ end of the first polynucleotide is optionally covalently linked to the 5’ end of the second polynucleotide. In certain embodiments, the first polynucleotide is covalently linked to the second polynucleotide by at least one bond that is not a phosphorothioate or phosphodiester linkage. In some embodiments, the template is about 15 nucleotides in length, e.g., 15 nucleotides in length. In some embodiments, the DRS is about 12 nucleotides in length, e.g., 12 nucleotides in length. Insome embodiments, the tgRNA comprises one or more internal linkers. In some embodiments, the tgRNA does not comprise an internal linker. In some embodiments, the first polynucleotide comprises a sequence selected from any one of SEQ ID NOs:238-245; 248-255; 258-278; or 281-290.In some embodiments, the present disclosure provides for a tgRNA comprising a first polynucleotide and a second polynucleotide, wherein (1) the first polynucleotide comprises (i) a spacer that is complementary to a target region of a target strand of a DNA duplex target nucleic acid; and (ii) an Nme2-Cas9 scaffold; and (2) the second polynucleotide (optionally operably linked to the first polynucleotide) comprises (a) a template sequence that is at least 10 nucleotides in length and complementary to at least a portion of a non-target strand of the DNA duplex target nucleic acid, wherein the template sequence comprises a 3’ end and a 5’ end; and wherein the template comprises DNA nucleotides; (b) a DNA-dependent DNA polymerase recruiting sequence (DRS) that is 6-18 nucleotides in length, optionally 8-18 or 10-12 nucleotides in length and having a 3’ end and a 5’ end; wherein the 5’ end of the DRS is covalently attached to the 3’ end of the template sequence, and wherein the DRS comprises a sequence that is complementary to at least 6 nucleotides of a DRS-complementary region of the non-target strand of the DNA duplex target nucleic acid. In some embodiments, the DRS of the tgRNA comprises RNA nucleotides. In some embodiments, the DRS of the tgRNA comprises DNA nucleotides. In some embodiments, the DRS of the tgRNA comprises RNA nucleotide(s) and DNA nucleotide(s).In some embodiments, the template is about 15 nucleotides in length, e.g., 15 nucleotides in length. In some embodiments, the DRS is about 12 nucleotides in length, e.g., 12 nucleotides in length. In some embodiments, the tgRNA comprises one or more internal linkers. In some embodiments, the tgRNA does not comprise an internal linker. In some embodiments, the first polynucleotide comprises a sequence selected from any one of SEQ ID NOs: 238-245; 248-255; 258-278; or 281-290, or a sequence that is at least 85%, 90%, or 95% identical to any one of SEQ ID NOs: 238-245; 248-255; 258-278; or 281-290. In some embodiments, the second polynucleotide is covalently linked to an aptamer, optionally wherein the 3’ end of the aptamer is covalently linked to the 5’ end of the template.In some embodiments, the present disclosure provides for a tgRNA comprising a first polynucleotide and a second polynucleotide, wherein (1) the first polynucleotide comprises aguide RNA (gRNA) comprising: (a) a spacer sequence of 21-24 nucleotides in length, and (b) a conserved portion comprising the nucleotide sequence of any one of SEQ ID NOs: 238-245; 248-255; 258-278; or 281-290, or a sequence that is at least 85%, 90%, or 95% identical to any one of SEQ ID NOs: 238-245; 248-255; 258-278; or 281-290; and (2) the second polynucleotide comprises (a) a template sequence that is at least 10 nucleotides in length and complementary to at least a portion of a non-target strand of the DNA duplex target nucleic acid, wherein the template sequence comprises a 3’ end and a 5’ end; and wherein the template comprises DNA nucleotides; (b) a DNA-dependent DNA polymerase recruiting sequence (DRS) that is 6-20 nucleotides in length, optionally 10-16 or 12-14 nucleotides in length, and having a 3’ end and a 5’ end; wherein the 5’ end of the DRS is covalently attached to the 3’ end of the template sequence, and wherein the DRS comprises a sequence that is complementary to at least 6 nucleotides of a DRS-complementary region of the non-target strand of the DNA duplex target nucleic acid comprising nucleotides 5-105’ of the PAM in the non-target strand of the DNA duplex target nucleic acid. In some embodiments, the DRS of the tgRNA comprises RNA nucleotides. In some embodiments, the DRS of the tgRNA comprises DNA nucleotides. In some embodiments, the DRS of the tgRNA comprises RNA nucleotide(s) and DNA nucleotide(s).In some embodiments, the template is about 15 nucleotides in length, e.g., 15 nucleotides in length. In some embodiments, the DRS is about 12 nucleotides in length, e.g., 12 nucleotides in length. In some embodiments, the tgRNA comprises one or more internal linkers. In some embodiments, one or both of the R / AR and hairpin 1 region comprises an internal linker. In some embodiments, the R / AR region comprises an internal linker. In some embodiments, the internal linker substitutes for about 8 nucleotides within the R / AR region, e.g., 8 nucleotides within the R / AR region. In some embodiments, the internal linker substitutes for US3 through US 10. In some embodiments, the hairpin 1 region comprises an internal linker. In some embodiments, internal linker substitutes for about 6 nucleotides within the hairpin 1 region, e.g., 6 nucleotides within the hairpin 1 region. In some embodiments, the internal linker substitutes for Hl -5 through Hl -8. In some embodiments, the internal linker is LI. In some embodiments, the tgRNA does not comprise an internal linker. In some embodiments, the first polynucleotide comprises a sequence selected from any one of SEQ ID NOs: 238-245; 248-255; 258-278; or 281-290.EnzymesIn some embodiments, the compositions, systems, methods, and other aspects set forth herein, make use of a Nme2-nCas9 that is operably linked to a DNA-dependent DNA polymerase. In some embodiments, the Nme2-nCas9 is operably linked to the DNA-dependent DNA polymerase. In some embodiments, the Nme2-nCas9 is operably linked to a DNA-dependent DNA polymerase and one or more 3’ extension-recruiting domains. In some embodiments, the Nme2-nCas9 generates a single-strand break (i.e., a nick) within a second region of a non-target strand of a target genomic sequence, thereby creating a flap with an available 3’ end, 5’ of the nick. Following hybridization of the DRS to the flap with an available 3’ end, 5’ of the nick, the DNA-dependent DNA polymerase uses the 3’ end of the flap as a primer for DNA synthesis, with the template sequence 5’ of the DRS serving as its template.Nme2Cas9In some embodiments, the scaffold of the Nme-Cas9 guide RNA binds to an Nme2-nCas9. In some embodiments, the Nme2-nCas9 comprises an endonucleolytic active site that has been inactivated, e.g., by one or more alterations (e.g., point mutations) in a catalytic domain. See, e.g., US Pat. No. 8,889,356 for discussion of Cas nickases and exemplary catalytic domain alterations. Exemplary nickase mutations for use in the compositions and methods provided herein art the H588A and H588S mutations.The NmeCas9 polypeptides described herein comprise amino acid substitutions relative to the amino acid sequence of a wildtype Nme2Cas9 polypeptide (SEQ ID NO: 1).In certain embodiments, the NmeCas9 polypeptide comprises one or more amino acid substitutions that enhance an activity of the NmeCas9 polypeptide (e.g., DNA binding, cleaving, or nicking) relative to wild-type NmeCas9.In some embodiments, the NmeCas9 polypeptide is an Nme2Cas9 polypeptide and comprises at least one amino acid substitution. In certain embodiments, the Nme2Cas9 polypeptide (e.g., an enhanced Nme2Cas9 variant) comprises an enhancing amino substitution described herein and comprises at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the amino acid sequence of SEQ ID NO: 1 (i.e., a wildtype Nme2 Cas9 polypeptide). In some embodiments, the amino acid sequence of theNme2Cas9 polypeptide comprise one or more (e.g., one or more, two or more, three or more, four or more, five or more, six or more, or more than six) amino acid substitutions at positions K53, K145, G197, K266, K333, K351, K390, D418, K419, Q422, E508, K517, K549, K555, Q679, L846, E868, K870, K929, T930, E932, K962, K963, K965, Q967, K989, K1005, K1026, K1044, S1051, Q1053, or N1054 of SEQ ID NO: 1 (i.e., a wildtype Nme2 Cas9 polypeptide). In some such embodiments, the NmeCas9 polypeptide is an Nme2Cas9 polypeptide and comprises at least one amino acid substitution selected from K53R, K145R, G197K, K266R, K333R, K351R, K390R, D418K, K419R, Q422K / R, E508K / R, K517R, K549R, K555R, Q679R, L846K / Y, E868K / R, K870R, K929R, T930K, E932K / R, K962R, K963R, K965R, Q967R, K989R, K1005R, N1026K / R, K1044R, S1051K, Q1053K, or N1054K / R relative to SEQ ID NO: 1.In some embodiments, the amino acid sequence of the Nme2Cas9 polypeptide comprises one or more (e.g., one or more, two or more, three or more, four or more, five or more, six or more, se...
Claims
WE CLAIM:
1. A polypeptide system comprising a Neisseria meningitidis 2 Cas9 nickase (Nme2-nCas9) and a DNA-dependent DNA polymerase (DDP).
2. The polypeptide system of claim 1, wherein the Nme2-nCas9 and the DDP are covalently linked.
3. The polypeptide system of claim 1 or 2, wherein the Nme2-nCas9 and the DDP form a fusion protein.
4. The polypeptide system of claim 3, wherein the Nme2-nCas9 is positioned upstream of the N-terminus of the DDP or the Nme2-nCas9 is positioned downstream of the C-terminus of the DDP.
5. The polypeptide system of claim 3 or 4, wherein the fusion protein comprises an intein scar; optionally wherein the intein scar is 6 amino acid long, optionally wherein the intein scar comprises the sequence RGKCFN, GWNCML, GLTCMY, RGKCWE, GALCWN, AEKCWL, and GDLCKQ.
6. The polypeptide system of claim 1, wherein the Nme2-nCas9 and the DDP are not covalently linked.
7. The polypeptide system of claim 6, wherein the Nme2-nCas9 and the DDP each comprise a heterodimerization domain which are complementary wherein the complementary heterodimerization domains are capable of self-assembling the Nme2-nCas9 and the DDP into a stable heterodimer.
8. The polypeptide system of claim 7, wherein each heterodimerization domain is a coiled coil heterodimerization domain, optionally wherein the coiled coil heterodimerization domains are a KI domain and an El domain; or a KV domain and an EV domain.
9. The polypeptide system of any one of claims 1-8, wherein the DDP is selected from the group consisting of DNA polymerase kappa (polK), phage T5 DNA polymerase (T5 pol), DNA polymerase 0, E. coli DNA polymerase I, or DNA polymerase N, optionally wherein the DNA-dependent DNA polymerase is polK or T5 DNA polymerase.
10. The polypeptide system of any one of claims 1-8, wherein the DDP is a T5 DNA polymerase.
11. The polypeptide system of claim 10, wherein the T5 pol comprises an amino acid sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO: 1116 or 1121.
12. The polypeptide system of claim 10 or 11, wherein the T5 pol comprises one or more mutations at positions selected from D164, E166, N30, C24, C63, K425, and A593 relative to SEQ ID NO: 1116.
13. The polypeptide system of claim 12, wherein the T5 pol comprises one or more mutations selected from D164A, E166A, N30del, C24del, C63del, K425I, and A593 R relative to SEQ ID NO: 1116.
14. The polypeptide system of claim 12, wherein the T5 pol comprises a mutation at DI 64 or El 66, or mutations at DI 64 and El 66 relative to SEQ ID NO: 1116.
15. The polypeptide system of claim 12, wherein the T5 pol comprises one or more mutations selected from D164A and E166A, relative to SEQ ID NO: 1116.
16. The polypeptide system of any one of claims 1-15, wherein the DDP is polK.
17. The polypeptide system of claim 16, wherein polK comprises an amino acid sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to amino acid residues 1-526, optionally amino acid residues 19-526 of SEQ ID NO: 1021, optionally wherein the polK includes or lacks an N-terminal methionine relative to SEQ ID NO: 1021.
18. The polypeptide system of claim 16, wherein the polK comprises a human polK.
19. The polypeptide system of claim 16, wherein the polK comprises an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to amino acids residues 1-526, optionally amino acid residues 19-526 of human polK.
20. The polypeptide system of any one of claims 16-19, wherein the polK comprises one or more mutations selected from G411R and E412V.
21. The polypeptide system of any one of claims 1-20, wherein the Nme2-nCas9 comprises an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 1, 8, 10, 14, 32, 69, 91, 311, and 322.
22. The polypeptide system of any one of claims 1-21, wherein the amino acid sequence of the Nme2-nCas9 comprises one or more mutations at positions K266, Q422, D418, E868, H588, E932, N1026, and / or KI 044 relative to SEQ ID NO: 10 or 14.
23. The polypeptide system of any one of claims 1-21, wherein the amino acid sequence of the Nme2-nCas9 comprises one or more mutations selected from K266R, Q422K, D418K, E868R, H588A, E932R, E932K, N1026R, and K1044R relative to SEQ ID NO: 10 or 14.
24. The polypeptide system of any one of claims 1-23, wherein the Nme2-nCas9 or the DDP is operably linked, e.g., by a peptide bond, to an aptamer binding domain (ABD).
25. The polypeptide system of claim 24, wherein the ABD is an MS2 coat protein (MCP).
26. The polypeptide system of claim 25, wherein the ABD, e.g., MCP, is positioned upstream of the N-terminus of the DDP, downstream of the C-terminus of DDP, upstream of the N-terminus of the Nme2-nCas9, or downstream of the C-terminus of the Nme2-nCas9.
27. The polypeptide system of claim 25 or 26, wherein the ABD, e.g., MCP, comprises an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 1520.
28. The polypeptide system of any one of claims 1-27, wherein the Nme2-nCas9 and / or the DDP is operably linked, e.g., by a peptide bond, to a peptide linker, optionally wherein the peptide linker comprises one or more heterologous nuclear localization signals (NLSs), e.g. SV40 NLS, SV40-c-Myc, or nucleoplasmin29. The polypeptide system of claim 28, wherein the NLS comprises an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NOs: 1666-1669 and 1671.
30. The polypeptide system of claim 28 or 29, wherein the one or more NLSs are each upstream of the N-terminus of the DDP, downstream of the C-terminus of DDP, upstream of the N-terminus of the Nme2-nCas9, or downstream of the C-terminus of Nme2-nCas9.
31. The polypeptide system of any one of claims 28-30, wherein the NLS comprises the amino acid sequence set forth in SEQ ID NO: 1666-1669, 1671, 1706, and 1727.
32. The polypeptide system of any one of claims 1-31, wherein the Nme2-nCas9 and / or the DDP is operably linked, e.g., by a peptide bond, to a chromatin remodeler, e.g., High Mobility Group Box 1 (HMGB1), HMGN1, HMGN2, HMGN3a, HMGN3b, HMGN4, HMGN5, histone H1.0, histone H1.2, CHD1, ISWI, DNA helicase, TOPI, herpesvirus 8 LANA, CMV IE1; or a domain thereof.
33. The polypeptide system of claim 32, wherein the chromatin remodeler is a High MobilityGroup Box 1 (HMGB1).
34. The polypeptide system of claim 32 or 33, wherein chromatin remodeler, e.g., HMGB1, is positioned upstream of the N-terminus of the DDP, downstream of the C-terminus of DDP, upstream of the N-terminus of the Nme2-nCas9, or downstream of the C-terminus of Nme2-nCas9.
35. The polypeptide system of claim 33 or 34, wherein the HMGB1 comprises the amino acid sequence set forth in SEQ ID NO: 1783-1792 and 1803-1804, optionally SEQ ID NO: 1789.
36. The polypeptide system of any one of claims 1-3, wherein the DDP and Nme2-nCas9 are operably linked sequentially by a peptide bond, from N-terminus to C-terminus, in an order selected from:a) PolK - Nme2-nCas9;b) Nme2-nCas9 - PolK;c) T5 pol - Nme2-nCas9;d) Nme2-nCas9 - T5 pol;e) PolK(GE> RV)-Nme2-nCas9;f) Nme2-nCas9-PolK(GE> RV);g) MCP-PolK (GE> RV)- Nme2-nCas9;h) MCP-PolK (GE> RV)- Nme2-nCas9-HMGB 1;i) MCP-PolK(l-526, GE> RV)-linkerNLS- Nme2-nCas9;j) MCP-PolK(l-526, GE> RV)-linkerNLS- Nme2-nCas9-HMGB 1k) MCP-PolK(l-526, GE> RV)- linker-NLS-linker- Nme2-nCas9-HMGB 1;l) MCP-PolK(l-526, GE> RV)-linkerNLS-linker- Nme2-nCas9-HMGB1;m) MCP-PolK-Nme2-Cas9(H588A);n) MCP-PolK-Nme2-Cas9(H588A, E932K, Kl 044R);o) MCP-PolK-Nme2-Cas9(H588A)-HMGB1;p) MCP-PolK-Nme2-Cas9(H588A, E932K, Kl 044R)-HMGB 1;q) MCP-PolK-Nme2-Cas9(H588S, E932K, Kl 044R)-HMGB 1;r) MCP-PolK (GE> RV, S423R)-Nme2-Cas9 (H588A / E932R);s) Nme2-Cas9 (H588A / E932R)-PolK 1-526 GE> RV;t) PolK 1-526 GE> RV-Nme2-Cas9 (H588A / E932R);u) polK-Nme2-nCas9(E932R);v) polK-Nme2-nCas9(E932R);w) MCP-polK-Nme2-nCas9(E932R);x) MCP-T5-Nme2-nCas9;y) MCP-T5-Nme2-nCas9-HMGB1;z) MCP-T5-Nme2-nCas9 (H588A / E932R);aa) MCP-T5Pol-Nme2-nCas9 (H588A, E932R);optionally wherein the polypeptide system further comprises one or more of:(a) a HMGB1 positioned downstream of the C-terminus of the DDP- Nme2-nCas9 fusion protein;(b) a HMGB1 positioned upstream of the N-terminus of the DDP- Nme2-nCas9 fusion protein;(c) a HMGB1 positioned between the DDP and Nme2-nCas9 fusion protein;(d) a MCP positioned downstream of the C-terminus of the DDP- Nme2-nCas9 fusion protein;(e) a MCP positioned upstream of the N-terminus of the DDP- Nme2-nCas9 fusion protein;(f) a MCP positioned between the DDP and Nme2-nCas9;(g) one or more NLSs positioned downstream of the C-terminus of the DDP- Nme2-nCas9 fusion protein;(h) one or more NLSs positioned upstream of the N-terminus of the DDP- Nme2-nCas9 fusion protein;(i) one or more NLSs positioned between the DDP and Nme2-nCas9;(j) the DDP and / or the Nme2-nCas9 comprises one or more mutations or one or more additional mutations.
37. The polypeptide system of claim 36, further comprising:(a) an intein scar positioned between DDP and Nme2-nCas9;(b) an intein scar positioned within the DDP; or(c) an intein scar positioned within the Nme2-nCas9.
38. The polypeptide system of any one of claims 1-37, wherein the polypeptide system is encoded by one or more mRNAs listed in Table 6 or exemplified in Examples 1-15.
39. The polypeptide system of any one of claims 1-38, wherein the polypeptide system comprises one or more amino acid sequences that are at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% of any one of the amino acid sequences listed in Tables 6 or exemplified in Examples 1-15.
40. The polypeptide system of any one of claims 1-39, further comprising a Vpx and / or a FEN1, optionally wherein the Vpx and or the FEN1 is not covalently linked to DDP or Nme2-nCas9.
41. A polynucleotide system encoding the polypeptide system of any one of claims 1-40, the polynucleotide system comprising:(a) a first polynucleotide comprising a nucleotide sequence encoding the Nme2-nCas9 or a portion thereof; and(b) a second polynucleotide comprising a nucleotide sequence encoding the DDP or a portion thereof.
42. The polynucleotide system of claim 41, wherein:(a) the first polynucleotide is covalently linked to the second polynucleotide; or(b) the first polynucleotide is not covalently linked to the second polynucleotide.
43. The polynucleotide system of claim 42, wherein:(a) the first polynucleotide encodes the Nme2-nCas9, or a portion thereof, operably linked to a first split intein; and(b) the second polynucleotide encodes the DDP or a portion thereof, operatively linked to a second split-intein,wherein the first split-intein and the second split-intein are capable of undergoing trans-splicing reaction, resulting in the formation of a single fusion polypeptide comprising, the Nme2-nCas9 and the DDP.
44. The polynucleotide system of claim 43, wherein:(1) the first split intein and the second split intein are CfaN and CfaC, respectively; or(2) the first split intein and the second split intein are CfaC and CfaN, respectively.
45. The polynucleotide system of claim 43, wherein the mass ratio between the first polynucleotide and the second polynucleotide is between 10:1 and 1:10, between 4: 1 and 1:4, between 2: 1 and 1:2, or about 1:1.
46. The polynucleotide system of claim 42, wherein:(a) the first polynucleotide encodes the Nme2-nCas9 that is operatively linked to a first heterodimerization domain; and(b) the second polynucleotide encodes the DDP that is operatively linked to a second heterodimerization domain,wherein the first and the second heterodimerization domains are complementary and capable of self-assembling the Nme2-nCas9 and the DDP into a stable heterodimer.
47. The polynucleotide system of any one of claims 41-46, wherein the polynucleotide is a mRNA.
48. The polynucleotide system of claim 47, wherein the mRNA comprises: (1) one or more nucleotide sequences that are at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% of any one of the nucleotide sequences listed in Table 6 or exemplified in Examples 1-15; or (2) wherein the mRNA comprises one or more of nucleotide sequences that are at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% of any one of SEQ ID NOs 1840, 1115, 1841, 1842 or 1843.
49. The polynucleotide system of claim 47 or 48, wherein the mRNA wherein at least 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99%, or 100% of undine in the mRNA is substituted with a modified uridine, optionally wherein the modified uridine is one or more of N1 -methyl-pseudouridine, pseudouridine, 5 -methoxyuridine, or 5-iodouridine.
50. The polynucleotide system of claim 49, wherein at least 90%, 95%, 99%, or 100% of the uridine in the mRNA is substituted with N1 -methyl-pseudouridine.
51. The polynucleotide system of any one of claims 41-50, further comprising a nicking guide RNA (ngRNA), wherein the ngRNA comprises a spacer that is complementary to the nontarget strand of the DNA duplex target nucleic acid,52. The polynucleotide system of claim 51, wherein the ngRNA comprises a spacer that hybridizes to a sequence on the non-target strand such that(i) the nick site of the ngRNA is within 200 nucleotides 5’ or 3’ from the nick site of the template guide RNA;(ii) the nick site of the ngRNA is 20-200 nucleotides 5 ’ or 3 ’ from the nick site of the template guide RNA; or(iii) the nick site of the ngRNA is outside of the genomic locus of the spacer sequence of the template guide RNA.
53. The polynucleotide system of any one of claims 41-46, wherein the polynucleotide therein is a DNA, optionally wherein the DNA is a plasmid DNA or ssDNA, optionally wherein the ssDNA is a viral genome (e.g., rAAV).
54. A template guide RNA (tgRNA), wherein the tgRNA comprises a first polynucleotide and a second polynucleotide, wherein:a) the first polynucleotide is an Nme single guide RNA (sgRNA) comprising, from 5’ to3’:i) a spacer that is complementary to a target region of a target strand of a DNA duplex target nucleic acid; andii) a scaffold comprising, from 5’ to 3’: a repeat / antir epeat region, a hairpin 1 region and a hairpin 2 region;wherein the first polynucleotide is capable of specifically binding to an Nme2Cas9, and b) the second polynucleotide comprises, 5’ to 3’:i) a template sequence that is complementary to at least a portion of a non-target strand of the DNA duplex target nucleic acid and the template comprising DNA nucleotides; and ii) a DNA-dependent DNA polymerase recruiting sequence (DRS) having a 3’ end and a 5’ end; wherein the 5’ end of the DRS is covalently attached to the 3’ end of the template sequence, and wherein the DRS comprises a sequence that is complementary to at least 6 nucleotides of a DRS-complementary region of the non-target strand of the DNA duplex target nucleic acid, and optionally wherein the DRS comprises one or more of:(i) one or more RNA nucleotide bases;(ii) a sequence not fully complementary to the DRS-complementary region of the non-target strand of the DNA duplex target nucleic acid;(iii) a 1-5 nucleotide, optionally a 1-3 nucleotide 3’ terminal tail comprising a 3’ terminal modified uridine nucleotide.
55. The tgRNA of claim 54, wherein the first polynucleotide comprises:(a) a spacer region 20-25 nucleotides in length;(b) a shortened repeat / anti-repeat region, wherein the shortened repeat / anti-repeat region lacks 2-24 nucleotides within nucleotides 25-76 of SEQ ID NO: 253, wherein(i) one or more of nucleotides 37-48 and 53-64 is deleted and optionally one or more of nucleotides 37-64 is substituted relative to SEQ ID NO: 253; and(ii) nucleotide 36 is linked to nucleotide 65 of SEQ ID NO: 253 by at least 2 nucleotides or an internal linker; or(c) a shortened hairpin 1 region, wherein the shortened hairpin 1 lacks 2-10, optionally 2-8 nucleotides within nucleotides 78-100 of SEQ ID NO: 253, wherein(i) one or more of nucleotides 82-86 and 91-95 is deleted and optionally one or more of positions 82-96 is substituted relative to SEQ ID NO: 253; and(ii) nucleotide 81 is linked to nucleotide 96 of SEQ ID NO: 253 by at least 4 nucleotides or an internal linker; or(d) a shortened hairpin 2 region, wherein the shortened hairpin 2 lacks 2-18, optionally 2-16 nucleotides within nucleotides 102-143 of SEQ ID NO: 253, wherein(i) one or more of nucleotides 113-121 and 126-134 are deleted and optionally one or more of nucleotides 113-134 are substituted relative to SEQ ID NO: 253; and(ii) nucleotide 112 is linked to nucleotide 135 of SEQ ID NO: 253 by at least 4 nucleotides or an internal linker; wherein one or both nucleotides 144-145 are optionally deleted relative to SEQ ID NO: 253.
56. The tgRNA of claim 54, wherein the first polynucleotide comprises:(a) a shortened repeat / anti-repeat region, wherein the shortened repeat / anti-repeat region lacks 2-24 nucleotides within nucleotides 25-76 of SEQ ID NO: 253, wherein(i) one or more of nucleotides 37-48 and 53-64 is deleted and optionally one or more of nucleotides 37-64 is substituted relative to SEQ ID NO: 253; and(ii) nucleotide 36 is linked to nucleotide 65 of SEQ ID NO: 253 by at least 2 nucleotides or an internal linker.
57. The tgRNA of any of claims 54-56, wherein the spacer region has a length of 23-24 nucleotides, optionally wherein the spacer region has a length of 24 nucleotides.
58. The tgRNA of any of claims 54-57, wherein the first polynucleotide comprises an internal linker in at least one of the repeat / anti-repeat region, the hairpin 1 region, or the hairpin 2 region, optionally wherein the internal linker comprises one or more S18 or dS linkers.
59. The tgRNA of any of claims 54-58, wherein the tgRNA further comprises a 3’ tail, wherein the 3’ tail is optionally 1-4 nucleotides in length.
60. The tgRNA of any of claims 54-59, wherein the first polynucleotide is covalently linked to the second polynucleotide.
61. The tgRNA of claim 54, wherein:(1) the first polynucleotide and the second polynucleotide are covalently linked to each other by a phosphodiester or phosphorothioate bond; or(2) the first polynucleotide and the second polynucleotide are covalently linked to each other by a flexible linker, optionally wherein the internal linker comprises one or more S18 or dS linkers.
62. The tgRNA of claim 60 or 61, wherein the 3’ end of the first polynucleotide is covalently linked to the 5’ end of the second polynucleotide.
63. The tgRNA of claim 60 or 61, wherein the second polynucleotide is inserted into the hairpin 2 region of the first polynucleotide.
64. The tgRNA of claim 61, wherein the first polynucleotide and the second polynucleotide are not directly linked to each other by a phosphodiester or phosphorothioate bond.
65. The tgRNA of any one of claims 54-59, wherein the first polynucleotide is not covalently linked to the second polynucleotide.
66. The tgRNA of claim 65, wherein the second polynucleotide is covalently linked to one or more affinity tags, optionally wherein the one or more affinity tags comprise an aptamer sequence, optionally wherein the aptamer sequences is covalently linked to the 5’ terminus of the second polynucleotide.
67. The tgRNA of claim 66, wherein the one or more affinity tags comprises one or more MS2 hairpins, optionally wherein the one or more affinity tags comprises a single MS2 hairpin.
68. The tgRNA of any one of claims 54-67, wherein the first polynucleotide comprises a nucleotide sequence selected from SEQ ID NO: 238-245.
69. The tgRNA of any one of claims 54-68, wherein one or both of the first polynucleotide and the second polynucleotide comprise chemically modified nucleotides.
70. The tgRNA of any one of claims 54-68, wherein both the first polynucleotide and the second polynucleotide comprise chemically modified nucleotides and are modified at at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the nucleotides.
71. The tgRNA of claim 69, wherein the first polynucleotide comprises a chemically modified nucleotide structure selected from SEQ ID NO: 258-278.
72. A template guide RNA (tgRNA), wherein the tgRNA comprises a first polynucleotide and a second polynucleotide, wherein:a) the first polynucleotide is an Nme single guide RNA (sgRNA) comprising, from 5’ to 3’:i) a spacer that is complementary to a target region of a target strand of a DNA duplex target nucleic acid; andii) a scaffold comprising, from 5’ to 3’: a repeat / antirepeat region, a hairpin 1 region and a portion of a hairpin 2 region wherein the portion of the hairpin 2 region does not comprise a duplex portion;wherein the first polynucleotide capable of binding to an NmeCas9, andb) the second polynucleotide comprises, 5’ to 3’:i) a template sequence that is complementary to at least a portion of a non-target strand of the DNA duplex target nucleic acid and the template comprising DNA nucleotides;ii) a DNA-dependent DNA polymerase recruiting sequence (DRS) having a 3’ end and a 5’ end; wherein the 5’ end of the DRS is covalently attached to the 3’ end of the template sequence, and wherein the DRS comprises a sequence that is complementary to at least 6 nucleotides of a DRS-complementary region of the non-target strand of the DNA duplex target nucleic acid; andiii) a nucleotide sequence capable of forming a duplex with the hairpin 2 region of the first polynucleotide, wherein the duplex comprises 6 base pairs, optionally wherein the duplex comprises 10 base pairs.
73. The tgRNA of claim 72, wherein the first polynucleotide comprises:(a) a spacer region 20-25 nucleotides in length;(b) a shortened repeat / anti-repeat region, wherein the shortened repeat / anti-repeat region lacks 2-24 nucleotides within nucleotides 25-76 of SEQ ID NO: 253, wherein(i) one or more of nucleotides 37-48 and 53-64 is deleted and optionally one or more of nucleotides 37-64 is substituted relative to SEQ ID NO: 253; and(ii) nucleotide 36 is linked to nucleotide 65 of SEQ ID NO: 253 by at least 2 nucleotides or an internal linker; or(c) a shortened hairpin 1 region, wherein the shortened hairpin 1 lacks 2-10, optionally 2-8 nucleotides within nucleotides 78-100 of SEQ ID NO: 253, wherein(i) one or more of nucleotides 82-86 and 91-95 is deleted and optionally one or more of positions 82-96 is substituted relative to SEQ ID NO: 253; and(ii) nucleotide 81 is linked to nucleotide 96 of SEQ ID NO: 253 by at least 4 nucleotides or an internal linker; or(d) a hairpin 2 region comprising nucleotides 102-112 of SEQ ID NO: 253; and(e) the second polynucleotide comprises a nucleotide sequence that forms a duplex with nucleotides 102-112 of SEQ ID NO: 253, wherein the duplex comprises 6 base pairs, optionally wherein the duplex comprises 10 base pairs.
74. The tgRNA of claim 72 or 73, wherein the second polynucleotide comprises, from 5’ to 3’,(a) 5’ -template - DRS - duplex forming nucleotide sequence-3’; or(b) 5’ - duplex forming nucleotide sequence - template - DRS.
75. The tgRNA of claim 74, wherein the second polynucleotide comprises an internal linker adjacent to the duplex forming nucleotide sequence, optionally wherein the internal linker comprises one or more S18 or dS linkers.
76. The tgRNA of any one of claims 72-74, wherein one or both of the first polynucleotide and the second polynucleotide comprise chemically modified nucleotides.
77. The tgRNA of any one of claims 72-74, wherein both the first polynucleotide and the second polynucleotide comprise chemically modified nucleotides and are modified at at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the nucleotides.5 78. The tgRNA of any one of claims 54-77, wherein the 5’ end and the 3’ end of each the first polynucleotide and the second polynucleotide comprise at least two modified nucleotides.
79. The tgRNA of any one of claims 54-77, wherein the first polynucleotide or the second polynucleotide comprises a modified nucleotide selected from:lOi) 2’-O-methyl (2’-0-Me) modified nucleotide;ii) 2’-fluoro (2’-F) modified nucleotide;iii) an amine modified nucleotide;iv) an alkoxy modified nucleotide;v) an LNA modified nucleotide;15vi) methoxy ethyl modified nucleotide;vii) a halo modified nucleotide; orviii) phosphorothioate (PS) linkage modified nucleotide.
80. The tgRNA of claim 79, wherein the first polynucleotide comprises a 2’-O-methyl (2’-O-20 Me) modified nucleotide or a phosphorothioate (PS) linkage modified nucleotide.
81. The tgRNA of any one of claims 54-80, wherein the DRS comprises at least one of:(i) one or more RNA nucleotide bases;(ii) a sequence not fully complementary to the DRS-complementary region of the25 non-target strand of the DNA duplex target nucleic acid; or(iii) a 1-5 nucleotide, optionally a 1-3 nucleotide 3’ terminal tail comprising a 3’ terminal modified uridine nucleotide.
82. The tgRNA of any one of claims 54-81, wherein the 3’ terminal nucleotide of the 30 template is a DNA nucleotide.
83. The tgRNA of any one of claims 54-82, wherein (i) the 5’ terminal nucleotide of the DRS is a DNA nucleotide; or (ii) the penultimate 5’ terminal nucleotide of the DRS is an RNA nucleotide.
84. The tgRNA of any one of claims 54-83, wherein the 3’ terminal nucleotide of the template and the 5’ terminal nucleotide of the DRS are DNA nucleotides, and the penultimate 5’ terminal nucleotide of the DRS is an RNA nucleotide.
85. The tgRNA of any one of claims 54-84, wherein the 3’ terminal nucleotide in the DRS is an RNA nucleotide and the remaining nucleotides in the DRS are DNA nucleotides.
86. The tgRNA of any one of claims 54-85, wherein the template consists of DNA nucleotides.
87. The tgRNA of any one of claims 54-82, wherein the DRS consists of RNA nucleotides.
88. The tgRNA of any one of claims 54-87, wherein the template comprises a mismatch to the genomic sequence, optionally 1-4 mismatches to the genomic sequence.
89. The tgRNA of any one of claims 54-88, wherein the mismatch that directs a templatebased edit in the genomic DNA is within nucleotides T1-T25, optionally within nucleotides Tl-T15 of the template.
90. The tgRNA of any one of claims 54-89, wherein the template comprises DNA nucleotides.
91. The tgRNA of any one of claims 54-90, wherein: (i) the 3’ terminal nucleotide of the template is a DNA nucleotide; or (ii) the template consists of DNA nucleotides from nucleotide 4 (T4) from the 3’ end of the template to the 5’ end of the template.
92. The tgRNA of any one of claims 54-91, wherein the template consists of DNA nucleotides.
93. The tgRNA of any one of claims 54-92, wherein the template comprises RNA nucleotides.
94. The tgRNA of any one of claims 54-91 and 93, wherein the template comprises both RNA nucleotide(s) and DNA nucleotide(s), optionally wherein at least one nucleotide at positions T1 or T2 of the template is an RNA nucleotide.
95. The tgRNA of any one of claims 54-94, wherein (i) the DRS is 6-18 nucleotides in length, optionally 8-18 or 10-12 nucleotides in length; or (ii) the DRS is 10-16 or 12-14 nucleotides in length.
96. A template-based editing system comprising the polypeptide system of any one of claims 1-40 and the tgRNA of any one of claims 54-95.
97. A template-based editing system comprising any one of combinations of a polypeptide system and a tgRNA exemplified in Tables 1-2D, 4-6, and 8-21.
98. The template-based editing system of claim 96 or 97, wherein(a) the polypeptide system comprises an ABD, optionally wherein the ABD is a MCP, and(b) the tgRNA comprises an aptamer, optionally wherein the aptamer is a MS2.
99. A template-based editing system comprising the polynucleotide system of any one of claims 41-53 and the tgRNA of any one of claims 54-95.
100. A template-based editing system comprising any one of combinations of a polynucleotide system and a tgRNA exemplified in Tables 1-2D, 4-6, and 8-21.
101. The template-based editing system of claim 99 or 100, wherein(a) the polynucleotide system comprises nucleic acid sequences encoding an ABD, optionally wherein the ABD is a MCP, and(b) the tgRNA comprises an aptamer, optionally wherein the aptamer is a MS2.
102. The template-based editing system of claim 101, comprising a polynucleotide system comprising:(a) a first polynucleotide and a second polynucleotide encoding a Nme2-nCas9, or a portion thereof, that is operatively linked to a first split-intein; and(b) a second polynucleotide encoding a DDP, or a portion thereof, that is operatively linked to a second split-intein,wherein the mass ratio between the first polynucleotide and the second nucleotide is 1: 1 and the mass ratio between tgRNA and total polynucleotide system is between 1: 8 and 4:1, between 1:4 and 4: 1, between 1: 1 and 4: 1, or about 2: 1.
103. A pharmaceutical composition comprising the template-based editing system of any one of claims 96-102, and a pharmaceutically acceptable carrier.
104. An LNP composition comprising the template-based editing system of any one of claims 96-102 wherein the different components of the template-based editing system are associated with the same LNP or the different components of the template-based editing system are associated with different LNPs.
105. A cell comprising the template-based editing system of any one of claims 96-102, optionally wherein the cell is a mammalian cell.
106. A method for editing a target nucleic acid in a cell or a subject, the method comprising delivering the template-based editing system of any one of claims 1-53, the pharmaceutical composition of claim 103, or the LNP of claim 104 to the cell or the subject.
107. Use of the polypeptide system, the polynucleotide system, the tgRNA, the composition, or the LNP of any one of claims 1-104 for editing a target nucleic acid in a cell or a subject.
